

(51) International Patent Classification:
A01N 43/78 (2006.01)(21) International Application Number:
PCT/US2013/022659(22) International Filing Date:
23 January 2013 (23.01.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/594,054 2 February 2012 (02.02.2012) US(71) Applicant: DOW AGROSCIENCES LLC [US/US];
9330 Zionsville Road, Indianapolis, IN 46268 (US).(72) Inventors: BAUM, Erich W.; 772 Burr Oak Drive, Green-
wood, IN 46143 (US). CROUSE, Gary D.; 5069 East
146th Street, Noblesville, IN 46062 (US). DENT, William
Hunter; 8350 Pine Branch Lane, Indianapolis, IN 46234
(US). SPARKS, Thomas C.; 1322 Greenhills Road,
Greenfield, IN 46140 (US). CREEMER, Lawrence C.;
1763 N. James Blvd, Greenfield, IN 46140 (US).(74) Agent: CORVIN, Carl; Dow AgroSciences LLC, 9330
Zionsville Rd, Indianapolis, Indiana 46268 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO

(57) Abstract: This document discloses molecules having the following formulas ("Formula One" & "Formula Two" and "Formula Three") The Ar₁, Het, Ar₂, R₁, R₂, R₃, R₄, and R₅ are further described herein.

PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This Application claims priority from U.S. provisional application 61/594,054 filed on February 2, 2012. The entire content of this provisional application is hereby incorporated by reference into this Application.

FIELD OF THE INVENTION

10 The invention disclosed in this document is related to the field of processes to produce molecules that are useful as pesticides (*e.g.*, acaricides, insecticides, molluscicides, and nematocides), such molecules, and processes of using such molecules to control pests.

BACKGROUND OF THE INVENTION

15 Pests cause millions of human deaths around the world each year. Furthermore, there are more than ten thousand species of pests that cause losses in agriculture. The world-wide agricultural losses amount to billions of U.S. dollars each year.

Termites cause damage to all kinds of private and public structures. The world-wide termite damage losses amount to billions of U.S. dollars each year.

20 Stored food pests eat and adulterate stored food. The world-wide stored food losses amount to billions of U.S. dollars each year, but more importantly, deprive people of needed food.

There is an acute need for new pesticides. Certain pests are developing resistance to pesticides in current use. Hundreds of pest species are resistant to one or more pesticides. The development of resistance to some of the older pesticides, such as DDT, the carbamates, and the organophosphates, is well known, but resistance has even developed to some of the newer pesticides.

Therefore, for many reasons, including the above reasons, a need exists for new pesticides.

30 DEFINITIONS

The examples given in the definitions are generally non-exhaustive and must not be construed as limiting the invention disclosed in this document. It is understood that a substituent should comply with chemical bonding rules and steric compatibility constraints in relation to the particular molecule to which it is attached.

“**Acaricide Group**” is defined under the heading “**ACARICIDES**”.

“**AI Group**” is defined after the place in this document where the “Herbicide Group” is defined.

“**Alkenyl**” means an acyclic, unsaturated (at least one carbon-carbon double bond),
5 branched or unbranched, substituent consisting of carbon and hydrogen, for example, vinyl, allyl, butenyl, pentenyl, and hexenyl.

“**Alkenyloxy**” means an alkenyl further consisting of a carbon-oxygen single bond, for example, allyloxy, butenyloxy, pentenyloxy, hexenyloxy.

“**Alkoxy**” means an alkyl further consisting of a carbon-oxygen single bond, for
10 example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, and tert-butoxy.

“**Alkyl**” means an acyclic, saturated, branched or unbranched, substituent consisting of carbon and hydrogen, for example, methyl, ethyl, propyl, isopropyl, butyl, and tert-butyl.

“**Alkynyl**” means an acyclic, unsaturated (at least one carbon-carbon triple bond),
15 branched or unbranched, substituent consisting of carbon and hydrogen, for example, ethynyl, propargyl, butynyl, and pentynyl.

“**Alkynyloxy**” means an alkynyl further consisting of a carbon-oxygen single bond, for example, pentynyloxy, hexynyloxy, heptynyloxy, and octynyloxy.

“**Aryl**” means a cyclic, aromatic substituent consisting of hydrogen and carbon, for example, phenyl, naphthyl, and biphenyl.

20 “**Cycloalkenyl**” means a monocyclic or polycyclic, unsaturated (at least one carbon-carbon double bond) substituent consisting of carbon and hydrogen, for example, cyclobutenyl, cyclopentenyl, cyclohexenyl, norbornenyl, bicyclo[2.2.2]octenyl, tetrahydronaphthyl, hexahydronaphthyl, and octahydronaphthyl.

“**Cycloalkenyloxy**” means a cycloalkenyl further consisting of a carbon-oxygen
25 single bond, for example, cyclobutenyloxy, cyclopentenyl, norbornenyloxy, and bicyclo[2.2.2]octenyloxy.

“**Cycloalkyl**” means a monocyclic or polycyclic, saturated substituent consisting of carbon and hydrogen, for example, cyclopropyl, cyclobutyl, cyclopentyl, norbornyl, bicyclo[2.2.2]octyl, and decahydronaphthyl.

30 “**Cycloalkoxy**” means a cycloalkyl further consisting of a carbon-oxygen single bond, for example, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, norbornyloxy, and bicyclo[2.2.2]octyloxy.

“**Fungicide Group**” is defined under the heading “**FUNGICIDES**.”

“**Halo**” means fluoro, chloro, bromo, and iodo.

“**Haloalkoxy**” means an alkoxy further consisting of, from one to the maximum possible number of identical or different, halos, for example, fluoromethoxy, trifluoromethoxy, 2,2-difluoropropoxy, chloromethoxy, trichloromethoxy, 1,1,2,2-tetrafluoroethoxy, and pentafluoroethoxy.

5 “**Haloalkyl**” means an alkyl further consisting of, from one to the maximum possible number of, identical or different, halos, for example, fluoromethyl, trifluoromethyl, 2,2-difluoropropyl, chloromethyl, trichloromethyl, and 1,1,2,2-tetrafluoroethyl.

“**Herbicide Group**” is defined under the heading “**HERBICIDES.**”

10 “**Heterocyclyl**” means a cyclic substituent that may be fully saturated, partially unsaturated, or fully unsaturated, where the cyclic structure contains at least one carbon and at least one heteroatom, where said heteroatom is nitrogen, sulfur, or oxygen. Examples of aromatic heterocyclyls include, but are not limited to, benzofuranyl, benzoisothiazolyl, benzoisoxazolyl, benzoxazolyl, benzothienyl, benzothiazolyl cinnoliny, furanyl, indazolyl, indolyl, imidazolyl, isoindolyl, isoquinoliny, isothiazolyl, isoxazolyl, oxadiazolyl, 15 oxazoliny, oxazolyl, phthalaziny, pyraziny, pyrazoliny, pyrazolyl, pyridaziny, pyridyl, pyrimidiny, pyrroly, quinazoliny, quinoliny, quinoxaliny, tetrazolyl, thiazoliny, thiazolyl, thienyl, triaziny, and triazolyl. Examples of fully saturated heterocyclyls include, but are not limited to, piperaziny, piperidiny, morpholiny, pyrrolidiny, tetrahydrofuranyl, and tetrahydropyranyl. Examples of partially unsaturated heterocyclyls include, but are not 20 limited to, 1,2,3,4-tetrahydro-quinoliny, 4,5-dihydro-oxazolyl, 4,5-dihydro-1H-pyrazolyl, 4,5-dihydro-isoxazolyl, and 2,3-dihydro-[1,3,4]-oxadiazolyl.


“**Insecticide Group**” is defined under the heading “**INSECTICIDES.**”

“**Nematicide Group**” is defined under the heading “**NEMATOCIDES**”


25 “**Synergist Group**” is defined under the heading “**SYNERGISTIC MIXTURES AND SYNERGISTS**”

DETAILED DESCRIPTION OF THE INVENTION


30 This document discloses molecules having the following formulas (“**Formula One**” & “**Formula Two**” and “**Formula Three**”): (In the following formulas the nitrogens are numbered 1, 2, and 3, solely for the purpose of identifying them and being able to refer to them throughout this document for clarity purposes)



Formula 1



Formula 2



Formula 3

wherein:

5 (a) Ar₁ is

- (1) furanyl, phenyl, pyridazinyl, pyridyl, pyrimidinyl, thienyl, or
- (2) substituted furanyl, substituted phenyl, substituted pyridazinyl,

substituted pyridyl, substituted pyrimidinyl, or substituted thienyl,

wherein said substituted furanyl, substituted phenyl, substituted

10 pyridazinyl, substituted pyridyl, substituted pyrimidinyl, and substituted thienyl, have one or more substituents independently selected from H, F, Cl, Br, I, CN, NO₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl),
 15 C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, phenoxy, substituted phenyl, and substituted phenoxy,

20 wherein such substituted phenyl and substituted phenoxy have one or more substituents independently selected from H, F, Cl, Br, I, CN, NO₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl),
 25 C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆

alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl) phenyl, and phenoxy;

(b) Het is a 5 or 6 membered, saturated or unsaturated, heterocyclic ring, containing one or more heteroatoms independently selected from nitrogen, sulfur, or oxygen, and where Ar₁ and Ar₂ are not ortho to each other (but may be meta or para, such as, for a five membered ring they are 1,3 and for a 6 membered ring they are either 1,3 or 1,4), and where said heterocyclic ring may also be substituted with one or more substituents

independently selected from H, F, Cl, Br, I, CN, NO₂, oxo, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, phenoxy, substituted phenyl and substituted phenoxy,

wherein such substituted phenyl and substituted phenoxy have one or more substituents independently selected from H, F, Cl, Br, I, CN, NO₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, and phenoxy;

(c) Ar₂ is

- (1) furanyl, phenyl, pyridazinyl, pyridyl, pyrimidinyl, thienyl, or
- (2) substituted furanyl, substituted phenyl, substituted pyridazinyl, substituted pyridyl, substituted pyrimidinyl, or substituted thienyl,

wherein said substituted furanyl, substituted phenyl, substituted pyridazinyl, substituted pyridyl, substituted pyrimidinyl, and substituted thienyl, have one or more substituents independently selected from H, F, Cl, Br, I, CN, NO₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-

C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl),
 C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆
 haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl),
 C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆
 5 alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, phenoxy, substituted
 phenyl and substituted phenoxy,

wherein such substituted phenyl and substituted phenoxy have one or
 more substituents independently selected from H, F, Cl, Br, I, CN, NO₂, C₁-C₆ alkyl, C₁-C₆
 haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆
 10 halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-
 C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H,
 C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆
 haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl),
 C(=O)(C₁-C₆ haloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-
 15 C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, and
 phenoxy;

(d) R₁ is selected from H, CN, F, Cl, Br, I, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆
 cycloalkoxy, C₁-C₆ alkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), OSO₂(C₁-C₆
 20 alkyl), C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl),
 C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆
 alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆
 alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, or phenoxy,

wherein each alkyl, cycloalkyl, cycloalkoxy, alkoxy, alkenyl, alkynyl, phenyl,
 25 and phenoxy, are optionally substituted with one or more substituents independently selected
 from F, Cl, Br, I, CN, NO₂, oxo, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆
 halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy,
 C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆
 alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl),
 30 C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆
 cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-
 C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆
 alkyl), phenyl, and phenoxy;

(e) R2 is H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C(=O)H, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, C₁-C₆ alkylphenyl, C₁-C₆ alkyl-O-phenyl, C(=O)Het-1, Het-1, C₁-C₆ alkylHet-1, or C₁-C₆ alkyl-O-Het-1,

wherein each alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, and Het-1 are optionally substituted with one or more substituents independently selected from F, Cl, Br, I, CN, NO₂, NR_xR_y, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₃-C₆ cycloalkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, phenoxy, and Het-1;

(f) R3 is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C(=O)H, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, C₁-C₆ alkylphenyl, C₁-C₆ alkyl-O-phenyl, C(=O)Het-1, Het-1, C₁-C₆ alkylHet-1, C₁-C₆ alkyl-O-C(=O)C₁-C₆ alkyl-O-C₁-C₆ alkyl, C₁-C₆ alkyl-O-C(=O)C₁-C₆ alkyl-O-C₁-C₆ alkyl-O-C₁-C₆ alkyl, C₁-C₆ alkyl-O-C(=O)C₁-C₆ alkyl-O-C₁-C₆ haloalkyl, C₁-C₆ alkyl-O-C(=O)C₁-C₆ alkyl-N(R_x)C(=O)-O-phenyl, C₁-C₆ alkyl-O-C(=O)C₁-C₆ alkyl-N(R_x)C(=O)-O-C₁-C₆ alkylphenyl, C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkyl, C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkylHet-1C(=O)-O-C₁-C₆ alkyl, C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkylHet-1, C₁-C₆ alkylC(=O)Het-1, C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkyl(N(R_x)(R_y))(C(=O)OH), C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkylN(R_x)(R_y), C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkylN(R_x)C(=O)-O-C₁-C₆ alkyl, C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkyl(N(R_x)C(=O)-O-C₁-C₆ alkyl)(C(=O)OH), C₁-C₆ alkylC(=O)Het-1C(=O)-O-C₁-C₆ alkyl, C₁-C₆ alkyl-O-C(=O)-O-C₁-C₆ alkyl, C₁-C₆ alkyl-O-C(=O)C₁-C₆ alkyl, C₁-C₆ alkyl-O-C(=O)C₃-C₆ cycloalkyl, C₁-C₆ alkyl-O-C(=O)Het-1, C₁-C₆ alkyl-O-C(=O)C₁-C₆ alkyl-N(R_x)C(=O)-O-C₁-C₆ alkyl, C₁-C₆ alkyl-NR_xR_y, or C₁-C₆ alkyl-O-Het-1,

wherein each alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, and Het-1 are

optionally substituted with one or more substituents independently selected from F, Cl, Br, I, CN, NO₂, NR_xR_y, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₃-C₆ cycloalkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)OH, C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, phenoxy, Si(C₁-C₆ alkyl)₃, S(=O)_nNR_xR_y, and Het-1;

(g) R₄ is H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C(=O)H, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, C₁-C₆ alkylphenyl, C₁-C₆ alkyl-O-phenyl, C(=O)Het-1, Het-1, C₁-C₆ alkylHet-1, or C₁-C₆ alkyl-O-Het-1,

wherein each alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, and Het-1 are optionally substituted with one or more substituents independently selected from F, Cl, Br, I, CN, NO₂, NR_xR_y, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₃-C₆ cycloalkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, phenoxy, and Het-1;

(h) R₅ is a 1 membered saturated or a 2 to 4 membered saturated or unsaturated hydrocarbyl linkage where said linkage may also be substituted with F, Cl, Br, I, CN, NO₂, oxo, NR_xR_y, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₃-C₆ cycloalkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)OH, C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, phenoxy, and Het-1;

haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, phenoxy, and Het-1,

wherein each alkyl, cycloalkyl, cycloalkoxy, alkoxy, alkenyl, alkynyl, phenyl, phenoxy, and Het-1, are optionally substituted with one or more substituents independently selected from F, Cl, Br, I, CN, NO₂, oxo, NR_xR_y, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₃-C₆ cycloalkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)OH, C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, halophenyl, phenoxy, and Het-1;

(i) n= 0, 1, or 2;

(j) R_x and R_y are independently selected from H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), and phenyl,

wherein each alkyl, cycloalkyl, cycloalkoxy, alkoxy, alkenyl, alkynyl, phenyl, phenoxy, and Het-1, are optionally substituted with one or more substituents independently selected from F, Cl, Br, I, CN, NO₂, oxo, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₃-C₆ cycloalkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)OH, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, halophenyl, phenoxy, and Het-1,

or R_x and R_y together can optionally form a 5- to 7-membered saturated or unsaturated cyclic group which may contain one or more heteroatoms selected from nitrogen, sulfur, and oxygen, and where said cyclic group can contain >C=O or >C=S, and where said cyclic group may be substituted with F, Cl, Br, I, CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₃-C₆ cycloalkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, substituted phenyl, phenoxy, and Het-1; and

(k) Het-1 is a 5- or 6-membered, saturated or unsaturated, heterocyclic ring, containing one or more heteroatoms independently selected from nitrogen, sulfur or oxygen.


It is understood that in Formula 1, when R₂ is H, the compounds may exist in more than one tautomeric or isomeric form, wherein the hydrogen is attached to either of the nitrogen atoms; further, both E and Z isomers may exist. Any and all isomeric forms of the compounds of this invention are claimed.

In another embodiment Ar₁ is a substituted phenyl, wherein said substituted phenyl has one or more substituents independently selected from C₁-C₆ haloalkyl and C₁-C₆ haloalkoxy.


In another embodiment Ar₁ is a substituted phenyl, wherein said substituted phenyl has one or more substituents independently selected from CF₃, OCF₃, and OCF₂CF₃.

In another embodiment Het is selected from triazolyl, imidazolyl, or pyrazolyl, which can be substituted or unsubstituted.

In another embodiment Het is a 1,2,4-triazolyl




In another embodiment Het is 1,4-imidazolyl



5


In another embodiment Het is 1,3-pyrazolyl



In another embodiment Het is a substituted 1,3-pyrazolyl.

10

In another embodiment Het is 1,4-pyrazolyl



In another embodiment Ar₂ is a phenyl.

15

In another embodiment R₁ is H or C₁-C₆ alkyl.

In another embodiment R₁ is H or CH₃.

20

In another embodiment R₂ is H.

In another embodiment R₃ is selected from C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkylphenyl, C₁-C₆ alkylHet-1, C₁-C₆ alkyl-O-C(=O)-C₁-C₆ alkyl-O-C₁-C₆ alkyl, C₁-C₆

alkyl-O-C(=O)C₁-C₆ alkyl-O-C₁-C₆ alkyl-O-C₁-C₆ alkyl, C₁-C₆ alkyl-O-C(=O)C₁-C₆ alkyl-O-C₁-C₆ haloalkyl, C₁-C₆ alkyl-O-C(=O)C₁-C₆ alkyl-N(R_x)C(=O)-O-phenyl, C₁-C₆ alkyl-O-C(=O)C₁-C₆ alkyl-N(R_x)C(=O)-O-C₁-C₆ alkylphenyl, C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkyl, C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkylHet-1C(=O)-O-C₁-C₆ alkyl, C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkylHet-1, C₁-C₆ alkylC(=O)Het-1, C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkyl(N(R_x)(R_y))(C(=O)OH), C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkylN(R_x)(R_y), C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkylN(R_x)C(=O)-O-C₁-C₆ alkyl, C₁-C₆ alkylC(=O)N(R_x)C₁-C₆ alkyl(N(R_x)C(=O)-O-C₁-C₆ alkyl)(C(=O)OH), C₁-C₆ alkylC(=O)Het-1C(=O)-O-C₁-C₆ alkyl, C₁-C₆ alkyl-O-C(=O)-O-C₁-C₆ alkyl, C₁-C₆ alkyl-O-C(=O)C₁-C₆ alkyl, C₁-C₆ alkyl-O-C(=O)C₃-C₆ cycloalkyl, C₁-C₆ alkyl-O-C(=O)Het-1, or C₁-C₆ alkyl-O-C(=O)C₁-C₆ alkyl-N(R_x)C(=O)-O-C₁-C₆ alkyl, wherein each alkyl, alkenyl, alkynyl, phenyl, and Het-1 are optionally substituted with one or more substituents independently selected from F, Cl, Br, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, S(=O)_n(C₁-C₆ alkyl), C(=O)OH, C(=O)O(C₁-C₆ alkyl), phenyl, Si(C₁-C₆ alkyl)₃, and S(=O)_nNR_xR_y.

15

In another embodiment R₄ is phenyl, C₁-C₆ alkylphenyl, Het-1, or C₁-C₆ alkyl-O-phenyl, wherein each alkyl, Het-1, and phenyl are optionally substituted with one or more substituents independently selected from F, Cl, NR_xR_y, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ haloalkoxy, C(=O)O C₁-C₆ alkyl, or C₁-C₆ alkoxy.

20

In another embodiment R₅ is substituted with oxo, C(=O)OH, phenyl, and Het-1, wherein each phenyl and Het-1, may be optionally substituted with one or more substituents independently selected from oxo, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, C(=O)OH, and halophenyl.

25

In another embodiment R_x and R_y are independently selected from H and phenyl, wherein said phenyl, may be optionally substituted with one or more substituents independently selected from F and Cl.

30

In another embodiment:

Ar₁ is a substituted phenyl wherein said substituted phenyl, has one or more C₁-C₆ haloalkoxy;

Het is a triazolyl;

Ar₂ is a phenyl;

R1 is H;

R2 is H;

R3 is C₁-C₆ alkylHet-1 wherein said alkyl and Het-1 are optionally substituted with one or more substituents independently selected from F, Cl, Br, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, S(=O)_n(C₁-C₆ alkyl), C(=O)OH, C(=O)O(C₁-C₆ alkyl), phenyl, Si(C₁-C₆ alkyl)₃, and S(=O)_nNR_xR_y;

R4 is phenyl, wherein said phenyl is optionally substituted with one or more substituents independently selected from F, Cl, NR_xR_y, C₁-C₆ alkyl, or C₁-C₆ alkoxy; and

n= 0, 1, or 2;

R_x and R_y are independently selected from H and phenyl, wherein said phenyl, may be optionally substituted with one or more substituents independently selected from F and Cl; and

Het-1 is a 5- or 6-membered, saturated or unsaturated, heterocyclic ring, containing one or more heteroatoms independently selected from nitrogen, sulfur or oxygen.

15

In another embodiment Het-1 is selected from benzofuranyl, benzoisothiazolyl, benzoisoxazolyl, benzoxazolyl, benzothienyl, benzothiazolyl cinnoliny, furanyl, indazolyl, indolyl, imidazolyl, isoindolyl, isoquinoliny, isothiazolyl, isoxazolyl, oxadiazolyl, oxazoliny, oxazolyl, phthalazinyl, pyrazinyl, pyrazoliny, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazoliny, quinoliny, quinoxaliny, tetrazolyl, thiazoliny, thiazolyl, thienyl, triazinyl, triazolyl, piperazinyl, piperidinyl, morpholiny, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydro-quinoliny, 4,5-dihydro-oxazolyl, 4,5-dihydro-1H-pyrazolyl, 4,5-dihydro-isoxazolyl, and 2,3-dihydro-[1,3,4]-oxadiazolyl.

25

In another embodiment Het is selected benzofuranyl, benzoisothiazolyl, benzoisoxazolyl, benzoxazolyl, benzothienyl, benzothiazolyl cinnoliny, furanyl, indazolyl, indolyl, imidazolyl, isoindolyl, isoquinoliny, isothiazolyl, isoxazolyl, oxadiazolyl, oxazoliny, oxazolyl, phthalazinyl, pyrazinyl, pyrazoliny, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazoliny, quinoliny, quinoxaliny, tetrazolyl, thiazoliny, thiazolyl, thienyl, triazinyl, triazolyl, piperazinyl, piperidinyl, morpholiny, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydro-quinoliny, 4,5-dihydro-oxazolyl, 4,5-dihydro-1H-pyrazolyl, 4,5-dihydro-isoxazolyl, and 2,3-dihydro-[1,3,4]-oxadiazolyl.

30

In another embodiment Het-1 is selected from benzofuranyl, benzoisothiazolyl, benzoisoxazolyl, benzoxazolyl, benzothienyl, benzothiazolyl, benzothiadizolyl, cinnoliny, furanyl, indazolyl, indolyl, imidazolyl, isoindolyl, isoquinoliny, isothiazolyl, isoxazolyl, oxadiazolyl, oxazoliny, oxazolyl, phthalaziny, pyraziny, pyrazoliny, pyrazolyl, pyridaziny, pyridyl, pyrimidiny, pyrroly, quinazoliny, quinoliny, quinoxaliny, tetrazolyl, thiazoliny, thiazolyl, thienyl, thienylpyrazolyl, triaziny, triazolyl, piperaziny, piperidiny, morpholiny, pyrrolidiny, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydro-quinoliny, 4,5-dihydro-oxazolyl, 4,5-dihydro-1H-pyrazolyl, 4,5-dihydro-isoxazolyl, and 2,3-dihydro-[1,3,4]-oxadiazolyl.

In another embodiment Het-1 is selected from benzothiadizolyl, furanyl, oxazolyl, and thienylpyrazolyl.

While these embodiments have been expressed, other embodiments and combinations of these expressed embodiments and other embodiments are possible.

The Molecules of Formulae One, Two and Three will generally have a molecular mass of about 100 Daltons to about 1200 Daltons. However, it is generally preferred if the molecular mass is from about 120 Daltons to about 900 Daltons, and it is even more generally preferred if the molecular mass is from about 400 Daltons to about 800 Daltons.


PREPARATION OF TRIARYL INTERMEDIATES

Compounds of this invention can be prepared by making a triaryl intermediate, Ar₁-Het-Ar₂, and then linking it to the desired intermediate to form the desired compound. A wide variety of triaryl intermediates can be used to prepare compounds of this invention, provided that such triaryl intermediates contain a suitable functional group on Ar₂ to which the rest of the desired intermediate can be attached. Suitable functional groups include an oxoalkyl or a formyl group. These triaryl intermediates can be prepared by methods previously described in the chemical literature, including Crouse et al. PCT Int. Appl. Publ. WO2009/102736 A1.

PREPARATION OF HYDRAZONE-LINKED COMPOUNDS


Hydrazone-linked compounds can be prepared from the corresponding aryl aldehydes or ketones by one of three methods: (1) by reaction with a hydrazine, followed by reaction with an aryl isothiocyanate in tetrahydrofuran (THF), at temperatures between 0 and 100 °C

(Reaction A); (2) by reaction with methyl hydrazinecarbodithioate, followed by reaction with an aniline in a polar aprotic solvent such as *N,N*-dimethylformamide (DMF), at temperatures between 25 and 150 °C (Reaction B); or (3) by reaction with an aryl thiosemicarbazide, that is either commercially available or can be prepared by one who is skilled in the art, in a polar protic solvent such as ethyl alcohol (EtOH), at temperatures between 0 and 100 °C (Reaction C).




10 PREPARATION OF ALKYLATED HYDRAZONE-LINKED COMPOUNDS


Alkylated hydrazone-linked compounds can be prepared from the corresponding hydrazone-linked compounds by one of two methods: (1) by reaction with an alkylating agent in EtOH or acetone, at temperatures between 0 and 100 °C for from 1 to 24 h or (2) by reaction with an alkylating agent in chloroform (CHCl₃), dichloromethane (CH₂Cl₂), or other halocarbon solvent, with or without a base such as sodium bicarbonate, at from 20 to 60 °C.



Compounds of Formula Two, wherein R5 forms a ring with N₃ (see Scheme below) or of Formula Three, wherein R5 forms a ring with N₂, can be prepared from a suitable acyclic precursor by using α-halo acids, acid halides, esters, or ketones (F or G or H). For example, treatment of the thiosemicarbazone with a slight excess of an α-halo ester, in a protic solvent such as EtOH or methyl alcohol (CH₃OH) results in S-alkylation and subsequent ring closure exclusively onto N₃ (Reaction F; see for example, *J. Indian Chemical Society* **1966**, 43, 275-276, or *J. Heterocycl. Chem.* 1978, 15, 335-336). When an aprotic solvent such as CH₂Cl₂ or dichloroethane (ClCH₂CH₂Cl) is used at temperatures from 30 °C to 80 °C, the orientation of addition of α halo ketones also favors closure onto N₃, with subsequent dehydration to form an imino thiazoline (Reaction G). With α-halo acids or acid halides or esters in a halocarbon solvent such as CH₂Cl₂ or ClCH₂CH₂Cl, ring closure onto both N₂ (Reaction H) and N₃ is observed. Though these reactions often proceed in the absence of added base, a base such as sodium bicarbonate, sodium carbonate or sodium acetate, or an amine base such as pyridine or triethylamine, can be added.




Alternatively, 3-arylideneimino-2-aryliminothiazolin-4-ones can be prepared by treating an aldehyde or ketone, wherein R1 is as previously described, with a 3-amino-2-(arylimino)thiazolidin-4-one in acetic acid at from 30 to 70 °C as shown in the following scheme (I). The intermediate 1-amino-2-aryliminothiazolin-5-one, wherein R4 is phenyl, has been described (see for example, *J. Org. Chem.* **1962**, **27**, 2878); it was prepared in 80% yield by treatment of 4-phenyl thiosemicarbazide with ethyl 2-chloroacetate and sodium acetate in hot EtOH.




Alternatively, compounds of Formula 2 and Formula 3 may be formed by heating a thiosemicarbazone precursor with a di-halo group Hal1-R5-Hal2 such as 1-bromo-2-chloro ethane or diiodomethane, in acetone or 2-butanone or other suitable solvent, using a base

such as potassium carbonate or triethylamine, at temperatures between ambient and 100 °C for from 1 to 72 hours. The S-alkylated intermediate undergoes cyclization at N2 or N3 to generate compounds of Formula Two or Formula Three (Reaction J). In some cases, addition of KI may be required to accelerate the cyclization of the intermediate S-alkylated derivatives to the ring-closed products.



An alternative method of preparing compounds of this invention is by treatment of a thiosemicarbazone precursor with an unsaturated ester or acid chloride (Reaction L).



Substituted hydrazinecarbothioamide intermediates, such as those utilized in Method C above, can be prepared by a number methods known in the chemical literature.


Alternatively, compounds wherein R_a , R_b , and R_c are not derived from a commercially available aniline can be prepared according to the scheme below. For example, a 2-halo nitrobenzene, such as 2-bromonitrobenzene, substituted with one or multiple R_c substituents, wherein R_c can be H, alkyl, alkoxy, or halo, such as fluoro, can be reacted with a boronic acid

or boronate ester, such as the substituted 4,4,5,5-tetramethyl-1,3,2-dioxaborolane, wherein R_a and R_b are H, in the presence of a base, for example sodium carbonate, and a palladium catalyst, such as bis(triphenylphosphine)palladium(II)chloride, in an aqueous solvent system, such as 4:1 dioxane / water, at an elevated temperature, for example 80 °C, affords the

olefinic substituted nitrobenzene compounds. Alternatively, R_a and R_b can be taken together to form a ring, such as a cyclopentene, to give the corresponding 2-(cyclopent-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, which under the conditions described above affords the cyclic alkene substituted nitrobenzene. Treatment a solution of the olefinic nitrobenzenes in an aprotic solvent, such as ethyl acetate, wherein R_a , R_b , and R_c are as defined above, with

hydrogen gas in the presence of a catalyst, for example palladium on carbon (Pd/C), affords the corresponding alkyl or cycloalkyl substituted anilines. Treating a biphasic solution of the anilines, wherein R_a , R_b , and R_c are as defined, in a mixture of halogenated solvent and water, such as 2:1 dichloromethane /water, with a base, such as sodium hydrogencarbonate, followed by thiophosgene affords the intermediate isothiocyanatobenzenes. Separation of the

phases, followed by drying and evaporation of the organic solvent affords the crude intermediate which is immediately dissolved in an alcohol, such as ethanol, and treated with hydrazine hydrate to give the hydrazinecarbothioamide intermediates, wherein R_a , R_b , and R_c are as defined.




EXAMPLES

The examples are for illustration purposes and are not to be construed as limiting the invention disclosed in this document to only the embodiments disclosed in these examples.

Starting materials, reagents, and solvents that were obtained from commercial sources

were used without further purification. Anhydrous solvents were purchased as Sure/Seal™ from Aldrich and were used as received. Melting points were obtained on a Thomas Hoover Unimelt capillary melting point apparatus or an OptiMelt Automated Melting Point System from Stanford Research Systems and are uncorrected. Molecules are given their known
 5 names, named according to naming programs within MDL ISIS™/Draw 2.5, ChemBioDraw Ultra 12.0 or ACD Name Pro. If such programs are unable to name a molecule, the molecule is named using conventional naming rules. ¹H NMR spectral data are in ppm (δ) and were recorded at 300, 400 or 600 MHz, and ¹³C NMR spectral data are in ppm (δ) and were recorded at 75, 100 or 150 MHz, unless otherwise stated.

Example 1: Preparation of (*E*)-*N*-(4-dimethylamino)phenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazine-carbothioamide (Compound I-1) [Synthesis Method A].




Step 1. (*E*)-3-(4-(Hydrazonomethyl)phenyl)-1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazole. To a 250 milliliter (mL) round-bottomed flask containing hydrazine hydrate (64% aqueous (aq) solution; 7.27 mL, 15.0 millimoles (mmol)) in EtOH (100 mL) at 80 °C
 20 was added 4-[1-(4-trifluoromethoxyphenyl)-1*H*-[1,2,4]triazol-3-yl]-benzaldehyde (5.00 grams (g), 1.50 mmol) portionwise over 5 minutes (min). The solution was stirred at reflux for an additional 3 hours (h) before being diluted with water (H₂O; 300 mL) and cooled to 0 °C. The precipitated product was collected by vacuum filtration as a white solid (4.89 g, 93%); mp 222 – 226 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.59 (s, 1H), 8.22 (d, *J* = 8.2 Hz, 2H), 7.84-7.79 (m, 3H), 7.66 (d, *J* = 8.3 Hz, 2H), 7.41 (d, *J* = 8.2 Hz, 2H), 7.29 (s, 1H), 5.63 (br s, 2H); ESIMS *m/z* 348 (M+H).

Step 2. To a 25 mL round-bottomed flask containing (*E*)-3-(4-(hydrazonomethyl)-phenyl)-1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazole (250 mg, 0.720 mmol) in THF (10 mL) was added 4-isothiocyanato-*N,N*-dimethylaniline (385 mg, 2.16 mmol). The contents
 30 were heated at 65 °C with stirring for 2 h before the solvent was removed under reduced pressure. The residue was slurried in CH₂Cl₂ (10 mL) resulting in precipitation of product material. The desired product was obtained as a yellow solid via vacuum filtration (350 mg,

93%): mp 205 – 208 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.78 (s, 1H), 10.02 (s, 1H), 9.42 (s, 1H), 8.19-7.99 (m, 6H), 7.64 (d, *J* = 8.3 Hz, 2H), 7.28 (d, *J* = 8.3 Hz, 2H), 7.73 (d, *J* = 8.3 Hz, 2H), 2.92 (s, 6H); ESIMS *m/z* 526 (M+H).

5 **Example 2: Preparation of *N*-(3-(dimethylamino)phenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (Compound I-2) [Synthesis Method B].**



10


Step 1. (*E*)-Methyl 2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbodithioate. To a 250 mL round-bottom flask containing hydrazinecarbodithioic acid methyl ester (2.38 g, 1.95 mmol) in EtOH (100 mL) was added 4-[1-(4-trifluoromethoxyphenyl)-1*H*-[1,2,4]triazol-3-yl]-benzaldehyde (5.00 g, 1.50 mmol).

15 The vessel was heated at 80 °C for 3 h before being diluted with H₂O (300 mL) and cooled to 0 °C. The precipitated product was collected by vacuum filtration as an off-white solid (6.13 g, 93%): mp 204 – 206 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.39 (s, 1H), 9.43 (s, 1H), 8.38 (s, 1H), 8.21 (d, *J* = 8.3 Hz, 2H), 8.09 (d, *J* = 8.4 Hz, 2H), 7.88 (d, *J* = 8.4 Hz, 2H), 7.62 (d, *J* = 8.3 Hz, 2H), 2.57 (s, 3H); ESIMS *m/z* 438 (M+H).

20 **Step 2.** To a 50 mL round-bottomed flask containing (*E*)-methyl 2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbodithioate (250 mg, 0.571 mmol) in DMF (3 mL) was added *N*1,*N*1-dimethylbenzene-1,3-diamine (195 mg, 1.43 mmol). The contents were heated at 150 °C with stirring for 5 h before the solution was allowed to cool overnight. The mixture was filtered, and the filtrate was purified via RP-

25 HPLC to afford the desired material (235 mg, 78%) as an off-white solid: mp 192 – 194 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.82 (s, 1H), 10.04 (s, 1H), 9.41 (s, 1H), 8.19 (s, 1H), 8.16-7.99 (m, 6H), 7.61 (d, *J* = 8.3 Hz, 2H), 7.16 (t, *J* = 7.2 Hz, 1H), 7.01 (m, 1H), 6.87 (m, 1H), 6.58 (m, 1H), 2.88 (s, 6H); ESIMS *m/z* 526 ([M+H]⁺).


30 **Example 3: Preparation of *N*-benzyl-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (Compound I-3) [Synthesis Method C].**



To a 50 mL round-bottomed flask containing 4-[1-[4-(trifluoromethoxy)phenyl]-
 5 1,2,4-triazol-3-yl]benzaldehyde (500 mg, 1.5 mmol) in EtOH (3 mL) was added 4-
 benzylthiosemicarbazide (650 mg, 3.6 mmol). The reaction mixture was heated at 80 °C
 overnight. H₂O was added upon completion of the reaction, and the crude product material
 was isolated by vacuum filtration. The title compound was isolated via RP-HPLC as a white
 solid (390 mg, 52%): mp 220 – 224 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.29 (s, 1H), 8.59 (s,
 10 1H), 8.21 (d, *J* = 8.4 Hz, 2H), 7.85-7.79 (m, 3H), 7.71 (d, *J* = 8.4 Hz, 2H), 7.46-7.30 (m, 8H),
 5.01 (d, *J* = 5.8 Hz, 2H); ESIMS *m/z* 497.2 (M+H).

Compounds **I-4** through **I-31** in Table 1 were synthesized in accordance with the
 examples above. Other intermediates used in the preparation of compounds of this invention
 15 were prepared in accordance with the procedures described in Brown, et al, WO 2011017504
 A1, or by other known routes.

**Example 4: Preparation of *N*-(4-dimethylaminophenyl)-*S*-methyl-2-{4-[1-(4-
 trifluoromethoxyphenyl)-1*H*-[1,2,4]-triazol-3-yl]-benzylidene}-hydrazine-
 20 carbothioamide (Compound 1C) (Synthesis Method D)**




A solution containing (*E*)-*N*-(4-(dimethylamino)phenyl)-2-(4-(1-(4-
 25 (trifluoromethoxy)-phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (150
 mg, 0.285 mmol) and iodomethane (0.054 mL, 0.856 mmol) in EtOH (5 mL) was heated at
 80 °C for 3 h before the solvent was removed under reduced pressure. The residue was
 purified via normal phase flash chromatography (gradient elution with hexanes/EtOAc) to
 afford the title compound as an orange foam (93 milligrams (mg), 60%): ¹H NMR (400

MHz, DMSO-*d*₆) δ 8.61 (s, 1H), 8.48 (s, 1H), 8.22 (d, *J* = 8.24 Hz, 2H), 8.17 (s, 1H), 7.89 (d, *J* = 8.24 Hz, 2H), 7.80 (d, *J* = 8.28 Hz, 2H), 7.41 (d, *J* = 8.28 Hz, 2H), 7.19 (d, *J* = 8.24 Hz, 2H), 6.71 (d, *J* = 8.24 Hz, 2H), 2.99 (s, 6H), 2.42 (s, 3H); EIMS *m/z* 540 (*M*⁺).

5 Example 5: General procedure for S-alkylation of triaryl thiosemicarbazones (Synthesis Method E)

A stirred solution of the thiosemicarbazone and alkylating reagent in CH₂Cl₂ or chloroform (CHCl₃) was heated at from 35 to 50 °C for from 10 to 24 h. The cooled solution was concentrated under reduced pressure. The residue was generally purified via chromatography using a chloroform/methanol (CHCl₃/CH₃OH) or EtOAc-hexane solution as the eluent to afford the S-alkylated products.


Example 6: Preparation of (*S*)-*tert*-butyl 3-((2-((*Z*)-(2,6-dimethylphenylimino)-((*E*)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinyl)-methylthio)acetamido)methyl)piperidine-1-carboxylate (Compound 56C) (Synthesis Method E)



To a solution of bromoacetyl bromide (26 microliters (μL), 0.299 mmol) in dichloroethane (3 mL) was added dropwise a solution of (*S*)-*tert*-butyl 3-(aminomethyl)piperidine-1-carboxylate (63.9 mg, 0.298 mmol) in dichloromethane (1 mL), followed by *N*-ethyl-*N*-isopropylpropan-2-amine (76 mg, 0.588 mmol). This mixture was stirred at room temperature for 30 min, then (*E*)-*N*-(2,6-dimethylphenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazine-carbothioamide (100 mg, 0.196 mmol) was added as a solid and the mixture was heated to 40 °C for 90 min. It was then allowed to cool to room temperature and evaporated under reduced pressure, giving a light yellow glass, which was dissolved in acetonitrile (2 mL) and allowed to stand at room temperature. The resulting precipitate was isolated by centrifuge and decanting, washing with

fresh acetonitrile. The solid was dried under a nitrogen stream and then under high vacuum. The crude product was recrystallized from acetone-isopropyl alcohol. The title compound was isolated as a white solid (36.5 mg, 24%): mp 148 – 151 °C; ¹H NMR (400 MHz, methanol-*d*₄) δ 9.18 (s, 1H), 8.59 (s, 1H), 8.30 (d, *J* = 8.1 Hz, 2H), 8.12 (m, 2H), 8.07 – 8.00 (m, 2H), 7.58 – 7.43 (m, 2H), 7.33 (dd, *J* = 8.6, 6.5 Hz, 1H), 7.25 (d, *J* = 7.6 Hz, 2H), 4.02 (m, 2H), 3.97 – 3.75 (m, 2H), 3.21 (d, *J* = 6.9 Hz, 2H), 2.90 (m, 1H), 2.59 (m, 1H), 2.35 (s, 6H), 1.84 (m, 2H), 1.78 – 1.63 (m, 2H), 1.44 (s, 9H), 1.29 (m, 3H); ESIMS *m/z* 765 (M+H).


Example 7: Preparation of (1*Z*,2*E*)-2-oxo-2-(((*R*)-piperidin-3-ylmethyl)amino)ethyl *N*-(2,6-dimethylphenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbimidothioate trifluoroacetic acid (Compound 62C) (Synthesis Method K)



A solution of (*S*)-*tert*-butyl 3-((2-((*Z*)-(2,6-dimethylphenylimino)-((*E*)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinyl)methylthio)-acetamido)methyl)piperidine-1-carboxylate (32.0 mg, 0.042 mmol) in TFA (250 μL, 3.24 mmol) was stirred at room temperature for 10 min. Et₂O (10 mL) was then added giving a white precipitate, which was isolated by centrifuge and decanting, then rinsing with fresh Et₂O (5 mL). The solid was dried under nitrogen stream and then under high vacuum giving the title compound as a white solid (19.8 mg, 60%): mp 110 – 120 °C; ¹H NMR (400 MHz, methanol-*d*₄) δ 9.18 (s, 1H), 8.56 (m, 1H), 8.26 (m, 2H), 8.16 – 7.84 (m, 4H), 7.52 (m, 2H), 7.27 (m, 1H), 7.22 (m, 2H), 4.00 (s, 2H), 3.28 (m, 3H), 3.06 – 2.83 (m, 1H), 2.75 (t, *J* = 12.2 Hz, 1H), 2.34 (s, 6H), 2.21 – 1.83 (m, 4H), 1.72 (m, 1H), 1.47 – 1.19 (m, 2H); ESIMS *m/z* 665 (M+H).

Example 8: Preparation of 2-(((*Z*)-((4-methoxy-2,6-dimethylphenyl)imino)((*E*)-2-(4-(1-

(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinyl)methyl)-thio)acetic acid sodium salt (Compound 68C)




5

To a solution of 2-((*Z*)-(4-methoxy-2,6-dimethylphenylimino)((*E*)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinyl)methylthio)acetic acid (77.7 mg, 0.130 mmol) in THF (10 mL) was added slowly sodium methanolate (0.5 M in methanol; 260 μ L, 0.130 mmol) at room temperature. The mixture immediately turned a darker yellow and was then evaporated at room temperature under vacuum giving a light orange solid. This material was triturated with Et₂O (2X) and isolated by decanting using a centrifuge and drying under a nitrogen stream and then under high vacuum. The title compound was isolated as a light orange solid (32 mg, 39%). mp 146 – 154 °C; ¹H NMR (400 MHz, methanol-*d*₄) δ 9.11 (s, 1H), 8.64 – 7.68 (m, 7H), 7.51 (m, 2H), 6.70 (s, 2H), 3.85 – 3.70 (m, 4H), 3.61 (m, 1H), 2.29 (s, 6H); ESIMS *m/z* 599 (M+H).

15

Example 9: Preparation of (*Z*)-3-(4-methoxy-2,6-dimethylphenyl)-2-((*E*)-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazono)thiazolidin-4-one (Compound 69C) (Synthesis Method F)

20




To a solution of (*E*)-*N*-(4-methoxy-2,6-dimethylphenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazine-carbothioamide (250 mg, 0.462 mmol) in EtOH (5 mL) was added methyl bromoacetate (100 mg, 0.65 mmol), and

25


the mixture was heated to 70 °C for 4 h. The mixture was allowed to cool to room temperature and diluted with water (1 mL). The precipitate was vacuum filtered, giving the title compound as a white solid (204 mg, 76%): mp 188 – 190 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.56 (s, 1H), 8.33 (s, 1H), 8.22 (d, *J* = 8.1 Hz, 2H), 7.90 – 7.70 (m, 4H), 7.39 (d, *J* = 8.7 Hz, 2H), 6.72 (s, 2H), 4.01 (s, 2H), 3.87 – 3.73 (s, 3H), 2.18 (s, 6H); ESIMS *m/z* 581 (M+H).

Example 10: Preparation of 4-((2*Z*)-3-(2,6-dimethylphenyl)-2-((4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazono)-2,3-dihydrothiazol-4-yl)-*N,N*-diethylaniline (Compound 74C) (Synthesis Method G)



To a solution of (E)-N-(2,6-dimethylphenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazine-carbothioamide (74.7 mg, 0.144 mmol) in dichloroethane (5 mL), was added α-bromo-4-diethylamino)acetophenone (53.9 mg, 0.199 mmol), and the mixture was heated to 40 °C for 4 h. The mixture was then cooled to room temperature and evaporated under vacuum. The crude material was triturated with acetonitrile and decanted (2X). The resulting solid was dried under a stream of nitrogen, giving the title compound as a pale yellow solid (25 mg, 25%): mp 190 – 193 °C dec; ¹H NMR (400 MHz, methanol-*d*₄) δ 9.20 (s, 1H), 8.38 (s, 1H), 8.31 – 8.24 (m, 2H), 8.08 – 8.00 (m, 2H), 7.95 – 7.88 (m, 2H), 7.55 – 7.48 (m, 3H), 7.48 – 7.36 (m, 5H), 7.31 (d, *J* = 7.7 Hz, 2H), 3.60 (q, *J* = 7.2 Hz, 4H), 2.20 (s, 6H), 1.07 (t, *J* = 7.2 Hz, 6H); ESIMS *m/z* 682 (M+H).

Example 11: Preparation of (Z)-2-(2,6-dimethylphenylimino)-3-((E)-4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylideneamino)thiazolidin-4-one (Compound 81C) (Synthesis Method I)




To a solution of 1-(2,6-dimethylphenyl)thiourea (1.0 g, 5.55 mmol) in EtOH (10 mL) was added methyl 2-bromoacetate (1.0 g, 6.5 mmol) and sodium acetate (1.0 g, 12.2 mmol).

- 5 The solution was stirred and heated to reflux for 1 h, then it was cooled and the liquid was decanted from a small amount of solid material and the liquid was then diluted with water (10 mL). The precipitate was isolated by filtration to give (1.1 g, 83%) of (Z)-3-amino-2-(2,6-dimethylphenylimino)thiazolidin-4-one: mp 149 – 152 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.06 (d, *J* = 7.2 Hz, 2H), 6.98 (m, 1H), 4.75 (s, 2H), 3.80 (s, 2H), 2.12 (s, 6H); ESIMS *m/z* 236 (M+H).


- 10 A portion of this material (0.07 g, 0.3 mmol) was dissolved in glacial acetic acid (3 mL) and treated with 4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzaldehyde (0.10 g, 0.30 mmol), and the solution was heated to 60 °C for 2 h. The solution was then cooled and diluted with water (1 mL), and the resulting solid was filtered and air-dried to give the title compound (0.12 g, 67%): mp 209 – 213 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.42 (s, 1H), 8.59 (s, 1H), 8.28 (d, *J* = 8.4 Hz, 2H), 8.01 (d, *J* = 8.3 Hz, 2H), 7.80 – 7.77 (m, 2H), 7.43 – 7.34 (m, 2H), 7.07 (d, *J* = 7.5 Hz, 2H), 6.98 (dd, *J* = 8.2, 6.7 Hz, 1H), 3.90 (s, 2H), 2.17 (s, 6H); ESIMS *m/z* 551 (M+H).

- 20 **Example 12: Preparation of (2*Z*,*NE*)-2-((2-isopropylphenyl)imino)-N-(4-(1-(4-(trifluoromethyl)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)-1,3-thiazinan-3-amine and (Z)-3-(2-isopropylphenyl)-2-((*E*)-(4-(1-(4-(trifluoromethyl)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazono)-1,3-thiazinane (Compound 87C and 179C) (Synthesis Method J)**




To (*E*)-*N*-(2-isopropylphenyl)-2-(4-(1-(4-(trifluoromethyl)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (200 mg, 0.393 mmol) and potassium carbonate (217 mg, 1.57 mmol) in butanone (10 ml) in a 25 mL vial equipped with a stir bar and vigreux column was added 1-bromo-3-chloropropane (0.047 ml, 0.472 mmol). The reaction was heated to 60 °C overnight. The reaction was determined to be complete by LCMS. The reaction mixture was diluted with DCM and washed with water. The aqueous layer was extracted with DCM. The organic layers were poured through a phase separator and concentrated. Purification by flash column chromatography provided two compounds. The minor compound was dried overnight under house vacuum providing the title compound **87C** (*2Z,NE*)-2-((2-isopropylphenyl)imino)-*N*-(4-(1-(4-(trifluoromethyl)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)-1,3-thiazinan-3-amine (28.5 mg, 13%) as a yellow solid: mp 187-189 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.81 (s, 1H), 8.66 (s, 1H), 8.21 (d, *J* = 8.3 Hz, 2H), 7.92 (d, *J* = 8.4 Hz, 2H), 7.81 (t, *J* = 10.2 Hz, 4H), 7.30 – 7.26 (m, 2H), 7.17 – 7.04 (m, 1H), 6.83 (d, *J* = 6.4 Hz, 1H), 3.96 (t, *J* = 6.1 Hz, 2H), 3.13 (heptet, *J* = 6.9 Hz, 1H), 2.97 – 2.90 (m, 2H), 2.47 – 2.38 (m, 2H), 1.25 (d, *J* = 7.5 Hz, 6H); ESIMS *m/z* 550 (M+H). The major compound was recrystallized with MeOH. The solid was filtered, washed with MeOH and dried at 50°C under vacuum. The solid was then azeotroped with acetone (3x) and the resultant solid was dried at 50°C under vacuum providing the title compound **179C** (*Z*)-3-(2-isopropylphenyl)-2-((*E*)-(4-(1-(4-(trifluoromethyl)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazono)-1,3-thiazinane as a yellow solid (92.3 mg, 0.168 mmol, 43%): mp 212-213 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.64 (s, 1H), 8.15 (d, *J* = 8.4 Hz, 2H), 8.06 (s, 1H), 7.91 (d, *J* = 8.5 Hz, 2H), 7.79 (d, *J* = 8.6 Hz, 2H), 7.75 (d, *J* = 8.4 Hz, 2H), 7.38 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.33 (td, *J* = 7.5, 1.4 Hz, 1H), 7.29 – 7.23 (m, 1H), 7.18 (dd, *J* = 7.8, 1.4 Hz, 1H), 3.78 – 3.72 (m, 1H), 3.59 – 3.48 (m, 1H), 3.18 – 3.04 (m, 3H), 2.40 – 2.30 (m, 2H), 1.26 – 1.20 (m, 6H); ESIMS *m/z* 550 (M+H).

Example 13: Preparation of (*Z*)-3-(2-cyclopropylphenyl)-5-methyl-2-((*E*)-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazono)thiazolidin-4-one (Compound 127C) (Synthesis Method F)



To (*E*)-*N*-(2-cyclopropylphenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (100 mg, 0.191 mmol) and sodium acetate (63.0 mg, 0.765 mmol) in EtOH (4 mL) was added methyl 2-bromopropanoate (0.026 mL, 0.230 mmol). The reaction was heated to 60 °C overnight. The reaction was then heated to 85 °C for 72 hours. The reaction mixture was diluted with DCM and washed with water. The aqueous layer was extracted with DCM. The organic layers were poured through a phase separator and concentrated. Purification by flash column chromatography provided the title compound as a white solid (32.5 mg, 0.056 mmol, 30%): mp 112 – 115 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.58 (s, 1H), 8.32 (s, 1H), 8.22 (d, *J* = 8.3 Hz, 2H), 7.87 – 7.75 (m, 4H), 7.43 – 7.32 (m, 4H), 7.26 – 7.24 (m, 2H), 4.23 (q, *J* = 7.3 Hz, 1H), 1.85 – 1.78 (m, 4H), 0.90 – 0.78 (m, 2H), 0.78 – 0.69 (m, 1H), 0.65 – 0.55 (m, 1H); ESIMS *m/z* 578 (M+H).


Example 14: Preparation of (*Z*)-3-(2-isopropylphenyl)-2-((*E*)-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazono)thiazolidine (Compound 132C) (Synthesis Method J)



To (*E*)-*N*-(2-isopropylphenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (214 mg, 0.407 mmol) and potassium carbonate (225 mg, 1.63 mmol) in butanone (4 mL) was added 1-bromo-2-chloroethane (70.0 mg, 0.489 mmol). The reaction was heated to 90 °C overnight. The reaction was determined to be complete by LCMS. The reaction mixture was cooled, diluted with DCM and washed with water. The aqueous layer was extracted with DCM. The organic layers were filtered through

a phase separator and concentrated. Separation by flash column chromatography and drying the recovered solid at 55 °C under vacuum provided the title compound as a white solid (137 mg, 0.249 mmol, 61%): mp 193 – 196 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.56 (s, 1H), 8.22 (s, 1H), 8.17 (d, *J* = 8.4 Hz, 2H), 7.80 (ddd, *J* = 9.5, 6.9, 4.9 Hz, 4H), 7.43 – 7.33 (m, 4H), 7.31 – 7.21 (m, 2H), 4.05 (td, *J* = 9.4, 7.1 Hz, 1H), 3.97 – 3.87 (m, 1H), 3.42 – 3.33 (m, 1H), 3.33 – 3.24 (m, 1H), 3.12 (heptet, *J* = 6.8 Hz, 1H), 1.27 (d, *J* = 6.8 Hz, 3H), 1.22 (d, *J* = 6.9 Hz, 3H); ESIMS *m/z* 552 (M+H).


Example 15: Preparation of (Z)-3-(2-isopropylphenyl)-4-methyl-2-((E)-(4-(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,4-triazol-3-yl)benzylidene)hydrazono)thiazolidine (Compound 155C) (Synthesis Method J)



To (*E*)-*N*-(2-isopropylphenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (300 mg, 0.572 mmol) and potassium carbonate (316 mg, 2.29 mmol) in butanone (4 ml) was added 1,2-dibromopropane (0.072 ml, 0.686 mmol). The reaction was heated to 85 °C overnight. The reaction was determined to be complete by LCMS. The reaction mixture was diluted with DCM and washed with water. The aqueous layer was extracted with DCM. The organic layers were poured through a phase separator and concentrated. Purification by flash column chromatography provided a yellow solid. The solid was recrystallized from MeOH. The solid was filtered, washed with MeOH, and dried to provide the title compound as a yellow solid which was dissolved in acetone and concentrated (3x). The light yellow solid was collected and dried under to provide the title compound as a 1:1 mixture of rotational diastereoisomers (75.1 mg, 0.133 mmol, 23%): mp 201 – 204 °C; ¹H NMR of mixture (400 MHz, CDCl₃) δ 8.56 (s, 2H), 8.18 (dd, *J* = 10.8, 7.4 Hz, 6H), 7.84 – 7.73 (m, 8H), 7.45 – 7.30 (m, 8H), 7.30 – 7.23 (m, 2H), 7.20 (d, *J* = 6.7 Hz, 1H), 7.12 (dd, *J* = 7.8, 1.2 Hz, 1H), 4.43 – 4.33 (m, 1H), 4.16 (dd, *J* = 12.6, 6.3 Hz, 1H), 3.48 (dt, *J* = 13.3, 6.7 Hz, 1H), 3.37 (dd, *J* = 10.8, 6.2 Hz, 1H), 3.24 (dt, *J* = 13.7, 6.9 Hz, 1H), 3.08 – 2.92 (m, 3H), 1.33 – 1.16 (m, 18H); ESIMS *m/z* 566 (M+H).

Example 16: Preparation of (Z)-3-(2,6-dimethylphenyl)-4-methyl-2-((E)-(4-(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,4-triazol-3-yl)benzylidene)hydrazono)-2,3-dihydrothiazole (Compound 173C) (Synthesis Method G)


5



To a solution of (*E*)-*N*-(*o*-tolyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (257 mg, 0.520 mmol) in butanone (5 mL) was added triethylamine (0.14 mL, 1.0 mmol) and chloroacetone (0.06 mL, 0.73 mmol) and refluxed at 75 °C for 15 h. The mixture was allowed to cool to room temperature and then transferred to a separatory funnel containing water (5 mL) and extracted twice with dichloromethane. The organic layers were filtered through a phase separator, adsorbed onto silica gel, and purified by flash column chromatography to afford the title compound as a yellow solid (229 mg, 83%): mp 87 °C (dec); ¹H NMR (400 MHz, CDCl₃) δ 8.56 (s, 1H), 8.19-8.15 (m, 3H), 7.82 – 7.75 (m, 4H), 7.43 – 7.30 (m, 5H), 7.24 (d, *J* = 7.3 Hz, 1H), 5.88 (d, *J* = 1.3 Hz, 1H), 2.21 (s, 3H), 1.80 (d, *J* = 1.2 Hz, 3H); ESIMS *m/z* 536 (M+H).

Example 17: Preparation of (Z)-3-(2-isopropylphenyl)-5-methyl-2-((E)-(4-(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,4-triazol-3-yl)benzylidene)hydrazono)-1,3-thiazinane (Compound 178C) (Synthesis Method J)

20



25


To (*E*)-*N*-(2-isopropylphenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (100 mg, 0.191 mmol) and potassium carbonate (105 mg, 0.763 mmol) in butanone (4 mL) was added 1-bromo-3-chloro-2-methylpropane (39.0 mg, 0.229 mmol). The reaction was heated to 80 °C overnight. The reaction mixture

was then diluted with DCM and washed with water. The aqueous layer was extracted with DCM. The organic layers were poured through a phase separator and concentrated.

Purification by flash column chromatography provided the title compound as a light yellow solid as a mixture of rotational diastereoisomers: mp 186 – 190 °C; ¹H NMR (400 MHz,

5 CDCl₃) δ 8.55 (d, *J* = 3.6 Hz, 1H), 8.14 (d, *J* = 8.4 Hz, 2H), 8.06 (s, 1H), 7.84 – 7.77 (m, 2H), 7.74 (d, *J* = 8.4 Hz, 2H), 7.38 (d, *J* = 9.0 Hz, 3H), 7.32 (td, *J* = 7.5, 1.4 Hz, 1H), 7.26 (s, 1H), 7.17 (t, *J* = 7.1 Hz, 1H), 3.69 – 3.26 (m, 1H), 3.55 – 3.37 (m, 1H), 3.18 – 2.98 (m, 2H), 2.93 – 2.80 (m, 1H), 2.47 (d, *J* = 35.9 Hz, 1H), 1.31 – 1.12 (m, 9H); ESIMS *m/z* 580 (M+H).

10 **Example 18: Preparation of (*Z*)-3-(2,6-dimethylphenyl)-2-((*E*)-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazono)-1,3-thiazepane (Compound 211C) (Synthesis Method J)**



15

To (*E*)-*N*-(2,6-dimethylphenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (500 mg, 0.979 mmol) and potassium carbonate (541 mg, 3.92 mmol) in acetone (4 ml) was added 1-bromo-4-chlorobutane (0.135 ml, 1.18 mmol). The reaction was heated to 60 °C overnight. The alkylation was determined

20 to be complete by ultra performance liquid chromatography (“UPLC”). The reaction mixture was diluted with DCM and washed with water. The aqueous layer was extracted with DCM. The organic layers were poured through a phase separator and concentrated. Purification by flash column chromatography provided (1*Z,N'E*)-4-chlorobutyl *N*-(2,6-dimethylphenyl)-*N'*-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)carbamo

25 hydrazonothioate (427 mg, 0.710 mmol, 73%) as a yellow gum which was used without further purification. To (1*Z,N'E*)-4-chlorobutyl *N*-(2,6-dimethylphenyl)-*N'*-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)-carbamo hydrazonothioate (427 mg, 0.710 mmol), potassium iodide (236 mg, 1.42 mmol) and potassium carbonate (393 mg, 2.84 mmol) was added acetone (7 ml). The reaction was heated to 65°C for 72 h. The reaction


30 was cooled to room temperature, diluted with DCM and washed with water. The aqueous

layer was extracted with DCM. The organic layers were poured through a phase separator and concentrated. Purification by flash column chromatography provided a yellow oil. The yellow oil was recrystallized from MeOH, filtered, washed with MeOH and dried to provide the title compound as a yellow solid (100 mg, 0.177 mmol, 25%): mp 100 – 106 °C; ¹H

5 NMR (400 MHz, CDCl₃) δ 8.55 (s, 1H), 8.15 (d, *J* = 8.4 Hz, 2H), 8.10 (s, 1H), 7.79 (dt, *J* = 10.4, 5.8 Hz, 4H), 7.38 (d, *J* = 8.3 Hz, 2H), 7.11 (s, 3H), 3.85 – 3.78 (m, 2H), 3.20 – 3.12 (m, 2H), 2.30 (s, 6H), 2.13 – 2.07 (m, 2H), 1.87 – 1.82 (m, 2H); ESIMS *m/z* 566 (M+H).

Example 19: Preparation of (Z)-3-(2-isopropylphenyl)-2-((E)-4-(1-(4-

10 **(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazono)-1,3-thiazinan-4-one (Compound 224C) (Synthesis Method L)**




15 To (*E*)-*N*-(2-isopropylphenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (500 mg, 0.953 mmol) in butanone (9.5 ml) was added acryloyl chloride (0.077 ml, 0.953 mmol). The reaction was stirred at ambient temperature for 10 min followed by 50 °C for 2 h. The reaction was cooled to 40 °C overnight. The reaction was determined to be complete by LCMS. The reaction mixture was

20 diluted with DCM and washed with saturated sodium bicarbonate. The aqueous layer was extracted with DCM. The organic layers were poured through a phase separator and concentrated. Purification by flash column chromatography provided a yellow oil. The oil was recrystallized with diethyl ether/hexanes to provide the title compound as a light yellow solid (125 mg, 0.217 mmol, 23%): mp 118 °C (dec); ¹H NMR (400 MHz, CDCl₃) δ 8.57 (s,

25 1H), 8.21 (d, *J* = 8.4 Hz, 2H), 8.16 (s, 1H), 7.85 – 7.75 (m, 4H), 7.46 – 7.36 (m, 4H), 7.33 – 7.26 (m, 1H), 7.10 (d, *J* = 7.6 Hz, 1H), 3.26 – 3.14 (m, 4H), 2.81 (heptet, *J* = 6.9 Hz, 1H), 1.21 (t, *J* = 7.2 Hz, 6H); ESIMS *m/z* 580 (M+H).

Example 20: Preparation of (Z)-3-(2,6-difluorophenyl)-2-((E)-4-(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,4-triazol-3-yl)benzylidene)hydrazono)-1,3-thiazetidine (Compound 245C) (Synthesis Method J)



5

To a mixture of (*E*)-N-(2,6-difluorophenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1H-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (0.50 g, 0.96 mmol) and potassium carbonate (0.53 g, 3.9 mmol) in butanone (10 mL) in a 25 mL vial equipped with a magnetic stir bar was added diiodomethane (0.093 mL, 1.2 mmol). The reaction was heated to 55 °C and stirred for two days. The reaction mixture was diluted with DCM, washed with water, and the phases separated. The aqueous phase was extracted with DCM and the combined organic phases were dried by passing through a phase separator cartridge and then concentrated. Purification by flash column chromatography provided a yellow oil which crystallized upon standing. The solid was slurried in diethyl ether and hexanes and collected by vacuum filtration. The solid was washed with hexanes and dried to provide the title compound (0.086 g, 0.16 mmol, 17%) as a light yellow solid: mp 144 – 146 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.58 (s, 1H), 8.34 (s, 1H), 8.20 (d, *J* = 8.3 Hz, 2H), 7.81 (d, *J* = 8.8 Hz, 4H), 7.40 (d, *J* = 8.3 Hz, 2H), 7.31 – 7.23 (m, 1H), 7.03 – 6.97 (m, 2H), 5.05 (s, 2H); ESIMS *m/z* 532 (M+H).

20

Compounds **240 – 244** and **246 – 261**, shown in Table 3, were prepared according to the method described in Example 20 from the appropriately substituted intermediates disclosed in Table 1. Characterization data for these compounds is reported in Table 4.

25

Example 21: Separation of rotationally stable atropisomers from racemic mixtures


Separation of constituent isomers from racemic mixtures can be carried out utilizing one of the following chiral HPLC methods.

30

Separation Method A: The column used for separation was a Chiral Technologies INC Chiral Pak 1A 5 μm , 4.6 X 250 mm column (Part number 80325). The method consists of a 1.0 mL/min flow rate from 0 to 30 min with an isocratic hold at 25% B for the duration of the run. The A eluent is *n*-hexane, the B eluent is *iso*-propyl alcohol.

Separation Method B: The column used for separation was a Chiral Technologies INC Chiral Pak 1B 5 μm , 4.6 X 250 mm column (Part number 81325). The method consists of a 1.0 mL/min flow rate from 0 to 30 min with an isocratic hold at 15% B for the duration of the run. The A eluent is *n*-pentane, the B eluent is *n*-butyl alcohol.

Example 22: Preparation of (*E*)-*N*-(2-fluoro-6-isopropylphenyl)-2-(4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (Compound I-40; Synthesis Method C)



Step 1: Preparation of 1-fluoro-2-nitro-3-(prop-1-en-2-yl)benzene (I-37, Method M). To a mixture of 1-bromo-3-fluoro-2-nitrobenzene (0.953 g, 4.33 mmol) in a 100 mL round-bottomed flask equipped with a magnetic stir bar and nitrogen inlet were added dioxane (17.3 mL), sodium carbonate (0.551 g, 5.20 mmol), water (4.33 mL), and 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (0.977 mL, 5.20 mmol). To this mixture was added bis(triphenyl-phosphine)palladium(II)chloride (0.243 g, 0.347 mmol). The flask was evacuated and purged with nitrogen (3 x) and then heated to 80 °C and stirred overnight. The reaction was cooled to room temperature, filtered through Celite ®, and the pad was washed with ethyl acetate. The phases were separated and the organic phase was

concentrated. Purification by flash column chromatography provided the title compound (0.590 g, 3.26 mmol, 75 % yield) as a light yellow oil: ^1H NMR (400 MHz, CDCl_3) δ 7.48 – 7.36 (m, 1H), 7.21 – 7.06 (m, 2H), 5.23 (p, J = 1.5 Hz, 1H), 5.05 (q, J = 1.1 Hz, 1H), 2.09 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 153.56 (d, J_{CF} = 257.5 Hz), 139.62, 139.60, 138.83, 131.48 (d, J_{CF} = 8.6 Hz), 124.47 (d, J_{CF} = 3.6 Hz), 117.60, 115.51 (d, J_{CF} = 19.1 Hz), 23.18.

Step 2: Preparation of 2-fluoro-6-isopropylaniline (I-38, Method M). To a solution of 1-fluoro-2-nitro-3-(prop-1-en-2-yl)benzene (0.590 g, 3.26 mmol) in ethyl acetate (32.6 mL) in a 250 mL round-bottomed flask equipped with a magnetic stir bar and nitrogen inlet was added palladium on carbon (5% Pd / C, 0.693 g, 0.326 mmol). The reaction flask was evacuated and purged with hydrogen (2 x) and then placed under 1 atmosphere (atm) of hydrogen and stirred at room temperature overnight. The reaction was filtered through Celite® and the pad was washed with ethyl acetate. The filtrate was concentrated to give the title compound (0.423 g, 2.76 mmol, 85 % yield) as clear and colorless oil: IR (neat) 3476 (m), 3392 (m), 2966 (m), 2872 (m), 1628 (s), 1474 (s), 1270 (m) cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 6.92 (dt, J = 7.7, 1.2 Hz, 1H), 6.86 (ddd, J = 10.8, 8.1, 1.4 Hz, 1H), 6.69 (td, J = 8.0, 5.6 Hz, 1H), 3.71 (bs, 2H), 2.92 (hept, J = 6.8 Hz, 1H), 1.26 (d, J = 6.8 Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 151.91 (d, J = 237.6 Hz), 135.10 (d, J = 2.3 Hz), 131.60 (d, J = 11.8 Hz), 120.52 (d, J = 3.0 Hz), 117.99 (d, J = 8.0 Hz), 112.28 (d, J = 19.6 Hz), 27.77 (d, J = 2.9 Hz), 22.22.

Step 3: Preparation of *N*-(2-fluoro-6-isopropylphenyl)hydrazinecarbothioamide (I-39, Method M). To a 100 mL round-bottomed flask equipped with a stir bar and nitrogen inlet were added 2-fluoro-6-isopropylaniline (0.415 g, 2.71 mmol), dichloromethane (13.6 mL), water (6.78 mL), and sodium bicarbonate (0.683 g, 8.13 mmol). To this biphasic mixture was added thiophosgene (0.199 mL, 2.60 mmol) and the reaction was stirred vigorously for 2 hours. The suspension was filtered through a phase separator cartridge and the organic phase was concentrated in a 100 mL round-bottomed flask. The flask was equipped with a magnetic stir bar and nitrogen inlet and the residue was dissolved in ethanol (6.78 mL). To the resulting solution was added hydrazine hydrate (0.131 mL, 2.71 mmol) and the reaction was stirred at room temperature for 2 days. The solution was concentrated and the resulting residue was suspended in a mixture of diethyl ether and hexanes and re-concentrated to give a solid. The solid was suspended in a minimal amount of diethyl ether and the mixture was diluted with hexanes. The majority of the diethyl ether was evaporated and the resulting solid was collected by vacuum filtration, washed with hexanes and then dried under house vacuum to provide the title compound (0.518 g, 2.28 mmol, 84 % yield) as

a white solid: mp 122-124 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.56 (bs, 1H), 7.52 (bs, 1H), 7.32 (td, *J* = 8.1, 5.6 Hz, 1H), 7.17 – 7.12 (m, 1H), 7.00 (ddd, *J* = 9.5, 8.2, 1.4 Hz, 1H), 4.07 (bs, 2H), 3.15 (hept, *J* = 7.0 Hz, 1H), 1.24 (d, *J* = 6.9 Hz, 6H); ESIMS *m/z* 229 ([M+H]⁺).

Step 4: Preparation of (*E*)-*N*-(2-fluoro-6-isopropylphenyl)-2-(4-(1-(4-

(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzylidene)hydrazinecarbothioamide (I-40, Method C). To a solution of 4-(1-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,4-triazol-3-yl)benzaldehyde (0.760 g, 2.28 mmol) in methanol (22.8 mL) in a 100 mL round-bottomed flask equipped with a magnetic stir bar and reflux condenser was added *N*-(2-fluoro-6-isopropylphenyl)hydrazinecarbothioamide (0.518 g, 2.28 mmol), and the reaction was heated to 65°C and stirred for 6 hours. The temperature was lowered to 50°C and the reaction was stirred overnight. The reaction was cooled to room temperature and the resulting solid was filtered, washed with methanol, and dried under vacuum (25 in Hg) at 55 °C to give the title compound (0.907 g, 1.67 mmol, 73 % yield) as a white solid: mp 210-212 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.54 (s, 1H), 8.60 (s, 1H), 8.56 (s, 1H), 8.30 – 8.22 (m, 2H), 7.92 (s, 1H), 7.86 – 7.76 (m, 4H), 7.44 – 7.38 (m, 2H), 7.35 (dd, *J* = 8.1, 5.6 Hz, 1H), 7.18 (d, *J* = 7.9 Hz, 1H), 7.04 (ddd, *J* = 9.4, 8.2, 1.3 Hz, 1H), 3.22 (p, *J* = 6.9 Hz, 1H), 1.29 (d, *J* = 6.9 Hz, 6H); ESIMS *m/z* 544 ([M+H]⁺).

Intermediate compounds **I-32 – I-36** and **I-41 – I-65**, shown in Table 1, were prepared according to the methods outlined in **Example 22, Steps 1-4**. Characterization data for these intermediates is shown in Table 2.

Example 23: BIOASSAYS ON BEET ARMYWORM (“BAW”) AND CORN EARWORM (“CEW”)

BAW has few effective parasites, diseases, or predators to lower its population. BAW infests many weeds, trees, grasses, legumes, and field crops. In various places, it is of economic concern upon asparagus, cotton, corn, soybeans, tobacco, alfalfa, sugar beets, peppers, tomatoes, potatoes, onions, peas, sunflowers, and citrus, among other plants. CEW is known to attack corn and tomatoes, but it also attacks artichoke, asparagus, cabbage, cantaloupe, collards, cowpeas, cucumbers, eggplant, lettuce, lima beans, melon, okra, peas, peppers, potatoes, pumpkin, snap beans, spinach, squash, sweet potatoes, and watermelon, among other plants. CEW is also known to be resistant to certain insecticides. Consequently, because of the above factors control of these pests is important. Furthermore, molecules that control these pests are useful in controlling other pests.

Certain molecules disclosed in this document were tested against BAW and CEW using procedures described in the following examples. In the reporting of the results, the “BAW & CEW Rating Table” was used (See Table Section).

5 **BIOASSAYS ON BAW (*Spodoptera exigua*)**

Bioassays on BAW were conducted using a 128-well diet tray assay. One to five second instar BAW larvae were placed in each well (3 mL) of the diet tray that had been previously filled with 1 mL of artificial diet to which 50 µg/cm² of the test compound (dissolved in 50 µL of 90:10 acetone-water mixture) had been applied (to each of eight wells) and then allowed to dry. Trays were covered with a clear self-adhesive cover and held at 25 °C, 14:10 light-dark for five to seven days. Percent mortality was recorded for the larvae in each well; activity in the eight wells was then averaged. The results are indicated in the table entitled “Table 5: Biological Results” (See Table Section).

15 **BIOASSAYS ON CEW (*Helicoverpa zea*)**

Bioassays on CEW were conducted using a 128-well diet tray assay. One to five second instar CEW larvae were placed in each well (3 mL) of the diet tray that had been previously filled with 1 mL of artificial diet to which 50 µg/cm² of the test compound (dissolved in 50 µL of 90:10 acetone-water mixture) had been applied (to each of eight wells) and then allowed to dry. Trays were covered with a clear self-adhesive cover and held at 25 °C, 14:10 light-dark for five to seven days. Percent mortality was recorded for the larvae in each well; activity in the eight wells was then averaged. The results are indicated in the table entitled “Table 5: Biological Results” (See Table Section).

25 **Example 24: BIOASSAYS ON GREEN PEACH APHID (“GPA”) (*Myzus persicae*).**

GPA is the most significant aphid pest of peach trees, causing decreased growth, shriveling of the leaves, and the death of various tissues. It is also hazardous because it acts as a vector for the transport of plant viruses, such as potato virus Y and potato leafroll virus to members of the nightshade/potato family *Solanaceae*, and various mosaic viruses to many other food crops. GPA attacks such plants as broccoli, burdock, cabbage, carrot, cauliflower, daikon, eggplant, green beans, lettuce, macadamia, papaya, peppers, sweet potatoes, tomatoes, watercress, and zucchini, among other plants. GPA also attacks many ornamental crops such as carnation, chrysanthemum, flowering white cabbage, poinsettia, and roses. GPA has developed resistance to many pesticides.

Certain molecules disclosed in this document were tested against GPA using procedures described in the following example. In the reporting of the results, the “**GPA Rating Table**” was used (See Table Section).

Cabbage seedlings grown in 3-inch pots, with 2-3 small (3-5 cm) true leaves, were used as test substrate. The seedlings were infested with 20-50 GPA (wingless adult and nymph stages) one day prior to chemical application. Four pots with individual seedlings were used for each treatment. Test compounds (2 mg) were dissolved in 2 mL of acetone/methanol (1:1) solvent, forming stock solutions of 1000 ppm test compound. The stock solutions were diluted 5X with 0.025% Tween 20 in H₂O to obtain the solution at 200 ppm test compound. A hand-held aspirator-type sprayer was used for spraying a solution to both sides of cabbage leaves until runoff. Reference plants (solvent check) were sprayed with the diluent only containing 20% by volume of acetone/methanol (1:1) solvent. Treated plants were held in a holding room for three days at approximately 25 °C and ambient relative humidity (RH) prior to grading. Evaluation was conducted by counting the number of live aphids per plant under a microscope. Percent Control was measured by using Abbott’s correction formula (W.S. Abbott, “A Method of Computing the Effectiveness of an Insecticide” J. Econ. Entomol. 18 (1925), pp.265-267) as follows.

$$\text{Corrected \% Control} = 100 * (X - Y) / X$$

where

X = No. of live aphids on solvent check plants and

Y = No. of live aphids on treated plants

The results are indicated in the table entitled “**Table 5: Biological Results**” (See Table Section).

PESTICIDALLY ACCEPTABLE ACID ADDITION SALTS, SALT DERIVATIVES, SOLVATES, ESTER DERIVATIVES, POLYMORPHS, ISOTOPES AND RADIONUCLIDES

Molecules of Formulas One, Two and Three may be formulated into pesticidally acceptable acid addition salts. By way of a non-limiting example, an amine function can form salts with hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, benzoic, citric, malonic, salicylic, malic, fumaric, oxalic, succinic, tartaric, lactic, gluconic, ascorbic, maleic, aspartic, benzenesulfonic, methanesulfonic, ethanesulfonic, hydroxymethanesulfonic, and hydroxyethanesulfonic acids. Additionally, by way of a non-limiting example, an acid function can form salts including those derived from alkali or alkaline earth metals and those

derived from ammonia and amines. Examples of preferred cations include sodium, potassium, and magnesium.

Molecules of Formulas One, Two and Three may be formulated into salt derivatives. By way of a non-limiting example, a salt derivative can be prepared by contacting a free base with a sufficient amount of the desired acid to produce a salt. A free base may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium hydroxide (NaOH), potassium carbonate, ammonia, and sodium bicarbonate. As an example, in many cases, a pesticide, such as 2,4-D, is made more water-soluble by converting it to its dimethylamine salt.

Molecules of Formulas One, Two and Three may be formulated into stable complexes with a solvent, such that the complex remains intact after the non-complexed solvent is removed. These complexes are often referred to as "solvates." However, it is particularly desirable to form stable hydrates with water as the solvent.

Molecules of Formulas One, Two and Three may be made into ester derivatives.

These ester derivatives can then be applied in the same manner as the invention disclosed in this document is applied.

Molecules of Formulas One, Two and Three may be made as various crystal polymorphs. Polymorphism is important in the development of agrochemicals since different crystal polymorphs or structures of the same molecule can have vastly different physical properties and biological performances.

Molecules of Formulas One, Two and Three may be made with different isotopes. Of particular importance are molecules having ^2H (also known as deuterium) in place of ^1H .

Molecules of Formulas One, Two and Three may be made with different radionuclides. Of particular importance are molecules having ^{14}C .

STEREoisomers

Molecules of Formulas One, Two and Three may exist as one or more stereoisomers. Thus, certain molecules can be produced as racemic mixtures. It will be appreciated by those skilled in the art that one stereoisomer may be more active than the other stereoisomers.

Individual stereoisomers may be obtained by known selective synthetic procedures, by conventional synthetic procedures using resolved starting materials, or by conventional resolution procedures.

INSECTICIDES

Molecules of Formulas One, Two and Three may also be used in combination (such as, in a compositional mixture, or a simultaneous or sequential application) with one or more of the following insecticides – 1,2-dichloropropane, abamectin, acephate, acetamiprid,

5 acethion, acetoprole, acrinathrin, acrylonitrile, alanycarb, aldicarb, aldoxycarb, aldrin, allethrin, allosamidin, allyxycarb, *alpha*-cypermethrin, *alpha*-ecdysone, *alpha*-endosulfan, amidithion, aminocarb, amiton, amiton oxalate, amitraz, anabasine, athidathion, azadirachtin, azamethiphos, azinphos-ethyl, azinphos-methyl, azothoate, barium hexafluorosilicate, barthrin, bendiocarb, benfuracarb, bensultap, *beta*-cyfluthrin, *beta*-cypermethrin, bifenthrin,

10 bioallethrin, bioethanomethrin, biopermethrin, bistrifluron, borax, boric acid, bromfenvinfos, bromocyclen, bromo-DDT, bromophos, bromophos-ethyl, bufencarb, buprofezin, butacarb, butathiofos, butocarboxim, butonate, butoxycarboxim, cadusafos, calcium arsenate, calcium polysulfide, camphechlor, carbanolate, carbaryl, carbofuran, carbon disulfide, carbon tetrachloride, carbophenothion, carbosulfan, cartap, cartap hydrochloride, chlorantraniliprole,

15 chlobicyclen, chlordane, chlordecone, chlordimeform, chlordimeform hydrochloride, chlorethoxyfos, chlorfenapyr, chlorfenvinphos, chlorfluazuron, chlormephos, chloroform, chloropicrin, chlorphoxim, chlorprazophos, chlorpyrifos, chlorpyrifos-methyl, chlorthiophos, chromafenozide, cinerin I, cinerin II, cinerins, cismethrin, cloethocarb, closantel, clothianidin, copper acetoarsenite, copper arsenate, copper naphthenate, copper oleate,

20 coumaphos, coumithoate, crotamiton, crotoxyphos, crufomate, cryolite, cyanofenphos, cyanophos, cyanthoate, cyantraniliprole, cyclethrin, cycloprothrin, cyfluthrin, cyhalothrin, cypermethrin, cyphenothrin, cypropen, cyromazine, cythioate, DDT, decarbofuran, deltamethrin, demephion, demephion-O, demephion-S, demeton, demeton-methyl, demeton-O, demeton-O-methyl, demeton-S, demeton-S-methyl, demeton-S-methylsulphon,

25 diafenthion, dialifos, diatomaceous earth, diazinon, dicapthon, dichlofenthion, dichlorvos, dicresyl, dicrotophos, dicyclanil, dieldrin, diflubenzuron, dilor, dimefluthrin, dimefox, dimetan, dimethoate, dimethrin, dimethylvinphos, dimetilan, dinex, dinex-diclexine, dinoprop, dinosam, dinotefuran, diofenolan, dioxabenzofos, dioxacarb, dioxathion, disulfoton, dithicrofos, d-limonene, DNOC, DNOC-ammonium, DNOC-potassium, DNOC-

30 sodium, doramectin, ecdysterone, emamectin, emamectin benzoate, EMPC, empenthrin, endosulfan, endothion, endrin, EPN, epofenonane, eprinomectin, esdepalléthrine, esfenvalerate, etaphos, ethiofencarb, ethion, ethiprole, ethoate-methyl, ethoprophos, ethyl formate, ethyl-DDD, ethylene dibromide, ethylene dichloride, ethylene oxide, etofenprox, etrimfos, EXD, famphur, fenamiphos, fenazaflor, fenchlorphos, fenethacarb, fenfluthrin,

fenitrothion, fenobucarb, fenoxacrim, fenoxycarb, fenpirithrin, fenpropathrin, fensulfothion, fenthion, fenthion-ethyl, fenvalerate, fipronil, flometoquin, flonicamid, flubendiamide (additionally resolved isomers thereof), flucofuron, flucycloxuron, flucythrinate, flufenerim, flufenoxuron, flufenprox, flufiprole, flupyradifurone, fluvalinate, fonofos, formetanate, 5 formetanate hydrochloride, formothion, formparanate, formparanate hydrochloride, fosmethilan, fospirate, fosthietan, fufenozide, furathiocarb, furethrin, *gamma*-cyhalothrin, *gamma*-HCH, halfenprox, halofenozide, HCH, HEOD, heptachlor, heptenophos, heterophos, hexaflumuron, HHDN, hydramethylnon, hydrogen cyanide, hydroprene, hyquincarb, imidacloprid, imidaclothiz, imiprothrin, indoxacarb, iodomethane, IPSP, isazofos, isobenzan, 10 isocarbophos, isodrin, isofenphos, isofenphos-methyl, isoprocab, isoprothiolane, isothioate, isoxathion, ivermectin, jasmolin I, jasmolin II, jodfenphos, juvenile hormone I, juvenile hormone II, juvenile hormone III, kelevan, kinoprene, lambda-cyhalothrin, lead arsenate, lepimectin, leptophos, lindane, lirimfos, lufenuron, lythidathion, malathion, malonoben, mazidox, ME-5343, MEB-5343, mecarbam, mecarphon, menazon, meperfluthrin, 15 mephosfolan, mercurous chloride, mesulfenfos, metaflumizone, methacrifos, methamidophos, methidathion, methiocarb, methocrotophos, methomyl, methoprene, methothrin, methoxychlor, methoxyfenozide, methyl bromide, methyl isothiocyanate, methylchloroform, methylene chloride, metofluthrin, metolcarb, metoxadiazone, mevinphos, mexacarbate, milbemectin, milbemycin oxime, mipafox, mirex, molosultap, monocrotophos, 20 monomehypo, monosultap, morphothion, moxidectin, naftalofos, naled, naphthalene, nicotine, nifluridide, nitenpyram, nithiazine, nitrilacarb, novaluron, noviflumuron, omethoate, oxamyl, oxydemeton-methyl, oxydeprofos, oxydisulfoton, para-dichlorobenzene, parathion, parathion-methyl, penfluron, pentachlorophenol, permethrin, phenkapton, phenothrin, phenthoate, phorate, phosalone, phosfolan, phosmet, phosnichlor, phosphamidon, phosphine, 25 phoxim, phoxim-methyl, pirimetaphos, pirimicarb, pirimiphos-ethyl, pirimiphos-methyl, potassium arsenite, potassium thiocyanate, pp'-DDT, prallethrin, precocene I, precocene II, precocene III, primidophos, profenofos, profluralin, profluthrin, promacyl, promecarb, propaphos, propetamphos, propoxur, prothidathion, prothiofos, prothoate, protrifenbute, pymetrozine, pyraclofos, pyrafluprole, pyrazophos, pyresmethrin, pyrethrin I, pyrethrin II, 30 pyrethrins, pyridaben, pyridalyl, pyridaphenthion, pyrifluquinazon, pyrimidifen, pyrimitate, pyriprole, pyriproxyfen, quassia, quinalphos, quinalphos-methyl, quinothion, rafoxanide, resmethrin, rotenone, ryania, sabadilla, schradan, selamectin, silafluofen, silica gel, sodium arsenite, sodium fluoride, sodium hexafluorosilicate, sodium thiocyanate, sophamide, spinetoram, spinosad, spiromesifen, spirotetramat, sulcofuron, sulcofuron-sodium,

sulfluramid, sulfotep, sulfoxaflor, sulfuryl fluoride, sulprofos, tasmanone, tau-fluvalinate, tazimcarb, TDE, tebufenozide, tebufenpyrad, tebupirimfos, teflubenzuron, tefluthrin, temephos, TEPP, terallethrin, terbufos, tetrachloroethane, tetrachlorvinphos, tetramethrin, tetramethylfluthrin, *theta*-cypermethrin, thiacloprid, thiamethoxam, thicrofos, thiocarboxime, thiocyclam, thiocyclam oxalate, thiodicarb, thiofanox, thiometon, thiosultap, thiosultap-
 5 disodium, thiosultap-monosodium, thuringiensin, tolfenpyrad, tralomethrin, transfluthrin, transpermethrin, triarathene, triazamate, triazophos, trichlorfon, trichlormetaphos-3, trichloronat, trifenofos, triflumuron, trimethacarb, triprene, vamidothion, vaniliprole, XMC, xylylcarb, zeta-cypermethrin, and zolaprofos (collectively these commonly named
 10 insecticides are defined as the “**Insecticide Group**”).

ACARICIDES

Molecules of Formulas One, Two and Three may also be used in combination (such as, in a compositional mixture, or a simultaneous or sequential application) with one or more
 15 of the following acaricides – acequinocyl, amidoflumet, arsenous oxide, azobenzene, azocyclotin, benomyl, benoxafos, benzoximate, benzyl benzoate, bifenazate, binapacryl, bromopropylate, chinomethionat, chlorbenside, chlorfenethol, chlorfenson, chlorfensulphide, chlorobenzilate, chloromebuform, chloromethiuron, chloropropylate, clofentezine, cyenopyrafen, cyflumetofen, cyhexatin, dichlofluanid, dicofol, dienochlor, diflovidazin,
 20 dinobuton, dinocap, dinocap-4, dinocap-6, dinoceton, dinopenton, dinosulfon, dinoterbon, diphenyl sulfone, disulfiram, dofenapyn, etoxazole, fenazaquin, fenbutatin oxide, fenothiocarb, fenpyroximate, fenson, fentrifanil, fluacrypyrim, fluazuron, flubenzimine, fluenetil, flumethrin, fluorbenside, hexythiazox, mesulfen, MNAF, nikkomycins, proclonol, propargite, quintiofos, spirodiclofen, sulfiram, sulfur, tetradifon, tetranactin, tetrasul, and
 25 thioquinox (collectively these commonly named acaricides are defined as the “**Acaricide Group**”).

NEMATOCIDES

Molecules of Formulas One, Two and Three may also be used in combination (such as, in a compositional mixture, or a simultaneous or sequential application) with one or more
 30 of the following nematocides – 1,3-dichloropropene, benclothiaz, dazomet, dazomet-sodium, DBCP, DCIP, diamidafos, fluensulfone, fosthiazate, furfural, imicyafos, isamidofos, isazofos, metam, metam-ammonium, metam-potassium, metam-sodium, phosphocarb, and thionazin (collectively these commonly named nematocides are defined as the “**Nematicide Group**”).

FUNGICIDES

Molecules of Formulas One, Two and Three may also be used in combination (such as, in a compositional mixture, or a simultaneous or sequential application) with one or more of the following fungicides – (3-ethoxypropyl)mercury bromide, 2-methoxyethylmercury chloride, 2-phenylphenol, 8-hydroxyquinoline sulfate, 8-phenylmercurioxyquinoline, acibenzolar, acibenzolar-S-methyl, acypetacs, acypetacs-copper, acypetacs-zinc, aldimorph, allyl alcohol, ametoctradin, amisulbrom, ampropylfos, anilazine, aureofungin, azaconazole, azithiram, azoxystrobin, barium polysulfide, benalaxyl, benalaxyl-M, benodanil, benomyl, benquinox, bentazon, benthialacarb, benthialacarb-isopropyl, benzalkonium chloride, benzamyl, benzamyl-isobutyl, benzamyl, benzothiazole, bethoxazole, binapacryl, biphenyl, bitertanol, bithionol, bixafen, blastoxin-S, Bordeaux mixture, boscalid, bromoxazole, bupirimate, Burgundy mixture, buthiolate, butylamine, calcium polysulfide, captan, carbendazim, carboxin, carpropamid, carvone, Cheshunt mixture, chinomethionat, chlorobenzothiazole, chloranil, chlorfenazole, chlorodinitrobenzene, chloroneb, chloropicrin, chlorothalonil, chlorquinox, chlozoxazole, climbazole, clotrimazole, copper acetate, copper carbonate, basic, copper hydroxide, copper naphthenate, copper oleate, copper oxychloride, copper silicate, copper sulfate, copper zinc chromate, cresol, cufraneb, cuproban, cuprous oxide, cyazofamid, cyclofuramid, cycloheximide, cyflufenamid, cymoxanil, cypendazole, cyproconazole, cyprodinil, dazomet, dazomet-sodium, DBCP, debacarb, decafenin, dehydroacetic acid, dichlofuanil, dichlor, dichlorophen, dichlozoline, diclobutrazol, diclocymet, diclomezin, diclomezin-sodium, dicloran, diethofencarb, diethyl pyrocarbonate, difenoconazole, diflumetorim, dimethirimol, dimethomorph, dimoxystrobin, diniconazole, diniconazole-M, dinobuton, dinocap, dinocap-4, dinocap-6, dinocron, dinopenton, dinosulfon, dinoterbon, diphenylamine, dipyrithione, disulfiram, ditalimfos, dithianon, DNOC, DNOC-ammonium, DNOC-potassium, DNOC-sodium, dodemorph, dodemorph acetate, dodemorph benzoate, dodicin, dodicin-sodium, dodine, drazoxolon, edifenphos, epoxiconazole, etaconazole, etem, ethaboxam, ethirimol, ethoxyquin, ethylmercury 2,3-dihydroxypropyl mercaptide, ethylmercury acetate, ethylmercury bromide, ethylmercury chloride, ethylmercury phosphate, etridiazole, famoxadone, fenamidone, fenaminosulf, fenapanil, fenarimol, fenbuconazole, fenfuram, fenhexamid, fenitropan, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, fentin, fentin chloride, fentin hydroxide, ferbam, ferimzone, fluazinam, fludioxonil, flumetover, flumorph, flupicolide, flupyrax, fluoroimide, fluotrimazole, fluoxastrobin, fluquinconazole,

flusilazole, flusulfamide, flutianil, flutolanil, flutriafol, fluxapyroxad, folpet, formaldehyde,
 fosetyl, fosetyl-aluminium, fuberidazole, furalaxyl, furametpyr, furcarbanil, furconazole,
 furconazole-cis, furfural, furnecyclox, furophanate, glyodin, griseofulvin, guazatine,
 halacrinat, hexachlorobenzene, hexachlorobutadiene, hexaconazole, hexylthiofos,
 5 hydrargaphen, hymexazol, imazalil, imazalil nitrate, imazalil sulfate, imibenconazole,
 iminoctadine, iminoctadine triacetate, iminoctadine trialbesilate, iodomethane, ipconazole,
 iprobenfos, iprodione, iprovalicarb, isoprothiolane, isopyrazam, isotianil, isovalledione,
 kasugamycin, kresoxim-methyl, mancopper, mancozeb, mandipropamid, maneb, mebenil,
 mecarbinzid, mepanipyrin, mepronil, meptyldinocap, mercuric chloride, mercuric oxide,
 10 mercurous chloride, metalaxyl, metalaxyl-M, metam, metam-ammonium, metam-potassium,
 metam-sodium, metazoxolon, metconazole, methasulfocarb, methfuroxam, methyl bromide,
 methyl isothiocyanate, methylmercury benzoate, methylmercury dicyandiamide,
 methylmercury pentachlorophenoxide, metiram, metominostrobin, metrafenone, metsulfovax,
 milneb, myclobutanil, myclozolin, N-(ethylmercury)-p-toluenesulphonanilide, nabam,
 15 natamycin, nitrostyrene, nitrothal-isopropyl, nuarimol, OCH, octhilinone, ofurace,
 orysastrobin, oxadixyl, oxine-copper, oxpoconazole, oxpoconazole fumarate, oxycarboxin,
 pefurazoate, penconazole, pencycuron, penflufen, pentachlorophenol, penthiopyrad,
 phenylmercuriurea, phenylmercury acetate, phenylmercury chloride, phenylmercury
 derivative of pyrocatechol, phenylmercury nitrate, phenylmercury salicylate, phosdiphen,
 20 phthalide, picoxystrobin, piperalin, polycarbamate, polyoxins, polyoxorim, polyoxorim-zinc,
 potassium azide, potassium polysulfide, potassium thiocyanate, probenazole, prochloraz,
 procymidone, propamocarb, propamocarb hydrochloride, propiconazole, propineb,
 proquinazid, prothiocarb, prothiocarb hydrochloride, prothioconazole, pyracarbolid,
 pyraclostrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyrazophos, pyribencarb,
 25 pyridinitril, pyrifenoxy, pyrimethanil, pyriofenone, pyroquilon, pyroxychlor, pyroxyfur,
 quinacetol, quinacetol sulfate, quinazamid, quinconazole, quinoxifen, quintozone,
 rabenzazole, salicylanilide, sedaxane, silthiofam, simeconazole, sodium azide, sodium
 orthophenylphenoxide, sodium pentachlorophenoxide, sodium polysulfide, spiroxamine,
 streptomycin, sulfur, sultropen, TCMTB, tebuconazole, tebufloquin, tecloftalam, tecnazene,
 30 tecoram, tetraconazole, thiabendazole, thiadifluor, thicyofen, thifluzamide, thiochlorfenphim,
 thiomersal, thiophanate, thiophanate-methyl, thioquinox, thiram, tiadinil, tioxyimid, tolclofos-
 methyl, tolylfluorid, tolylmercury acetate, triadimefon, triadimenol, triamiphos, triarimol,
 triazbutil, triazoxide, tributyltin oxide, trichlamide, tricyclazole, tridemorph, trifloxystrobin,
 triflumizole, triforine, triticonazole, uniconazole, uniconazole-P, validamycin, valifenalate,

vinclozolin, zarilamid, zinc naphthenate, zineb, ziram, zoxamide (collectively these commonly named fungicides are defined as the “**Fungicide Group**”).

HERBICIDES

5 Molecules of Formulas One, Two and Three may also be used in combination (such as, in a compositional mixture, or a simultaneous or sequential application) with one or more of the following herbicides – 2,3,6-TBA, 2,3,6-TBA-dimethylammonium, 2,3,6-TBA-sodium, 2,4,5-T, 2,4,5-T-2-butoxypropyl, 2,4,5-T-2-ethylhexyl, 2,4,5-T-3-butoxypropyl, 2,4,5-TB, 2,4,5-T-butometyl, 2,4,5-T-butotyl, 2,4,5-T-butyl, 2,4,5-T-isobutyl, 2,4,5-T-isooctyl, 10 2,4,5-T-isopropyl, 2,4,5-T-methyl, 2,4,5-T-pentyl, 2,4,5-T-sodium, 2,4,5-T-triethylammonium, 2,4,5-T-trolamine, 2,4-D, 2,4-D-2-butoxypropyl, 2,4-D-2-ethylhexyl, 2,4-D-3-butoxypropyl, 2,4-D-ammonium, 2,4-DB, 2,4-DB-butyl, 2,4-DB-dimethylammonium, 2,4-DB-isooctyl, 2,4-DB-potassium, 2,4-DB-sodium, 2,4-D-butotyl, 2,4-D-butyl, 2,4-D-diethylammonium, 2,4-D-dimethylammonium, 2,4-D-diolamine, 2,4-D-dodecylammonium, 15 2,4-DEB, 2,4-DEP, 2,4-D-ethyl, 2,4-D-heptylammonium, 2,4-D-isobutyl, 2,4-D-isooctyl, 2,4-D-isopropyl, 2,4-D-isopropylammonium, 2,4-D-lithium, 2,4-D-meptyl, 2,4-D-methyl, 2,4-D-octyl, 2,4-D-pentyl, 2,4-D-potassium, 2,4-D-propyl, 2,4-D-sodium, 2,4-D-tefuryl, 2,4-D-tetradecylammonium, 2,4-D-triethylammonium, 2,4-D-tris(2-hydroxypropyl)ammonium, 2,4-D-trolamine, 3,4-DA, 3,4-DB, 3,4-DP, 4-CPA, 4-CPB, 4-CPP, acetochlor, acifluorfen, 20 acifluorfen-methyl, acifluorfen-sodium, aclonifen, acrolein, alachlor, allidochlor, alloxydim, alloxydim-sodium, allyl alcohol, alorac, ametrifone, ametryn, amibuzin, amicarbazone, amidosulfuron, aminocyclopyrachlor, aminocyclopyrachlor-methyl, aminocyclopyrachlor-potassium, aminopyralid, aminopyralid-potassium, aminopyralid-tris(2-hydroxypropyl)ammonium, amiprofos-methyl, amitrole, ammonium sulfamate, anilofos, 25 anisuron, asulam, asulam-potassium, asulam-sodium, atraton, atrazine, azafenidin, azimsulfuron, aziprotryne, barban, BCPC, beflubutamid, benazolin, benazolin-dimethylammonium, benazolin-ethyl, benazolin-potassium, bencarbazone, benfluralin, benfuresate, bensulfuron, bensulfuron-methyl, bensulide, bentazone, bentazone-sodium, benzadox, benzadox-ammonium, benzfendizone, benzipram, benzobicyclon, benzofenap, 30 benzofluor, benzoylprop, benzoylprop-ethyl, benzthiazuron, bicyclopyrone, bifenox, bilanafos, bilanafos-sodium, bispyribac, bispyribac-sodium, borax, bromacil, bromacil-lithium, bromacil-sodium, bromobonil, bromobutide, bromofenoxim, bromoxynil, bromoxynil butyrate, bromoxynil heptanoate, bromoxynil octanoate, bromoxynil-potassium, brompyrazon, butachlor, butafenacil, butamifos, butenachlor, buthidazole, buthiuron,

butralin, butoxydim, buturon, butylate, cacodylic acid, cafenstrole, calcium chlorate, calcium cyanamide, cambendichlor, carbasulam, carbetamide, carboxazole, carfentrazone, carfentrazone-ethyl, CDEA, CEPC, chlomethoxyfen, chloramben, chloramben-ammonium, chloramben-diolamine, chloramben-methyl, chloramben-methylammonium, chloramben-sodium, chloranocryl, chlorazifop, chlorazifop-propargyl, chlorazine, chlorbromuron, chlorbufam, chloreturon, chlorfenac, chlorfenac-sodium, chlorfenprop, chlorfenprop-methyl, chlorflurazole, chlorflurenol, chlorflurenol-methyl, chloridazon, chlorimuron, chlorimuron-ethyl, chlornitrofen, chloropon, chlorotoluron, chloroxuron, chloroxynil, chlorprocarb, chlorpropham, chlorsulfuron, chlorthal, chlorthal-dimethyl, chlorthal-monomethyl, chlorthiamid, cinidon-ethyl, cinmethylin, cinosulfuron, cisanilide, clethodim, clidinate, clodinafop, clodinafop-propargyl, clofop, clofop-isobutyl, clomazone, clomeprop, cloprop, cloproxydim, clopyralid, clopyralid-methyl, clopyralid-olamine, clopyralid-potassium, clopyralid-tris(2-hydroxypropyl)ammonium, cloransulam, cloransulam-methyl, CMA, copper sulfate, CPMF, CPPC, credazine, cresol, cumyluron, cyanamide, cyanatryn, cyanazine, cycloate, cyclosulfamuron, cycloxydim, cycluron, cyhalofop, cyhalofop-butyl, cyperquat, cyperquat chloride, cyprazine, cyprazole, cypromid, daimuron, dalapon, dalapon-calcium, dalapon-magnesium, dalapon-sodium, dazomet, dazomet-sodium, delachlor, desmedipham, desmetryn, di-allate, dicamba, dicamba-dimethylammonium, dicamba-diolamine, dicamba-isopropylammonium, dicamba-methyl, dicamba-olamine, dicamba-potassium, dicamba-sodium, dicamba-trolamine, dichlobenil, dichloralurea, dichlormate, dichlorprop, dichlorprop-2-ethylhexyl, dichlorprop-butotyl, dichlorprop-dimethylammonium, dichlorprop-ethylammonium, dichlorprop-isooctyl, dichlorprop-methyl, dichlorprop-P, dichlorprop-P-dimethylammonium, dichlorprop-potassium, dichlorprop-sodium, diclofop, diclofop-methyl, diclosulam, diethamquat, diethamquat dichloride, diethatyl, diethatyl-ethyl, difenopenten, difenopenten-ethyl, difenoxuron, difenzoquat, difenzoquat metilsulfate, diflufenican, diflufenzopyr, diflufenzopyr-sodium, dimefuron, dimepiperate, dimethachlor, dimethametryn, dimethenamid, dimethenamid-P, dimexano, dimidazon, dinitramine, dinofenate, dinoprop, dinosam, dinoseb, dinoseb acetate, dinoseb-ammonium, dinoseb-diolamine, dinoseb-sodium, dinoseb-trolamine, dinoterb, dinoterb acetate, diphacinone-sodium, diphenamid, dipropetryn, diquat, diquat dibromide, disul, disul-sodium, dithiopyr, diuron, DMPA, DNOC, DNOC-ammonium, DNOC-potassium, DNOC-sodium, DSMA, EBEP, eglinazone, eglinazone-ethyl, endothal, endothal-diammonium, endothal-dipotassium, endothal-disodium, epronaz, EPTC, erbon, esprocarb, ethalfluralin, ethametsulfuron, ethametsulfuron-methyl, ethidimuron, ethiolate, ethofumesate, ethoxyfen, ethoxyfen-ethyl,

ethoxysulfuron, etinofen, etnipromid, etobenzanid, EXD, fenasulam, fenoprop, fenoprop-3-butoxypropyl, fenoprop-butometyl, fenoprop-butotyl, fenoprop-butyl, fenoprop-isooctyl, fenoprop-methyl, fenoprop-potassium, fenoxaprop, fenoxaprop-ethyl, fenoxaprop-P, fenoxaprop-P-ethyl, fenoxasulfone, fenteracol, fenthiaprop, fenthiaprop-ethyl, fentrazamide, fenuron, fenuron TCA, ferrous sulfate, flamprop, flamprop-isopropyl, flamprop-M, flamprop-methyl, flamprop-M-isopropyl, flamprop-M-methyl, flazasulfuron, florasulam, fluazifop, fluazifop-butyl, fluazifop-methyl, fluazifop-P, fluazifop-P-butyl, fluazolate, flucarbazone, flucarbazone-sodium, flucetosulfuron, fluchloralin, flufenacet, flufenican, flufenpyr, flufenpyr-ethyl, flumetsulam, flumezin, flumiclorac, flumiclorac-pentyl, flumioxazin, flumipropyn, fluometuron, fluorodifen, fluoroglycofen, fluoroglycofen-ethyl, fluoromidine, fluoronitrofen, fluothiuron, flupoxam, flupropacil, flupropanate, flupropanate-sodium, flupyrsulfuron, flupyrsulfuron-methyl-sodium, fluridone, flurochloridone, fluroxypyr, fluroxypyr-butometyl, fluroxypyr-meptyl, flurtamone, fluthiacet, fluthiacet-methyl, fomesafen, fomesafen-sodium, foramsulfuron, fosamine, fosamine-ammonium, furyloxyfen, glufosinate, glufosinate-ammonium, glufosinate-P, glufosinate-P-ammonium, glufosinate-P-sodium, glyphosate, glyphosate-diammonium, glyphosate-dimethylammonium, glyphosate-isopropylammonium, glyphosate-monoammonium, glyphosate-potassium, glyphosate-sesquisodium, glyphosate-trimesium, halosafen, halosulfuron, halosulfuron-methyl, haloxydine, haloxyfop, haloxyfop-etotyl, haloxyfop-methyl, haloxyfop-P, haloxyfop-P-etotyl, haloxyfop-P-methyl, haloxyfop-sodium, hexachloroacetone, hexaflurate, hexazinone, imazamethabenz, imazamethabenz-methyl, imazamox, imazamox-ammonium, imazapic, imazapic-ammonium, imazapyr, imazapyr-isopropylammonium, imazaquin, imazaquin-ammonium, imazaquin-methyl, imazaquin-sodium, imazethapyr, imazethapyr-ammonium, imazosulfuron, indanofan, indaziflam, iodobonil, iodomethane, iodosulfuron, iodosulfuron-methyl-sodium, ioxynil, ioxynil octanoate, ioxynil-lithium, ioxynil-sodium, ipazine, ipfencarbazone, iprymidam, isocarbamid, isocil, isomethiozin, isonoruron, isopollinate, isopropalin, isoproturon, isouron, isoxaben, isoxachlortole, isoxaflutole, isoxapyrifop, karbutilate, ketospiradox, lactofen, lenacil, linuron, MAA, MAMA, MCPA, MCPA-2-ethylhexyl, MCPA-butotyl, MCPA-butyl, MCPA-dimethylammonium, MCPA-diolamine, MCPA-ethyl, MCPA-isobutyl, MCPA-isooctyl, MCPA-isopropyl, MCPA-methyl, MCPA-olamine, MCPA-potassium, MCPA-sodium, MCPA-thioethyl, MCPA-trolamine, MCPB, MCPB-ethyl, MCPB-methyl, MCPB-sodium, mecoprop, mecoprop-2-ethylhexyl, mecoprop-dimethylammonium, mecoprop-diolamine, mecoprop-ethadyl, mecoprop-isooctyl, mecoprop-methyl, mecoprop-P, mecoprop-P-dimethylammonium, mecoprop-P-isobutyl, mecoprop-

potassium, mecoprop-P-potassium, mecoprop-sodium, mecoprop-trolamine, medinoterb, medinoterb acetate, mefenacet, mefluidide, mefluidide-diolamine, mefluidide-potassium, mesoprazine, mesosulfuron, mesosulfuron-methyl, mesotrione, metam, metam-ammonium, metamifop, metamitron, metam-potassium, metam-sodium, metazachlor, metazosulfuron, metflurazon, methabenzthiazuron, methalpropalin, methazole, methiobencarb, methiozolin, methiuron, methometon, methoprotrotryne, methyl bromide, methyl isothiocyanate, methylaldymron, metobenzuron, metolachlor, metosulam, metoxuron, metribuzin, metsulfuron, metsulfuron-methyl, molinate, monalide, monisouron, monochloroacetic acid, monolinuron, monuron, monuron TCA, morfamquat, morfamquat dichloride, MSMA, naproanilide, napropamide, naptalam, naptalam-sodium, neburon, nicosulfuron, nipyraclufen, nitralin, nitrofen, nitrofluorfen, norflurazon, noruron, OCH, orbencarb, ortho-dichlorobenzene, orthosulfamuron, oryzalin, oxadiargyl, oxadiazon, oxapyrazon, oxapyrazon-dimolamine, oxapyrazon-sodium, oxasulfuron, oxaziclomefone, oxyfluorfen, parafluron, paraquat, paraquat dichloride, paraquat dimetilsulfate, pebulate, pelargonic acid, pendimethalin, penoxsulam, pentachlorophenol, pentanochlor, pentoxazone, perfluidone, pethoxamid, phenisopham, phenmedipham, phenmedipham-ethyl, phenobenzuron, phenylmercury acetate, picloram, picloram-2-ethylhexyl, picloram-isooctyl, picloram-methyl, picloram-olamine, picloram-potassium, picloram-triethylammonium, picloram-tris(2-hydroxypropyl)ammonium, picolinafen, pinoxaden, piperophos, potassium arsenite, potassium azide, potassium cyanate, pretilachlor, primisulfuron, primisulfuron-methyl, procyzazine, prodiamine, proflumizox, profluralin, profoxydim, proglinazine, proglinazine-ethyl, prometon, prometryn, propachlor, propanil, propaquizafop, propazine, prophan, propisochlor, propoxycarbazone, propoxycarbazone-sodium, propyrisulfuron, propyzamide, prosulfalin, prosulfocarb, prosulfuron, proxan, proxan-sodium, prynachlor, pydanon, pyraclonil, pyraflufen, pyraflufen-ethyl, pyrasulfotole, pyrazolynate, pyrazosulfuron, pyrazosulfuron-ethyl, pyrazoxyfen, pyribenzoxim, pyributicarb, pyriclor, pyridafol, pyridate, pyriftalid, pyriminobac, pyriminobac-methyl, pyrimisulfan, pyriothiac, pyriothiac-sodium, pyroxasulfone, pyroxsulam, quinclorac, quinmerac, quinochloramine, quinonamid, quizalofop, quizalofop-ethyl, quizalofop-P, quizalofop-P-ethyl, quizalofop-P-tefuryl, rhodethanil, rimsulfuron, saflufenacil, seabuthylazine, sebumeton, sethoxydim, siduron, simazine, simeton, simetryn, SMA, S-metolachlor, sodium arsenite, sodium azide, sodium chlorate, sulcotrione, sulfallate, sulfentrazone, sulfometuron, sulfometuron-methyl, sulfosulfuron, sulfuric acid, sulglycapin, swep, TCA, TCA-ammonium, TCA-calcium, TCA-ethadyl, TCA-magnesium, TCA-sodium, tebutam, tebuthiuron, tefuryltrione, tembotrione, tepaloxymid,

terbacil, terbucarb, terbuchlor, terbumeton, terbuthylazine, terbutryn, tetrafluron, thenylchlor, thiazafluron, thiazopyr, thidiazimin, thidiazuron, thien carbazole, thien carbazole-methyl, thifensulfuron, thifensulfuron-methyl, thiobencarb, tiocarbazil, tioclorim, topramezone, tralkoxydim, tri-allate, triasulfuron, triaziflam, tribenuron, tribenuron-methyl, tricamba, triclopyr, triclopyr-butotyl, triclopyr-ethyl, triclopyr-triethylammonium, tridiphane, trietazine, trifloxysulfuron, trifloxysulfuron-sodium, trifluralin, triflusulfuron, triflusulfuron-methyl, trifop, trifop-methyl, trifopsime, trihydroxytriazine, trimeturon, tripropindan, tritac, tritosulfuron, vernolate, xylachlor, (collectively these commonly named herbicides are defined as the “**Herbicide Group**”).

BIOPESTICIDES

Molecules of Formulas One, Two and Three may also be used in combination (such as in a compositional mixture, or a simultaneous or sequential application) with one or more biopesticides. The term “biopesticide” is used for microbial biological pest control agents that are applied in a similar manner to chemical pesticides. Commonly these are bacterial, but there are also examples of fungal control agents, including *Trichoderma* spp. and *Ampelomyces quisqualis* (a control agent for grape powdery mildew). *Bacillus subtilis* are used to control plant pathogens. Weeds and rodents have also been controlled with microbial agents. One well-known insecticide example is *Bacillus thuringiensis*, a bacterial disease of Lepidoptera, Coleoptera, and Diptera. Because it has little effect on other organisms, it is considered more environmentally friendly than synthetic pesticides. Biological insecticides include products based on:

1. entomopathogenic fungi (*e.g. Metarhizium anisopliae*);
2. entomopathogenic nematodes (*e.g. Steinernema feltiae*); and
3. entomopathogenic viruses (*e.g. Cydia pomonella granulovirus*).

Other examples of entomopathogenic organisms include, but are not limited to, baculoviruses, bacteria and other prokaryotic organisms, fungi, protozoa and Microsporidia. Biologically derived insecticides include, but not limited to, rotenone, veratridine, as well as microbial toxins; insect tolerant or resistant plant varieties; and organisms modified by recombinant DNA technology to either produce insecticides or to convey an insect resistant property to the genetically modified organism. In one embodiment, the Molecules of Formula One, Two or Three may be used with one or more biopesticides in the area of seed treatments and soil amendments. *The Manual of Biocontrol Agents* gives a review of the available biological insecticide (and other biology-based control) products. Copping L.G. (ed.) (2004).

The Manual of Biocontrol Agents (formerly the *Biopesticide Manual*) 3rd Edition. British Crop Production Council (BCPC), Farnham, Surrey UK.

OTHER ACTIVE COMPOUNDS

- 5 Molecules of Formulas One, Two and Three may also be used in combination (such as in a compositional mixture, or a simultaneous or sequential application) with one or more of the following:
1. 3-(4-chloro-2,6-dimethylphenyl)-4-hydroxy-8-oxa-1-azaspiro[4,5]dec-3-en-2-one;
 2. 3-(4'-chloro-2,4-dimethyl[1,1'-biphenyl]-3-yl)-4-hydroxy-8-oxa-1-azaspiro[4,5]dec-
 - 10 3-en-2-one;
 3. 4-[[[(6-chloro-3-pyridinyl)methyl]methylamino]-2(5*H*)-furanone];
 4. 4-[[[(6-chloro-3-pyridinyl)methyl]cyclopropylamino]-2(5*H*)-furanone];
 5. 3-chloro-*N*2-[(1*S*)-1-methyl-2-(methylsulfonyl)ethyl]-*N*1-[2-methyl-4-[1,2,2,2-
 - 15 tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]-1,2-benzenedicarboxamide;
 6. 2-cyano-*N*-ethyl-4-fluoro-3-methoxy-benzenesulfonamide;
 7. 2-cyano-*N*-ethyl-3-methoxy-benzenesulfonamide;
 8. 2-cyano-3-difluoromethoxy-*N*-ethyl-4-fluoro-benzenesulfonamide;
 9. 2-cyano-3-fluoromethoxy-*N*-ethyl-benzenesulfonamide;
 10. 2-cyano-6-fluoro-3-methoxy-*N,N*-dimethyl-benzenesulfonamide;
 - 20 11. 2-cyano-*N*-ethyl-6-fluoro-3-methoxy-*N*-methyl-benzenesulfonamide;
 12. 2-cyano-3-difluoromethoxy-*N,N*-dimethylbenzenesulfonamide;
 13. 3-(difluoromethyl)-*N*-[2-(3,3-dimethylbutyl)phenyl]-1-methyl-1*H*-pyrazole-4-
 - carboxamide;
 14. *N*-ethyl-2,2-dimethylpropionamide-2-(2,6-dichloro- α,α,α -trifluoro-*p*-tolyl) hydrazone;
 - 25 15. *N*-ethyl-2,2-dichloro-1-methylcyclopropane-carboxamide-2-(2,6-dichloro- α,α,α -
 - trifluoro-*p*-tolyl) hydrazone nicotine;
 16. O-[(*E*)-[2-(4-chloro-phenyl)-2-cyano-1-(2-trifluoromethylphenyl)-vinyl]] S-methyl
 - thiocarbonate;
 17. (*E*)-*N*1-[(2-chloro-1,3-thiazol-5-ylmethyl)]-*N*2-cyano-*N*1-methylacetamidine;
 - 30 18. 1-(6-chloropyridin-3-ylmethyl)-7-methyl-8-nitro-1,2,3,5,6,7-hexahydro-imidazo[1,2-
 - a]pyridin-5-ol;
 19. 4-[4-chlorophenyl-(2-butyldiene-hydrazono)methyl]phenyl mesylate; and
 20. *N*-Ethyl-2,2-dichloro-1-methylcyclopropanecarboxamide-2-(2,6-dichloro-
 - alpha, alpha, alpha*-trifluoro-*p*-tolyl)hydrazone.

Molecules of Formulas One, Two and Three may also be used in combination (such as in a compositional mixture, or a simultaneous or sequential application) with one or more compounds in the following groups: algicides, antifeedants, avicides, bactericides, bird repellents, chemosterilants, herbicide safeners, insect attractants, insect repellents, mammal repellents, mating disrupters, molluscicides, plant activators, plant growth regulators, rodenticides, and/or virucides (collectively these commonly named groups are defined as the “**AI Group**”). It should be noted that compounds falling within the AI Group, Insecticide Group, Fungicide Group, Herbicide Group, Acaricide Group, or Nematicide Group might be in more than one group, because of multiple activities the compound has. For more information consult the “**COMPENDIUM OF PESTICIDE COMMON NAMES**” located at <http://www.alanwood.net/pesticides/index.html>. Also consult “**THE PESTICIDE MANUAL**” 14th Edition, edited by C D S Tomlin, copyright 2006 by British Crop Production Council, or its prior or more recent editions.

SYNERGISTIC MIXTURES AND SYNERGISTS

Molecules of Formulas One, Two and Three may be used with the compounds in the Insecticide Group to form synergistic mixtures where the mode of action of such compounds compared to the mode of action of the Molecules of Formula One and Two are the same, similar, or different. Examples of modes of action include, but are not limited to:

acetylcholinesterase inhibitor; sodium channel modulator; chitin biosynthesis inhibitor; GABA-gated chloride channel antagonist; GABA and glutamate-gated chloride channel agonist; acetylcholine receptor agonist; MET I inhibitor; Mg-stimulated ATPase inhibitor; nicotinic acetylcholine receptor; Midgut membrane disrupter; oxidative phosphorylation disrupter, and ryanodine receptor (RyRs). Additionally, Molecules of Formula One and Two may be used with compounds in the Fungicide Group, Acaricide Group, Herbicide Group, or Nematicide Group to form synergistic mixtures. Furthermore, Molecules of Formulas One, Two and Three may be used with other active compounds, such as the compounds under the heading “**OTHER ACTIVE COMPOUNDS**”, algicides, avicides, bactericides, molluscicides, rodenticides, virucides, herbicide safeners, adjuvants, and/or surfactants to form synergistic mixtures. Generally, weight ratios of the Molecules of Formulas One, Two and Three in a synergistic mixture with another compound are from about 10:1 to about 1:10, preferably from about 5:1 to about 1:5, and more preferably from about 3:1, and even more preferably about 1:1. Additionally, the following compounds are known as synergists and may be used with the molecules disclosed in Formula One: piperonyl butoxide, piprotal,

propyl isome, sesamex, sesamolin, sulfoxide, and tribufos (collectively these synergists are defined as the “**Synergists Group**”).

FORMULATIONS

5 A pesticide is rarely suitable for application in its pure form. It is usually necessary to add other substances so that the pesticide can be used at the required concentration and in an appropriate form, permitting ease of application, handling, transportation, storage, and maximum pesticide activity. Thus, pesticides are formulated into, for example, baits, concentrated emulsions, dusts, emulsifiable concentrates, fumigants, gels, granules, microencapsulations, seed treatments, suspension concentrates, suspoemulsions, tablets, 10 water soluble liquids, water dispersible granules or dry flowables, wettable powders, and ultra low volume solutions. For further information on formulation types see “Catalogue of Pesticide Formulation Types and International Coding System” Technical Monograph n°2, 5th Edition by CropLife International (2002).

15 Pesticides are applied most often as aqueous suspensions or emulsions prepared from concentrated formulations of such pesticides. Such water-soluble, water-suspendable, or emulsifiable formulations are either solids, usually known as wettable powders, or water dispersible granules, or liquids usually known as emulsifiable concentrates, or aqueous suspensions. Wettable powders, which may be compacted to form water dispersible granules, 20 comprise an intimate mixture of the pesticide, a carrier, and surfactants. The concentration of the pesticide is usually from about 10% to about 90% by weight. The carrier is usually chosen from among the attapulgitic clays, the montmorillonite clays, the diatomaceous earths, or the purified silicates. Effective surfactants, comprising from about 0.5% to about 10% of the wettable powder, are found among sulfonated lignins, condensed naphthalenesulfonates, naphthalenesulfonates, alkylbenzenesulfonates, alkyl sulfates, and non-ionic surfactants such 25 as ethylene oxide adducts of alkyl phenols.

 Emulsifiable concentrates of pesticides comprise a convenient concentration of a pesticide, such as from about 50 to about 500 grams per liter of liquid dissolved in a carrier that is either a water miscible solvent or a mixture of water-immiscible organic solvent and 30 emulsifiers. Useful organic solvents include aromatics, especially xylenes and petroleum fractions, especially the high-boiling naphthalenic and olefinic portions of petroleum such as heavy aromatic naphtha. Other organic solvents may also be used, such as the terpenic solvents including rosin derivatives, aliphatic ketones such as cyclohexanone, and complex alcohols such as 2-ethoxyethanol. Suitable emulsifiers for emulsifiable concentrates are

chosen from conventional anionic and non-ionic surfactants.

Aqueous suspensions comprise suspensions of water-insoluble pesticides dispersed in an aqueous carrier at a concentration in the range from about 5% to about 50% by weight. Suspensions are prepared by finely grinding the pesticide and vigorously mixing it into a carrier comprised of water and surfactants. Ingredients, such as inorganic salts and synthetic or natural gums may also be added, to increase the density and viscosity of the aqueous carrier. It is often most effective to grind and mix the pesticide at the same time by preparing the aqueous mixture and homogenizing it in an implement such as a sand mill, ball mill, or piston-type homogenizer.

Pesticides may also be applied as granular compositions that are particularly useful for applications to the soil. Granular compositions usually contain from about 0.5% to about 10% by weight of the pesticide, dispersed in a carrier that comprises clay or a similar substance. Such compositions are usually prepared by dissolving the pesticide in a suitable solvent and applying it to a granular carrier which has been pre-formed to the appropriate particle size, in the range of from about 0.5 to about 3 mm. Such compositions may also be formulated by making a dough or paste of the carrier and compound and crushing and drying to obtain the desired granular particle size.

Dusts containing a pesticide are prepared by intimately mixing the pesticide in powdered form with a suitable dusty agricultural carrier, such as kaolin clay, ground volcanic rock, and the like. Dusts can suitably contain from about 1% to about 10% of the pesticide. They can be applied as a seed dressing or as a foliage application with a dust blower machine.

It is equally practical to apply a pesticide in the form of a solution in an appropriate organic solvent, usually petroleum oil, such as the spray oils, which are widely used in agricultural chemistry.

Pesticides can also be applied in the form of an aerosol composition. In such compositions the pesticide is dissolved or dispersed in a carrier, which is a pressure-generating propellant mixture. The aerosol composition is packaged in a container from which the mixture is dispensed through an atomizing valve.

Pesticide baits are formed when the pesticide is mixed with food or an attractant or both. When the pests eat the bait they also consume the pesticide. Baits may take the form of granules, gels, flowable powders, liquids, or solids. They can be used in pest harborage.

Fumigants are pesticides that have a relatively high vapor pressure and hence can exist as a gas in sufficient concentrations to kill pests in soil or enclosed spaces. The toxicity of the fumigant is proportional to its concentration and the exposure time. They are

characterized by a good capacity for diffusion and act by penetrating the pest's respiratory system or being absorbed through the pest's cuticle. Fumigants are applied to control stored product pests under gas proof sheets, in gas sealed rooms or buildings or in special chambers.

Pesticides can be microencapsulated by suspending the pesticide particles or droplets in plastic polymers of various types. By altering the chemistry of the polymer or by changing factors in the processing, microcapsules can be formed of various sizes, solubility, wall thicknesses, and degrees of penetrability. These factors govern the speed with which the active ingredient within is released, which in turn, affects the residual performance, speed of action, and odor of the product.

Oil solution concentrates are made by dissolving pesticide in a solvent that will hold the pesticide in solution. Oil solutions of a pesticide usually provide faster knockdown and kill of pests than other formulations due to the solvents themselves having pesticidal action and the dissolution of the waxy covering of the integument increasing the speed of uptake of the pesticide. Other advantages of oil solutions include better storage stability, better penetration of crevices, and better adhesion to greasy surfaces.

Another embodiment is an oil-in-water emulsion, wherein the emulsion comprises oily globules which are each provided with a lamellar liquid crystal coating and are dispersed in an aqueous phase, wherein each oily globule comprises at least one compound which is agriculturally active, and is individually coated with a monolamellar or oligolamellar layer comprising: (1) at least one non-ionic lipophilic surface-active agent, (2) at least one non-ionic hydrophilic surface-active agent and (3) at least one ionic surface-active agent, wherein the globules having a mean particle diameter of less than 800 nanometers. Further information on the embodiment is disclosed in U.S. patent publication 20070027034 published February 1, 2007, having Patent Application serial number 11/495,228. For ease of use, this embodiment will be referred to as "OIWE".

For further information consult "Insect Pest Management" 2nd Edition by D. Dent, copyright CAB International (2000). Additionally, for more detailed information consult "Handbook of Pest Control – The Behavior, Life History, and Control of Household Pests" by Arnold Mallis, 9th Edition, copyright 2004 by GIE Media Inc.

OTHER FORMULATION COMPONENTS

Generally, when the molecules disclosed in Formulas One, Two and Three are used in a formulation, such formulation can also contain other components. These components include, but are not limited to, (this is a non-exhaustive and non-mutually exclusive list)

wetters, spreaders, stickers, penetrants, buffers, sequestering agents, drift reduction agents, compatibility agents, anti-foam agents, cleaning agents, and emulsifiers. A few components are described forthwith.

A wetting agent is a substance that when added to a liquid increases the spreading or penetration power of the liquid by reducing the interfacial tension between the liquid and the surface on which it is spreading. Wetting agents are used for two main functions in agrochemical formulations: during processing and manufacture to increase the rate of wetting of powders in water to make concentrates for soluble liquids or suspension concentrates; and during mixing of a product with water in a spray tank to reduce the wetting time of wettable powders and to improve the penetration of water into water-dispersible granules. Examples of wetting agents used in wettable powder, suspension concentrate, and water-dispersible granule formulations are: sodium lauryl sulfate; sodium dioctyl sulfosuccinate; alkyl phenol ethoxylates; and aliphatic alcohol ethoxylates.

A dispersing agent is a substance which adsorbs onto the surface of particles and helps to preserve the state of dispersion of the particles and prevents them from reaggregating. Dispersing agents are added to agrochemical formulations to facilitate dispersion and suspension during manufacture, and to ensure the particles redisperse into water in a spray tank. They are widely used in wettable powders, suspension concentrates and water-dispersible granules. Surfactants that are used as dispersing agents have the ability to adsorb strongly onto a particle surface and provide a charged or steric barrier to reaggregation of particles. The most commonly used surfactants are anionic, non-ionic, or mixtures of the two types. For wettable powder formulations, the most common dispersing agents are sodium lignosulfonates. For suspension concentrates, very good adsorption and stabilization are obtained using polyelectrolytes, such as sodium naphthalene sulfonate formaldehyde condensates. Tristyrylphenol ethoxylate phosphate esters are also used. Non-ionics such as alkylarylethylene oxide condensates and EO-PO block copolymers are sometimes combined with anionics as dispersing agents for suspension concentrates. In recent years, new types of very high molecular weight polymeric surfactants have been developed as dispersing agents. These have very long hydrophobic 'backbones' and a large number of ethylene oxide chains forming the 'teeth' of a 'comb' surfactant. These high molecular weight polymers can give very good long-term stability to suspension concentrates because the hydrophobic backbones have many anchoring points onto the particle surfaces. Examples of dispersing agents used in agrochemical formulations are: sodium lignosulfonates; sodium naphthalene sulfonate formaldehyde condensates; tristyrylphenol ethoxylate phosphate esters; aliphatic alcohol

ethoxylates; alkyl ethoxylates; EO-PO block copolymers; and graft copolymers.

An emulsifying agent is a substance which stabilizes a suspension of droplets of one liquid phase in another liquid phase. Without the emulsifying agent the two liquids would separate into two immiscible liquid phases. The most commonly used emulsifier blends
5 contain alkylphenol or aliphatic alcohol with twelve or more ethylene oxide units and the oil-soluble calcium salt of dodecylbenzenesulfonic acid. A range of hydrophile-lipophile balance (“HLB”) values from 8 to 18 will normally provide good stable emulsions. Emulsion stability can sometimes be improved by the addition of a small amount of an EO-PO block copolymer surfactant.

10 A solubilizing agent is a surfactant which will form micelles in water at concentrations above the critical micelle concentration. The micelles are then able to dissolve or solubilize water-insoluble materials inside the hydrophobic part of the micelle. The types of surfactants usually used for solubilization are non-ionics, sorbitan monooleates, sorbitan monooleate ethoxylates, and methyl oleate esters.

15 Surfactants are sometimes used, either alone or with other additives such as mineral or vegetable oils as adjuvants to spray-tank mixes to improve the biological performance of the pesticide on the target. The types of surfactants used for bioenhancement depend generally on the nature and mode of action of the pesticide. However, they are often non-ionics such as: alkyl ethoxylates; linear aliphatic alcohol ethoxylates; aliphatic amine ethoxylates.

20 A carrier or diluent in an agricultural formulation is a material added to the pesticide to give a product of the required strength. Carriers are usually materials with high absorptive capacities, while diluents are usually materials with low absorptive capacities. Carriers and diluents are used in the formulation of dusts, wettable powders, granules and water-dispersible granules.

25 Organic solvents are used mainly in the formulation of emulsifiable concentrates, oil-in-water emulsions, suspoemulsions, and ultra low volume formulations, and to a lesser extent, granular formulations. Sometimes mixtures of solvents are used. The first main groups of solvents are aliphatic paraffinic oils such as kerosene or refined paraffins. The second main group (and the most common) comprises the aromatic solvents such as xylene
30 and higher molecular weight fractions of C9 and C10 aromatic solvents. Chlorinated hydrocarbons are useful as cosolvents to prevent crystallization of pesticides when the formulation is emulsified into water. Alcohols are sometimes used as cosolvents to increase solvent power. Other solvents may include vegetable oils, seed oils, and esters of vegetable and seed oils.

Thickeners or gelling agents are used mainly in the formulation of suspension concentrates, emulsions and suspoemulsions to modify the rheology or flow properties of the liquid and to prevent separation and settling of the dispersed particles or droplets.

Thickening, gelling, and anti-settling agents generally fall into two categories, namely water-insoluble particulates and water-soluble polymers. It is possible to produce suspension concentrate formulations using clays and silicas. Examples of these types of materials, include, but are not limited to, montmorillonite, bentonite, magnesium aluminum silicate, and attapulgite. Water-soluble polysaccharides have been used as thickening-gelling agents for many years. The types of polysaccharides most commonly used are natural extracts of seeds and seaweeds or are synthetic derivatives of cellulose. Examples of these types of materials include, but are not limited to, guar gum; locust bean gum; carrageenan; alginates; methyl cellulose; sodium carboxymethyl cellulose (SCMC); hydroxyethyl cellulose (HEC). Other types of anti-settling agents are based on modified starches, polyacrylates, polyvinyl alcohol and polyethylene oxide. Another good anti-settling agent is xanthan gum.

Microorganisms can cause spoilage of formulated products. Therefore preservation agents are used to eliminate or reduce their effect. Examples of such agents include, but are not limited to: propionic acid and its sodium salt; sorbic acid and its sodium or potassium salts; benzoic acid and its sodium salt; *p*-hydroxybenzoic acid sodium salt; methyl *p*-hydroxybenzoate; and 1,2-benzisothiazolin-3-one (BIT).

The presence of surfactants often causes water-based formulations to foam during mixing operations in production and in application through a spray tank. In order to reduce the tendency to foam, anti-foam agents are often added either during the production stage or before filling into bottles. Generally, there are two types of anti-foam agents, namely silicones and non-silicones. Silicones are usually aqueous emulsions of dimethyl polysiloxane, while the non-silicone anti-foam agents are water-insoluble oils, such as octanol and nonanol, or silica. In both cases, the function of the anti-foam agent is to displace the surfactant from the air-water interface.

“Green” agents (*e.g.*, adjuvants, surfactants, solvents) can reduce the overall environmental footprint of crop protection formulations. Green agents are biodegradable and generally derived from natural and/or sustainable sources, *e.g.* plant and animal sources. Specific examples are: vegetable oils, seed oils, and esters thereof, also alkoxylated alkyl polyglucosides.

For further information, see “Chemistry and Technology of Agrochemical Formulations” edited by D.A. Knowles, copyright 1998 by Kluwer Academic Publishers.

Also see “Insecticides in Agriculture and Environment – Retrospects and Prospects” by A.S. Perry, I. Yamamoto, I. Ishaaya, and R. Perry, copyright 1998 by Springer-Verlag.

PESTS

5 In general, the Molecules of Formula Formulas One, Two and Three may be used to control pests *e.g.* beetles, earwigs, cockroaches, flies, aphids, scales, whiteflies, leafhoppers, ants, wasps, termites, moths, butterflies, lice, grasshoppers, locusts, crickets, fleas, thrips, bristletails, mites, ticks, nematodes, and symphylans.

10 In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests in the **Phyla Nematoda** and/or **Arthropoda**.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests in the **Subphyla Chelicerata, Myriapoda, and/or Hexapoda**.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests in the **Classes of Arachnida, Symphyla, and/or Insecta**.

15 In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Order Anoplura**. A non-exhaustive list of particular genera includes, but is not limited to, *Haematopinus* spp., *Hoplopleura* spp., *Linognathus* spp., *Pediculus* spp., and *Polyplax* spp. A non-exhaustive list of particular species includes, but is not limited to, *Haematopinus asini*, *Haematopinus suis*, *Linognathus setosus*, *Linognathus ovillus*,
20 *Pediculus humanus capitis*, *Pediculus humanus humanus*, and *Pthirus pubis*.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests in the **Order Coleoptera**. A non-exhaustive list of particular genera includes, but is not limited to, *Acanthoscelides* spp., *Agriotes* spp., *Anthonomus* spp., *Apion* spp., *Apogonia* spp., *Aulacophora* spp., *Bruchus* spp., *Cerosterna* spp., *Cerotoma* spp.,
25 *Ceutorhynchus* spp., *Chaetocnema* spp., *Colaspis* spp., *Ctenicera* spp., *Curculio* spp., *Cyclocephala* spp., *Diabrotica* spp., *Hypera* spp., *Ips* spp., *Lyctus* spp., *Megascelis* spp., *Meligethes* spp., *Otiorhynchus* spp., *Pantomorus* spp., *Phyllophaga* spp., *Phyllotreta* spp., *Rhizotrogus* spp., *Rhynchites* spp., *Rhynchophorus* spp., *Scolytus* spp., *Sphenophorus* spp., *Sitophilus* spp., and *Tribolium* spp. A non-exhaustive list of particular species includes, but is
30 not limited to, *Acanthoscelides obtectus*, *Agrilus planipennis*, *Anoplophora glabripennis*, *Anthonomus grandis*, *Ataenius spretulus*, *Atomaria linearis*, *Bothynoderes punctiventris*, *Bruchus pisorum*, *Callosobruchus maculatus*, *Carpophilus hemipterus*, *Cassida vittata*, *Cerotoma trifurcata*, *Ceutorhynchus assimilis*, *Ceutorhynchus napi*, *Conoderus scalaris*, *Conoderus stigmatosus*, *Conotrachelus nenuphar*, *Cotinis nitida*, *Crioceris asparagi*,

Cryptolestes ferrugineus, *Cryptolestes pusillus*, *Cryptolestes turcicus*, *Cylindrocopturus adspersus*, *Deporaus marginatus*, *Dermestes lardarius*, *Dermestes maculatus*, *Epilachna varivestis*, *Faustinus cubae*, *Hylobius pales*, *Hypera postica*, *Hypothenemus hampei*, *Lasioderma serricorne*, *Leptinotarsa decemlineata*, *Liogenys fuscus*, *Liogenys suturalis*,
 5 *Lissorhoptrus oryzophilus*, *Maecolaspis jolivetii*, *Melanotus communis*, *Meligethes aeneus*, *Melolontha melolontha*, *Oberea brevis*, *Oberea linearis*, *Oryctes rhinoceros*, *Oryzaephilus mercator*, *Oryzaephilus surinamensis*, *Oulema melanopus*, *Oulema oryzae*, *Phyllophaga cuyabana*, *Popillia japonica*, *Prostephanus truncatus*, *Rhyzopertha dominica*, *Sitona lineatus*, *Sitophilus granarius*, *Sitophilus oryzae*, *Sitophilus zeamais*, *Stegobium paniceum*,
 10 *Tribolium castaneum*, *Tribolium confusum*, *Trogoderma variabile*, and *Zabrus tenebrioides*.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Order Dermaptera**.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Order Blattaria**. A non-exhaustive list of particular species includes,
 15 but is not limited to, *Blattella germanica*, *Blatta orientalis*, *Parcoblatta pennsylvanica*, *Periplaneta americana*, *Periplaneta australasiae*, *Periplaneta brunnea*, *Periplaneta fuliginosa*, *Pycnoscelus surinamensis*, and *Supella longipalpa*.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Order Diptera**. A non-exhaustive list of particular genera includes, but
 20 is not limited to, *Aedes* spp., *Agromyza* spp., *Anastrepha* spp., *Anopheles* spp., *Bactrocera* spp., *Ceratitis* spp., *Chrysops* spp., *Cochliomyia* spp., *Contarinia* spp., *Culex* spp., *Dasineura* spp., *Delia* spp., *Drosophila* spp., *Fannia* spp., *Hylemyia* spp., *Liriomyza* spp., *Musca* spp., *Phorbia* spp., *Tabanus* spp., and *Tipula* spp. A non-exhaustive list of particular species includes, but is not limited to, *Agromyza frontella*, *Anastrepha suspensa*, *Anastrepha ludens*,
 25 *Anastrepha obliqua*, *Bactrocera cucurbitae*, *Bactrocera dorsalis*, *Bactrocera invadens*, *Bactrocera zonata*, *Ceratitis capitata*, *Dasineura brassicae*, *Delia platura*, *Fannia canicularis*, *Fannia scalaris*, *Gasterophilus intestinalis*, *Gracillia perseae*, *Haematobia irritans*, *Hypoderma lineatum*, *Liriomyza brassicae*, *Melophagus ovinus*, *Musca autumnalis*, *Musca domestica*, *Oestrus ovis*, *Oscinella frit*, *Pegomya betae*, *Psila rosae*, *Rhagoletis cerasi*, *Rhagoletis pomonella*, *Rhagoletis mendax*, *Sitodiplosis mosellana*, and *Stomoxys calcitrans*.
 30

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Order Hemiptera**. A non-exhaustive list of particular genera includes, but is not limited to, *Adelges* spp., *Aulacaspis* spp., *Aphrophora* spp., *Aphis* spp., *Bemisia*

spp., *Ceroplastes* spp., *Chionaspis* spp., *Chrysomphalus* spp., *Coccus* spp., *Empoasca* spp., *Lepidosaphes* spp., *Lagynotomus* spp., *Lygus* spp., *Macrosiphum* spp., *Nephotettix* spp., *Nezara* spp., *Philaenus* spp., *Phytocoris* spp., *Piezodorus* spp., *Planococcus* spp., *Pseudococcus* spp., *Rhopalosiphum* spp., *Saissetia* spp., *Therioaphis* spp., *Toumeyella* spp.,
5 *Toxoptera* spp., *Trialeurodes* spp., *Triatoma* spp. and *Unaspis* spp. A non-exhaustive list of particular species includes, but is not limited to, *Acrosternum hilare*, *Acyrtosiphon pisum*, *Aleyrodes proletella*, *Aleurodicus dispersus*, *Aleurothrixus floccosus*, *Amrasca biguttula biguttula*, *Aonidiella aurantii*, *Aphis gossypii*, *Aphis glycines*, *Aphis pomi*, *Aulacorthum solani*, *Bemisia argentifolii*, *Bemisia tabaci*, *Blissus leucopterus*, *Brachycorynella asparagi*,
10 *Brevinnia rehi*, *Brevicoryne brassicae*, *Calocoris norvegicus*, *Ceroplastes rubens*, *Cimex hemipterus*, *Cimex lectularius*, *Dagbertus fasciatus*, *Dichelops furcatus*, *Diuraphis noxia*, *Diaphorina citri*, *Dysaphis plantaginea*, *Dysdercus suturellus*, *Edessa meditabunda*, *Eriosoma lanigerum*, *Eurygaster maura*, *Euschistus heros*, *Euschistus servus*, *Helopeltis antonii*, *Helopeltis theivora*, *Icerya purchasi*, *Idioscopus nitidulus*, *Laodelphax striatellus*,
15 *Leptocorisa oratorius*, *Leptocorisa varicornis*, *Lygus hesperus*, *Maconellicoccus hirsutus*, *Macrosiphum euphorbiae*, *Macrosiphum granarium*, *Macrosiphum rosae*, *Macrosteles quadrilineatus*, *Mahanarva frimbiolata*, *Metopolophium dirhodum*, *Mictis longicornis*, *Myzus persicae*, *Nephotettix cinctipes*, *Neurocolpus longirostris*, *Nezara viridula*, *Nilaparvata lugens*, *Parlatoria pergandii*, *Parlatoria ziziphi*, *Peregrinus maidis*, *Phylloxera vitifoliae*,
20 *Physokermes piceae*, *Phytocoris californicus*, *Phytocoris relativus*, *Piezodorus guildinii*, *Poecilocapsus lineatus*, *Psallus vaccinicola*, *Pseudacysta perseae*, *Pseudococcus brevipes*, *Quadraspidiotus perniciosus*, *Rhopalosiphum maidis*, *Rhopalosiphum padi*, *Saissetia oleae*, *Scaptocoris castanea*, *Schizaphis graminum*, *Sitobion avenae*, *Sogatella furcifera*, *Trialeurodes vaporariorum*, *Trialeurodes abutiloneus*, *Unaspis yanonensis*, and *Zulia entrerriana*.
25

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Order Hymenoptera**. A non-exhaustive list of particular genera includes, but is not limited to, *Acromyrmex* spp., *Atta* spp., *Camponotus* spp., *Diprion* spp., *Formica* spp., *Monomorium* spp., *Neodiprion* spp., *Pogonomyrmex* spp., *Polistes* spp.,
30 *Solenopsis* spp., *Vespula* spp., and *Xylocopa* spp. A non-exhaustive list of particular species includes, but is not limited to, *Athalia rosae*, *Atta texana*, *Iridomyrmex humilis*, *Monomorium minimum*, *Monomorium pharaonis*, *Solenopsis invicta*, *Solenopsis geminata*, *Solenopsis molesta*, *Solenopsis richteri*, *Solenopsis xyloni*, and *Tapinoma sessile*.

In another embodiment, the Molecules of Formulas One, Two and Three may be used

to control pests of the **Order Isoptera**. A non-exhaustive list of particular genera includes, but is not limited to, *Coptotermes* spp., *Cornitermes* spp., *Cryptotermes* spp., *Heterotermes* spp., *Kalotermes* spp., *Incisitermes* spp., *Macrotermes* spp., *Marginitermes* spp., *Microcerotermes* spp., *Procornitermes* spp., *Reticulitermes* spp., *Schedorhinotermes* spp.,
 5 and *Zootermopsis* spp. A non-exhaustive list of particular species includes, but is not limited to, *Coptotermes curvignathus*, *Coptotermes frenchi*, *Coptotermes formosanus*, *Heterotermes aureus*, *Microtermes obesi*, *Reticulitermes banyulensis*, *Reticulitermes grassei*, *Reticulitermes flavipes*, *Reticulitermes hageni*, *Reticulitermes hesperus*, *Reticulitermes santonensis*, *Reticulitermes speratus*, *Reticulitermes tibialis*, and *Reticulitermes virginicus*.

10 In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Order Lepidoptera**. A non-exhaustive list of particular genera includes, but is not limited to, *Adoxophyes* spp., *Agrotis* spp., *Argyrotaenia* spp., *Cacoecia* spp., *Caloptilia* spp., *Chilo* spp., *Chrysodeixis* spp., *Colias* spp., *Crambus* spp., *Diaphania* spp., *Diatraea* spp., *Earias* spp., *Ephestia* spp., *Epimecis* spp., *Feltia* spp., *Gortyna* spp.,
 15 *Helicoverpa* spp., *Heliothis* spp., *Indarbela* spp., *Lithocolletis* spp., *Loxagrotis* spp., *Malacosoma* spp., *Peridroma* spp., *Phyllonorycter* spp., *Pseudaletia* spp., *Sesamia* spp., *Spodoptera* spp., *Synanthedon* spp., and *Yponomeuta* spp. A non-exhaustive list of particular species includes, but is not limited to, *Achaea janata*, *Adoxophyes orana*, *Agrotis ipsilon*, *Alabama argillacea*, *Amorbia cuneana*, *Amyelois transitella*, *Anacamptodes defectaria*,
 20 *Anarsia lineatella*, *Anomis sabulifera*, *Anticarsia gemmatalis*, *Archips argyrospila*, *Archips rosana*, *Argyrotaenia citrana*, *Autographa gamma*, *Bonagota cranaodes*, *Borbo cinnara*, *Bucculatrix thurberiella*, *Capua reticulana*, *Carposina niponensis*, *Chlumetia transversa*, *Choristoneura rosaceana*, *Cnaphalocrocis medinalis*, *Conopomorpha cramerella*, *Cossus cossus*, *Cydia caryana*, *Cydia funebrana*, *Cydia molesta*, *Cydia nigricana*, *Cydia pomonella*,
 25 *Darna diducta*, *Diatraea saccharalis*, *Diatraea grandiosella*, *Earias insulana*, *Earias vittella*, *Ecdytolopha aurantianum*, *Elasmopalpus lignosellus*, *Ephestia cautella*, *Ephestia elutella*, *Ephestia kuehniella*, *Epinotia aporema*, *Epiphyas postvittana*, *Erionota thrax*, *Eupoecilia ambiguella*, *Euxoa auxiliaris*, *Grapholita molesta*, *Hedylepta indicata*, *Helicoverpa armigera*, *Helicoverpa zea*, *Heliothis virescens*, *Hellula undalis*, *Keiferia lycopersicella*,
 30 *Leucinodes orbonalis*, *Leucoptera coffeella*, *Leucoptera malifoliella*, *Lobesia botrana*, *Loxagrotis albicosta*, *Lymantria dispar*, *Lyonetia clerkella*, *Mahasena corbetti*, *Mamestra brassicae*, *Maruca testulalis*, *Metisa plana*, *Mythimna unipuncta*, *Neoleucinodes elegantalis*, *Nymphula depunctalis*, *Operophtera brumata*, *Ostrinia nubilalis*, *Oxydia vesulia*, *Pandemis cerasana*, *Pandemis heparana*, *Papilio demodocus*, *Pectinophora gossypiella*, *Peridroma*

saucia, *Perileucoptera coffeella*, *Phthorimaea operculella*, *Phyllocnistis citrella*, *Pieris rapae*, *Plathypena scabra*, *Plodia interpunctella*, *Plutella xylostella*, *Polychrosis viteana*, *Prays endocarpa*, *Prays oleae*, *Pseudaletia unipuncta*, *Pseudoplusia includens*, *Rachiplusia nu*, *Scirpophaga incertulas*, *Sesamia inferens*, *Sesamia nonagrioides*, *Setora nitens*, *Sitotroga cerealella*, *Sparganothis pilleriana*, *Spodoptera exigua*, *Spodoptera frugiperda*, *Spodoptera eridania*, *Thecla basilides*, *Tineola bisselliella*, *Trichoplusia ni*, *Tuta absoluta*, *Zeuzera coffeae*, and *Zeuzera pyrina*.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Order Mallophaga**. A non-exhaustive list of particular genera includes, but is not limited to, *Anaticola* spp., *Bovicola* spp., *Chelopistes* spp., *Goniodes* spp., *Menacanthus* spp., and *Trichodectes* spp. A non-exhaustive list of particular species includes, but is not limited to, *Bovicola bovis*, *Bovicola caprae*, *Bovicola ovis*, *Chelopistes meleagridis*, *Goniodes dissimilis*, *Goniodes gigas*, *Menacanthus stramineus*, *Menopon gallinae*, and *Trichodectes canis*.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Order Orthoptera**. A non-exhaustive list of particular genera includes, but is not limited to, *Melanoplus* spp., and *Pterophylla* spp. A non-exhaustive list of particular species includes, but is not limited to, *Anabrus simplex*, *Gryllotalpa africana*, *Gryllotalpa australis*, *Gryllotalpa brachyptera*, *Gryllotalpa hexadactyla*, *Locusta migratoria*, *Microcentrum retinerve*, *Schistocerca gregaria*, and *Scudderella furcata*.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Order Siphonaptera**. A non-exhaustive list of particular species includes, but is not limited to, *Ceratophyllus gallinae*, *Ceratophyllus niger*, *Ctenocephalides canis*, *Ctenocephalides felis*, and *Pulex irritans*.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Order Thysanoptera**. A non-exhaustive list of particular genera includes, but is not limited to, *Caliothrips* spp., *Frankliniella* spp., *Scirtothrips* spp., and *Thrips* spp. A non-exhaustive list of particular sp. includes, but is not limited to, *Frankliniella fusca*, *Frankliniella occidentalis*, *Frankliniella schultzei*, *Frankliniella williamsi*, *Heliothrips haemorrhoidalis*, *Rhipiphorothrips cruentatus*, *Scirtothrips citri*, *Scirtothrips dorsalis*, and *Taeniothrips rhopalantennalis*, *Thrips hawaiiensis*, *Thrips nigropilosus*, *Thrips orientalis*, *Thrips tabaci*.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Order Thysanura**. A non-exhaustive list of particular genera includes,

but is not limited to, *Lepisma* spp. and *Thermobia* spp.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Order Acarina**. A non-exhaustive list of particular genera includes, but is not limited to, *Acarus* spp., *Aculops* spp., *Boophilus* spp., *Demodex* spp., *Dermacentor* spp., *Epitrimerus* spp., *Eriophyes* spp., *Ixodes* spp., *Oligonychus* spp., *Panonychus* spp., *Rhizoglyphus* spp., and *Tetranychus* spp. A non-exhaustive list of particular species includes, but is not limited to, *Acarapis woodi*, *Acarus siro*, *Aceria mangiferae*, *Aculops lycopersici*, *Aculus pelekassi*, *Aculus schlechtendali*, *Amblyomma americanum*, *Brevipalpus obovatus*, *Brevipalpus phoenicis*, *Dermacentor variabilis*, *Dermatophagoides pteronyssinus*, *Eotetranychus carpini*, *Notoedres cati*, *Oligonychus coffeae*, *Oligonychus ilicis*, *Panonychus citri*, *Panonychus ulmi*, *Phyllocoptruta oleivora*, *Polyphagotarsonemus latus*, *Rhipicephalus sanguineus*, *Sarcoptes scabiei*, *Tegolophus perseae*, *Tetranychus urticae*, and *Varroa destructor*.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pest of the **Order Symphyla**. A non-exhaustive list of particular sp. includes, but is not limited to, *Scutigerella immaculata*.

In another embodiment, the Molecules of Formulas One, Two and Three may be used to control pests of the **Phylum Nematoda**. A non-exhaustive list of particular genera includes, but is not limited to, *Aphelenchoides* spp., *Belonolaimus* spp., *Criconemella* spp., *Ditylenchus* spp., *Heterodera* spp., *Hirschmanniella* spp., *Hoplolaimus* spp., *Meloidogyne* spp., *Pratylenchus* spp., and *Radopholus* spp. A non-exhaustive list of particular sp. includes, but is not limited to, *Dirofilaria immitis*, *Heterodera zae*, *Meloidogyne incognita*, *Meloidogyne javanica*, *Onchocerca volvulus*, *Radopholus similis*, and *Rotylenchulus reniformis*.

For additional information consult “**HANDBOOK OF PEST CONTROL – THE BEHAVIOR, LIFE HISTORY, AND CONTROL OF HOUSEHOLD PESTS**” by Arnold Mallis, 9th Edition, copyright 2004 by GIE Media Inc.

APPLICATIONS

Molecules of Formulas One, Two and Three are generally used in amounts from about 0.01 grams per hectare to about 5000 grams per hectare to provide control. Amounts from about 0.1 grams per hectare to about 500 grams per hectare are generally preferred, and amounts from about 1 gram per hectare to about 50 grams per hectare are generally more preferred.

The area to which a molecule of Formulas One, Two and Three is applied can be any area inhabited (or maybe inhabited, or traversed by) a pest, for example: where crops, trees, fruits, cereals, fodder species, vines, turf and ornamental plants, are growing; where domesticated animals are residing; the interior or exterior surfaces of buildings (such as places where grains are stored), the materials of construction used in building (such as impregnated wood), and the soil around buildings. Particular crop areas to use a molecule of Formula One include areas where apples, corn, sunflowers, cotton, soybeans, canola, wheat, rice, sorghum, barley, oats, potatoes, oranges, alfalfa, lettuce, strawberries, tomatoes, peppers, crucifers, pears, tobacco, almonds, sugar beets, beans and other valuable crops are growing or the seeds thereof are going to be planted. It is also advantageous to use aluminum sulfate with a molecule of Formula One when growing various plants.

Controlling pests generally means that pest populations, pest activity, or both, are reduced in an area. This can come about when: pest populations are repulsed from an area; when pests are incapacitated in or around an area; or pests are exterminated, in whole, or in part, in or around an area. Of course, a combination of these results can occur. Generally, pest populations, activity, or both are desirably reduced more than fifty percent, preferably more than 90 percent. Generally, the area is not in or on a human; consequently, the locus is generally a non-human area.

The Molecules of Formulas One, Two and Three may be used in mixtures, applied simultaneously or sequentially, alone or with other compounds to enhance plant vigor (*e.g.* to grow a better root system, to better withstand stressful growing conditions). Such other compounds are, for example, compounds that modulate plant ethylene receptors, most notably 1-methylcyclopropene (also known as 1-MCP).

The Molecules of Formulas One, Two and Three can be applied to the foliar and fruiting portions of plants to control pests. The molecules will either come in direct contact with the pest, or the pest will consume the pesticide when eating leaf, fruit mass, or extracting sap, that contains the pesticide. The Molecules of Formulas One, Two and Three can also be applied to the soil, and when applied in this manner, root and stem feeding pests can be controlled. The roots can absorb a molecule taking it up into the foliar portions of the plant to control above ground chewing and sap feeding pests.

Generally, with baits, the baits are placed in the ground where, for example, termites can come into contact with, and/or be attracted to, the bait. Baits can also be applied to a surface of a building, (horizontal, vertical, or slant surface) where, for example, ants, termites, cockroaches, and flies, can come into contact with, and/or be attracted to, the bait.

Baits can comprise a molecule of Formula One, Two or Three.

The Molecules of Formulas One, Two and Three can be encapsulated inside, or placed on the surface of a capsule. The size of the capsules can range from nanometer size (about 100-900 nanometers in diameter) to micrometer size (about 10-900 microns in diameter).

Because of the unique ability of the eggs of some pests to resist certain pesticides, repeated applications of the Formula One, Two or Three may be desirable to control newly emerged larvae.

Systemic movement of pesticides in plants may be utilized to control pests on one portion of the plant by applying (for example by spraying an area) the Molecules of Formula One, Two or Three to a different portion of the plant. For example, control of foliar-feeding insects can be achieved by drip irrigation or furrow application, by treating the soil with for example pre- or post-planting soil drench, or by treating the seeds of a plant before planting.

Seed treatment can be applied to all types of seeds, including those from which plants genetically modified to express specialized traits will germinate. Representative examples include those expressing proteins toxic to invertebrate pests, such as *Bacillus thuringiensis* or other insecticidal toxins, those expressing herbicide resistance, such as "Roundup Ready" seed, or those with "stacked" foreign genes expressing insecticidal toxins, herbicide resistance, nutrition-enhancement, drought resistance, or any other beneficial traits. Furthermore, such seed treatments with the Molecules of Formula One, Two or Three may further enhance the ability of a plant to better withstand stressful growing conditions. This results in a healthier, more vigorous plant, which can lead to higher yields at harvest time. Generally, about 1 gram of the Molecules of Formula One, Two or Three to about 500 grams per 100,000 seeds is expected to provide good benefits, amounts from about 10 grams to about 100 grams per 100,000 seeds is expected to provide better benefits, and amounts from about 25 grams to about 75 grams per 100,000 seeds is expected to provide even better benefits.

It should be readily apparent that the Molecules of Formulas One, Two and Three may be used on, in, or around plants genetically modified to express specialized traits, such as *Bacillus thuringiensis* or other insecticidal toxins, or those expressing herbicide resistance, or those with "stacked" foreign genes expressing insecticidal toxins, herbicide resistance, nutrition-enhancement, or any other beneficial traits.

The Molecules of Formulas One, Two and Three may be used for controlling endoparasites and ectoparasites in the veterinary medicine sector or in the field of non-human

animal keeping. The Molecules of Formulas One, Two and Three are applied, such as by oral administration in the form of, for example, tablets, capsules, drinks, granules, by dermal application in the form of, for example, dipping, spraying, pouring on, spotting on, and dusting, and by parenteral administration in the form of, for example, an injection.

5 The Molecules of Formulas One, Two and Three may also be employed advantageously in livestock keeping, for example, cattle, sheep, pigs, chickens, and geese. They may also be employed advantageously in pets such as, horses, dogs, and cats. Particular pests to control would be fleas and ticks that are bothersome to such animals. Suitable formulations are administered orally to the animals with the drinking water or feed. The
10 dosages and formulations that are suitable depend on the species.

 The Molecules of Formulas One, Two and Three may also be used for controlling parasitic worms, especially of the intestine, in the animals listed above.

 The Molecules of Formula One, Two, and Three may also be employed in therapeutic methods for human health care. Such methods include, but are limited to, oral administration
15 in the form of, for example, tablets, capsules, drinks, granules, and by dermal application.

 Pests around the world have been migrating to new environments (for such pest) and thereafter becoming a new invasive species in such new environment. The Molecules of Formula One and Two may also be used on such new invasive species to control them in such new environment.

20 The Molecules of Formula One, Two, and Three may also be used in an area where plants, such as crops, are growing (*e.g.* pre-planting, planting, pre-harvesting) and where there are low levels (even no actual presence) of pests that can commercially damage such plants. The use of such molecules in such area is to benefit the plants being grown in the area. Such benefits, may include, but are not limited to, improving the health of a plant, improving
25 the yield of a plant (*e.g.* increased biomass and/or increased content of valuable ingredients), improving the vigor of a plant (*e.g.* improved plant growth and/or greener leaves), improving the quality of a plant (*e.g.* improved content or composition of certain ingredients), and improving the tolerance to abiotic and/or biotic stress of the plant.

 Before a pesticide can be used or sold commercially, such pesticide undergoes
30 lengthy evaluation processes by various governmental authorities (local, regional, state, national, and international). Voluminous data requirements are specified by regulatory authorities and must be addressed through data generation and submission by the product registrant or by a third party on the product registrant's behalf, often using a computer with a connection to the World Wide Web. These governmental authorities then review such data

and if a determination of safety is concluded, provide the potential user or seller with product registration approval. Thereafter, in that locality where the product registration is granted and supported, such user or seller may use or sell such pesticide.

5 A molecule according to Formula One, Two, and Three can be tested to determine its efficacy against pests. Furthermore, mode of action studies can be conducted to determine if said molecule has a different mode of action than other pesticides. Thereafter, such acquired data can be disseminated, such as by the internet, to third parties.

The headings in this document are for convenience only and must not be used to interpret any portion hereof.

10








TABLE SECTION








BAW & CEW Rating Table	
% Control (or Mortality)	Rating
50-100	A
More than 0 – Less than 50	B
Not Tested	C
No activity noticed in this bioassay	D








GPA Rating Table	
% Control (or Mortality)	Rating
80-100	A
More than 0 – Less than 80	B
Not Tested	C
No activity noticed in this bioassay	D









15









Table 1: Structures for Compounds









ID	Structure
I-4	
I-5	
I-6	
I-7	
I-8	
I-9	
I-10	









ID	Structure
I-11	
I-12	
I-13	
I-14	
I-15	
I-16	
I-17	









ID	Structure
I-18	
I-19	
I-20	
I-21	
I-22	
I-23	
I-24	

ID	Structure
I-25	
I-26	
I-27	
I-28	
I-29	
I-30	
I-31	
I-32	

ID	Structure
I-33	
I-34	
I-35	
I-36	
I-37	
I-38	
I-39	
I-40	

ID	Structure
I-41	
I-42	
I-43	
I-44	
I-45	
I-46	
I-47	
I-48	

ID	Structure
I-49	
I-50	
I-51	
I-52	
I-53	
I-54	
I-55	
I-56	

ID	Structure
I-57	
I-58	
I-59	
I-60	
I-61	
I-62	
I-63	
I-64	

ID	Structure
I-65	

Table 2: Analytical Data for Compounds in Table 1.

ID	Synthesis Method	MS	mp (°C)	¹ H, ¹³ C, or ¹⁹ F NMR (δ) ¹
I-4	A	551 (M+1)	209–211	(DMSO- <i>d</i> ₆) 12.06 (s, 1H), 10.19 (s, 1H), 9.42 (s, 1H), 8.22 (s, 1H), 8.17–8.03 (m, 5H), 7.66–7.57 (m, 4H), 7.42–7.38 (m, 2H)
I-5	C	511 (M+1)	220–225	(CDCl ₃) 9.30 (s, 1H), 8.69 (s, 1H), 8.60 (s, 1H), 8.26 (d, <i>J</i> = 8.4 Hz, 2H), 7.89 (s, 1H), 7.81 (m, 4H), 7.41 (d, <i>J</i> = 8.4 Hz, 2H), 7.19 (m, 3H), 2.35 (s, 6H)
I-6	C	555 (M+H)	206–209	(CDCl ₃) 8.90 (s, 1H), 8.80 (s, 1H), 8.6 (s, 1H), 8.28 (d, <i>J</i> = 8.4 Hz, 2H), 8.9–8.7 (m, 4H), 7.4 (d, <i>J</i> = 8.6 Hz, 2H), 6.7 (s, 2H), 3.80 (s, 3H), 2.39 (s, 3H), 2.32 (s, 6H)
I-7	C	541 (M+H)	202–210	(CDCl ₃) 9.88 (s, 1H), 8.61 (s, 1H), 8.60 (s, 1H), 8.27 (d, <i>J</i> = 8.4 Hz, 2H), 7.9 (s, 1H), 7.9–7.7 (m, 4H), 7.4 (d, <i>J</i> = 8.6 Hz, 2H), 6.7 (s, 2H), 3.81 (s, 3H), 2.33 (s, 6H)
I-8	B	581	195–199	(CDCl ₃) 10.2 (s, 1H), 8.7 (s, 1H), 8.6 (s, 1H), 8.25 (d, <i>J</i> = 8.4 Hz, 2H), 8.0 (s, 1H), 7.82 (m, 4H), 7.4 (d, <i>J</i> = 8.4 Hz, 2H), 7.0 (s, 2H), 3.82 (s, 3H)
I-9	C	591 (M+H)	233–236	(CDCl ₃) 9.89 (s, 1H), 8.60 (s, 2H), 8.25 (d, <i>J</i> = 8.5 Hz, 2H), 7.95 (s, 1H), 7.88–7.70 (m, 4H), 7.41 (d, <i>J</i> = 9.0 Hz, 2H), 6.70 (s, 2H), 3.81 (s, 3H), 2.31 (s, 6H)
I-10	C	525 (M+H)	230–240	(CDCl ₃) 9.93 (s, 1H), 8.69 (s, 1H), 8.60 (s, 1H), 8.26 (d, <i>J</i> = 8.4 Hz, 2H), 7.93 (d, <i>J</i> = 9.5 Hz, 2H), 7.95 (s, 1H), 7.86–7.75 (m, 4H), 6.69 (s, 2H), 3.81 (s, 3H), 2.31 (s, 6H)

ID	Synthesis Method	MS	mp (°C)	¹ H, ¹³ C, or ¹⁹ F NMR (δ) ¹
I-11	C	561 (M+H)	234–238	(CDCl ₃) 9.62 (s, 1H), 8.70 (s, 1H), 8.60 (s, 1H), 8.26 (d, <i>J</i> = 8.4 Hz, 2H), 7.92 (s, 1H), 7.86–7.75 (m, 4H), 7.41 (d, <i>J</i> = 9.0 Hz, 2H), 7.18 (m, 3H), 2.35 (s, 6H)
I-12	C	577 (M+H)	197–200	(CDCl ₃) 10.2 (s, 1H), 8.90 (s, 1H), 8.62 (s, 1H), 8.25 (d, <i>J</i> = 8.4 Hz, 2H), 7.98 (s, 1H), 7.9–7.7 (m, 4H), 7.4 (m, 3H), 6.8 (m, 2H), 3.82 (s, 3H), 2.37 (s, 3H)
I-13	B	541 (M+H)	180–186	(CDCl ₃) 9.9 (s, 1H), 8.6 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.9 (s, 1H), 7.8 (d, <i>J</i> = 8.6 Hz, 2H), 7.75 (d, <i>J</i> = 8.4 Hz, 2H), 7.7 (d, <i>J</i> = 7 Hz, 1H), 7.45–7.35 (m, 4H), 6.91 (d, <i>J</i> = 8 Hz, 2H), 5.73 (m, 1H), 3.80 (s, 3H), 1.65 (d, <i>J</i> = 7.2 Hz, 3H)
I-14	B	559 (M+H)	196–203	(CDCl ₃) 9.32 (s, 1H), 8.6 (s, 1H), 8.22 (d, <i>J</i> = 8.4 Hz, 2H), 7.85–7.7 (m, 5H), 7.6 (d, <i>J</i> = 6 Hz, 1H), 7.4 (d, <i>J</i> = 8.5 Hz, 2H), 7.25–7.15 (m, 2H), 6.93 (m, 1H), 5.7 (m, 1H), 3.89 (s, 3H), 1.67 (d, <i>J</i> = 6 Hz, 3H)
I-15	B	511 (M+H)	201–206	(CDCl ₃) 9.32 (s, 1H), 8.61 (s, 1H), 8.27 (d, <i>J</i> = 8.4 Hz, 2H), 7.9–7.7 (m, 6H), 7.5–7.3 (m, 7H), 5.76 (m, 1H), 1.67 (d, <i>J</i> = 7 Hz, 3H)
I-16	C	525 (M+1)	218–225	(CDCl ₃) 9.37 (s, 1H), 8.63 (s, 1H), 8.60 (s, 1H), 8.26 (d, <i>J</i> = 8.4 Hz, 2H), 7.89 (s, 1H), 7.85–7.76 (m, 4H), 7.41 (d, <i>J</i> = 8.4 Hz, 2H), 6.97 (s, 2H), 2.32 (s, 3H), 2.30 (s, 6H)
I-17	C	525 (M+H)	168–180	(CDCl ₃) 10.2 (s, 1H), 9.07 (s, 1H), 8.63 (s, 1H), 8.25 (d, <i>J</i> = 8.4 Hz, 2H), 8.0 (s, 1H), 7.9–7.7 (m, 4H), 7.65 (d, <i>J</i> = 8 Hz, 1H), 7.4–7.25 (m, 5H), 3.25 (heptet, <i>J</i> = 7 Hz, 1H), 1.35 (d, <i>J</i> = 7 Hz, 6H)
I-18	C	539 (M+1)	216–221	(CDCl ₃) δ 9.29 (s, 1H), 8.87 (s, 1H), 8.59 (s, 1H), 8.31 – 8.19 (m, 2H), 7.90 – 7.84 (m, 2H), 7.85 – 7.79 (m, 2H), 7.73 (dd, <i>J</i> = 7.5, 1.7 Hz, 1H), 7.39 (dd, <i>J</i> = 12.6, 5.1 Hz, 3H), 7.35 – 7.27 (m, 2H), 3.37 – 3.04 (m, 1H), 2.40 (s, 3H), 1.29 (d, <i>J</i> = 7.5 Hz, 6H)

ID	Synthesis Method	MS	mp (°C)	^1H , ^{13}C , or ^{19}F NMR (δ) ¹
I-19	C	509 (M+1)	223-225	(CDCl ₃) δ 9.74 (s, 1H), 9.06 (s, 1H), 8.69 (s, 1H), 8.31 – 8.20 (m, 2H), 7.98 – 7.84 (m, 3H), 7.80 (m, 4H), 7.65 (d, J = 1.4 Hz, 1H), 7.43 – 7.28 (m, 3H), 3.19 (heptet, J = 6.9 Hz, 1H), 1.32 (d, J = 6.9 Hz, 6H)
I-20	C	538 (M+H)	220 (dec)	(CDCl ₃) δ 9.52 (s, 1H), 9.31 (s, 1H), 8.66 (d, J = 8.2 Hz, 1H), 8.60 (s, 1H), 8.25 (d, J = 8.4 Hz, 2H), 7.87 (s, 1H), 7.86 – 7.80 (m, 2H), 7.77 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 8.3 Hz, 2H), 7.32 (ddd, J = 13.9, J = 7.2, 4.3 Hz, 1H), 7.24 – 7.15 (m, 2H), 6.27 (s, 1H), 2.03 (d, J = 1.3 Hz, 3H), 1.73 (d, J = 1.1 Hz, 3H)
I-21	C	540 (M+H)	207-210; 215-218	(CDCl ₃) δ 9.48 (s, 1H), 9.14 (s, 1H), 8.60 (s, 1H), 8.26 (d, J = 8.4 Hz, 2H), 7.92 (s, 1H), 7.87 (d, J = 7.7 Hz, 1H), 7.84 – 7.76 (m, 4H), 7.40 (d, J = 8.3 Hz, 2H), 7.30 (dt, J = 8.2, 3.7 Hz, 1H), 7.28 – 7.23 (m, 2H), 2.57 (d, J = 7.2 Hz, 2H), 1.93 (dq, J = 13.6, 6.7 Hz, 1H), 0.98 (d, J = 6.6 Hz, 6H)
I-22	C	540 (M+H)	210-215	(CDCl ₃) δ 9.46 (s, 1H), 9.05 (s, 1H), 8.60 (s, 1H), 8.26 (d, J = 8.4 Hz, 2H), 7.91 (s, 1H), 7.84 – 7.74 (m, 4H), 7.69 (d, J = 7.4 Hz, 1H), 7.40 (d, J = 8.3 Hz, 2H), 7.36 – 7.27 (m, 3H), 2.91 (dt, J = 13.9, 6.9 Hz, 1H), 1.75 – 1.58 (m, 2H), 1.30 (d, J = 6.9 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H).
I-23	C	560 (M+H)	213-216	(CDCl ₃) δ 9.41 (s, 1H), 9.01 (s, 1H), 8.74 (d, J = 7.7 Hz, 1H), 8.60 (s, 1H), 8.15 (d, J = 8.4 Hz, 2H), 7.86 – 7.78 (m, 2H), 7.69 (s, 1H), 7.57 – 7.44 (m, 6H), 7.42 (d, J = 9.1 Hz, 2H), 7.37 – 7.27 (m, 4H).
I-24	C	524 (M+H)	200-206; 210-211	(CDCl ₃) δ 9.65 (d, J = 17.9 Hz, 1H), 9.20 (s, 1H), 8.60 (s, 1H), 8.27 (dd, J = 8.0, 4.5 Hz, 3H), 7.89 (s, 1H), 7.86 – 7.75 (m, 4H), 7.41 (d, J = 8.3 Hz, 2H), 7.30 – 7.27 (m, 1H), 7.18 (q, J = 7.8 Hz, 2H), 2.00 – 1.90 (m, 1H), 1.09 – 1.01 (m, 2H), 0.81 – 0.73 (m, 2H).

ID	Synthesis Method	MS	mp (°C)	^1H , ^{13}C , or ^{19}F NMR (δ) ¹
I-25	C	550 (M+H)	221-223	(DMSO- <i>d</i> ₆) δ 12.13 (s, 1H), 10.07 (s, 1H), 9.44 (s, 1H), 8.23 (s, 1H), 8.16 (d, <i>J</i> = 8.4 Hz, 2H), 8.13 – 8.06 (m, 2H), 8.01 – 7.98 (m, 3H), 7.63 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 – 7.26 (m, 3H), 7.23 (t, <i>J</i> _{HF} = 74.1 Hz, 1H)
I-26	C	590 (M+H)	230-231	(CDCl ₃) δ 9.37 (s, 1H), 8.60 (s, 1H), 8.57 (s, 1H), 8.27 (d, <i>J</i> = 8.4 Hz, 2H), 7.90 (s, 1H), 7.81 (dt, <i>J</i> = 8.5, 4.8 Hz, 4H), 7.41 (d, <i>J</i> = 8.3 Hz, 2H), 7.31 (s, 2H), 2.31 (s, 6H)
I-27	C	556 (M+H)	190-192	(CDCl ₃) δ 9.39 (s, 1H), 9.15 (s, 1H), 8.61 (s, 1H), 8.29 (d, <i>J</i> = 8.4 Hz, 2H), 8.16 – 8.05 (m, 2H), 7.95 – 7.85 (m, 3H), 7.85 – 7.76 (m, 4H), 7.41 (d, <i>J</i> = 8.3 Hz, 2H), 4.39 (q, <i>J</i> = 7.1 Hz, 2H), 1.41 (t, <i>J</i> = 7.1 Hz, 3H)
I-28	C	528 (M+H)	219-221	(300 MHz, CDCl ₃) δ 10.17 (s, 1H), 9.09 (s, 1H), 9.03 (t, <i>J</i> = 5.4 Hz, 1H), 8.60 (s, 1H), 8.23 (t, <i>J</i> = 8.9 Hz, 2H), 7.89 – 7.76 (m, 5H), 7.39 (t, <i>J</i> = 7.2 Hz, 2H), 7.17 – 7.07 (m, 1H), 7.03 (d, <i>J</i> = 7.8 Hz, 1H), 6.94 (d, <i>J</i> = 6.9 Hz, 1H), 4.18 (q, <i>J</i> = 7.1 Hz, 2H), 1.61 (t, <i>J</i> = 7.0 Hz, 3H)
I-29	C	499 (M+1)	195-200	(DMSO- <i>d</i> ₆) δ 9.44 (s, 1H), 8.49 (s, 1H), 8.42 (d, <i>J</i> = 5.2 Hz, 1H), 8.29 – 8.21 (m, 2H), 8.16 (d, <i>J</i> = 8.5 Hz, 2H), 8.10 (d, <i>J</i> = 2.3 Hz, 1H), 8.08 (d, <i>J</i> = 3.0 Hz, 1H), 8.04 (t, <i>J</i> = 6.5 Hz, 2H), 7.63 (d, <i>J</i> = 8.3 Hz, 3H), 2.29 (s, 3H).
I-30	C	499 (M+1)	114-118	(CDCl ₃) δ 8.60 (s, 1H), 8.31 (s, 1H), 8.24 (d, <i>J</i> = 8.4 Hz, 2H), 8.16 (d, <i>J</i> = 3.9 Hz, 1H), 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.82 (d, <i>J</i> = 9.0 Hz, 2H), 7.55 (d, <i>J</i> = 6.7 Hz, 1H), 7.41 (s, 2H), 6.99 (dd, <i>J</i> = 7.4, 5.1 Hz, 1H), 2.35 (s, 3H).
I-31	C	513 (M+1)	122-125	(CDCl ₃) δ 8.60 (s, 1H), 8.32 (s, 1H), 8.25 (d, <i>J</i> = 8.4 Hz, 2H), 8.19 – 8.16 (m, 1H), 7.97 (d, <i>J</i> = 8.4 Hz, 2H), 7.84 – 7.81 (m, 2H), 7.58 (d, <i>J</i> = 7.5 Hz, 1H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.03 (dd, <i>J</i> = 7.5, 5.1 Hz, 1H), 2.67 (s, 2H), 1.35 (t, <i>J</i> = 7.5 Hz, 3H).

ID	Synthesis Method	MS	mp (°C)	^1H , ^{13}C , or ^{19}F NMR (δ) ¹
I-32	M	210 ([M+H] ⁺)	--	(CDCl ₃) δ 8.97 (bs, 1H), 7.74 – 7.11 (m, 5H), 4.06 (bs, 2H), 3.11 (hept, J = 6.9 Hz, 1H), 1.24 (d, J = 6.9 Hz, 6H)
I-33	C	575 ([M+H] ⁺)	214-216	(DMSO- <i>d</i> ₆) δ 11.87 (s, 1H), 10.08 (s, 1H), 9.44 (s, 1H), 8.20 (s, 1H), 8.17 – 8.02 (m, 6H), 7.63 (d, J = 9.0 Hz, 2H), 7.39 – 7.35 (m, 1H), 7.35 – 7.28 (m, 1H), 7.27 – 7.18 (m, 2H), 3.19 – 3.05 (m, 1H), 1.20 (d, J = 6.9 Hz, 6H); ^{19}F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -85.20, -86.94
I-34	P*	317 ([M+H] ⁺)	--	(CDCl ₃) δ 8.50 (s, 1H), 8.07 (d, J = 8.1 Hz, 2H), 7.56 (d, J = 2.1 Hz, 1H), 7.44 (dd, J = 8.6, 2.2 Hz, 1H), 7.29 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.6 Hz, 1H), 2.42 (s, 3H); ^{19}F NMR (376 MHz, CDCl ₃) δ -49.69
I-35	P*	330 ([M+H] ⁺)	--	(CDCl ₃) δ 10.09 (s, 1H), 8.55 (m, 1H), 8.37 (m, 1H), 8.22 (m, 1H), 8.00 (m, 1H), 7.57 (dd, J = 5.3, 2.2 Hz, 1H), 7.51 (m, 1H), 7.46 (m, 1H), 7.21 (m, 1H); ^{19}F NMR (376 MHz, CDCl ₃) δ -49.61
I-36	C	521 ([M+H] ⁺)	200 (dec.)	(CDCl ₃) δ 9.47 (s, 1H), 9.05 (s, 1H), 8.54 (s, 1H), 8.25 (d, J = 8.4 Hz, 2H), 7.92 (s, 1H), 7.78 (d, J = 8.4 Hz, 2H), 7.71 – 7.62 (m, 1H), 7.57 (t, J = 2.7 Hz, 1H), 7.46 (dd, J = 8.6, 2.2 Hz, 1H), 7.41 – 7.29 (m, 3H), 7.21 (d, J = 8.6 Hz, 1H), 3.19 (dt, J = 13.8, 6.9 Hz, 1H), 1.32 (d, J = 6.9 Hz, 6H); ^{19}F NMR (376 MHz, CDCl ₃) δ -49.62

ID	Synthesis Method	MS	mp (°C)	¹ H, ¹³ C, or ¹⁹ F NMR (δ) ¹
I-37	M	--	--	(CDCl ₃) δ 7.48 – 7.36 (m, 1H), 7.21 – 7.06 (m, 2H), 5.23 (p, <i>J</i> = 1.5 Hz, 1H), 5.05 (q, <i>J</i> = 1.1 Hz, 1H), 2.09 (s, 3H); ¹³ C NMR (101 MHz, CDCl ₃) δ 153.56 (d, <i>J</i> _{CF} = 257.5 Hz), 139.62, 139.60, 138.83, 131.48 (d, <i>J</i> _{CF} = 8.6 Hz), 124.47 (d, <i>J</i> _{CF} = 3.6 Hz), 117.60, 115.51 (d, <i>J</i> _{CF} = 19.1 Hz), 23.18
I-38	M	--	--	(CDCl ₃) δ 6.92 (dt, <i>J</i> = 7.7, 1.2 Hz, 1H), 6.86 (ddd, <i>J</i> = 10.8, 8.1, 1.4 Hz, 1H), 6.69 (td, <i>J</i> = 8.0, 5.6 Hz, 1H), 3.71 (bs, 2H), 2.92 (hept, <i>J</i> = 6.8 Hz, 1H), 1.26 (d, <i>J</i> = 6.8 Hz, 6H); ¹³ C NMR (101 MHz, CDCl ₃) δ 151.91 (d, <i>J</i> = 237.6 Hz), 135.10 (d, <i>J</i> = 2.3 Hz), 131.60 (d, <i>J</i> = 11.8 Hz), 120.52 (d, <i>J</i> = 3.0 Hz), 117.99 (d, <i>J</i> = 8.0 Hz), 112.28 (d, <i>J</i> = 19.6 Hz), 27.77 (d, <i>J</i> = 2.9 Hz), 22.22
I-39	M	229 ([M+H] ⁺)	122-124	(CDCl ₃) δ 8.56 (bs, 1H), 7.54 (bs, 1H), 7.32 (td, <i>J</i> = 8.1, 5.6 Hz, 1H), 7.17 – 7.09 (m, 1H), 7.00 (ddd, <i>J</i> = 9.5, 8.2, 1.4 Hz, 1H), 4.07 (bs, 2H), 3.15 (hept, <i>J</i> = 7.0 Hz, 1H), 1.24 (d, <i>J</i> = 6.9 Hz, 6H), 7.78 – 7.39 (m, 1H)
I-40	C	544 ([M+H] ⁺)	210-212	(CDCl ₃) δ 9.54 (s, 1H), 8.60 (s, 1H), 8.56 (s, 1H), 8.30 – 8.22 (m, 2H), 7.92 (s, 1H), 7.86 – 7.76 (m, 4H), 7.44 – 7.38 (m, 2H), 7.35 (dd, <i>J</i> = 8.1, 5.6 Hz, 1H), 7.18 (d, <i>J</i> = 7.9 Hz, 1H), 7.04 (ddd, <i>J</i> = 9.4, 8.2, 1.3 Hz, 1H), 3.22 (p, <i>J</i> = 6.9 Hz, 1H), 1.29 (d, <i>J</i> = 6.9 Hz, 6H);

ID	Synthesis Method	MS	mp (°C)	^1H , ^{13}C , or ^{19}F NMR (δ) ¹
I-41	M	--	--	(CDCl ₃) δ 7.60 (dd, J = 8.2, 2.5 Hz, 1H), 7.37 – 7.21 (m, 2H), 5.19 (p, J = 1.5 Hz, 1H), 4.97 – 4.89 (m, 1H), 2.11 – 2.04 (m, 3H); ^{13}C NMR (101 MHz, CDCl ₃) δ 160.96 (d, J = 250.8 Hz), 148.46, 141.88, 135.18 (d, J = 4.1 Hz), 132.09 (d, J = 7.8 Hz), 119.98 (d, J = 20.9 Hz), 115.99, 111.63 (d, J = 26.4 Hz), 23.35
I-42	M	--	--	(CDCl ₃) δ 7.05 (dd, J = 8.5, 6.4 Hz, 1H), 6.45 (td, J = 8.5, 2.6 Hz, 1H), 6.37 (dd, J = 10.6, 2.6 Hz, 1H), 3.74 (bs, 2H), 2.83 (hept, J = 6.8 Hz, 1H), 1.24 (d, J = 6.8 Hz, 6H); ^{13}C NMR (101 MHz, CDCl ₃) δ 161.75 (d, J = 241.3 Hz), 144.76 (d, J = 10.3 Hz), 128.11 (d, J = 2.8 Hz), 126.53 (d, J = 9.6 Hz), 105.06 (d, J = 20.7 Hz), 102.26 (d, J = 24.2 Hz), 27.27, 22.35
I-43	M	226 ([M-H] ⁺)	133-135	(CDCl ₃) δ 9.11 (bs, 1H), 7.44 (bs, 2H), 7.35 – 7.27 (m, 1H), 6.99 (s, 1H), 4.03 (bs, 2H), 3.05 (hept, J = 6.9 Hz, 1H), 1.23 (d, J = 6.9 Hz, 6H)
I-44	C	544 ([M+H] ⁺)	217-222	(CDCl ₃) δ 9.45 (s, 1H), 9.13 (s, 1H), 8.60 (s, 1H), 8.32 – 8.21 (m, 2H), 7.92 (s, 1H), 7.87 – 7.75 (m, 4H), 7.64 (dd, J = 9.9, 2.7 Hz, 1H), 7.46 – 7.37 (m, 2H), 7.32 (dd, J = 8.8, 6.2 Hz, 1H), 7.02 (td, J = 8.3, 2.8 Hz, 1H), 3.14 (hept, J = 6.9 Hz, 1H), 1.31 (d, J = 6.9 Hz, 6H)
I-45	M	--	--	(CDCl ₃) δ 7.96 (dd, J = 9.0, 5.1 Hz, 1H), 7.08 (ddd, J = 9.0, 7.4, 2.8 Hz, 1H), 7.02 (dd, J = 8.7, 2.8 Hz, 1H), 5.20 (p, J = 1.5 Hz, 1H), 4.96 (p, J = 1.0 Hz, 1H), 2.11 – 2.06 (m, 3H)

ID	Synthesis Method	MS	mp (°C)	^1H , ^{13}C , or ^{19}F NMR (δ) ¹
I-46	M	--	--	CDCl_3) δ 6.85 (dd, $J = 10.3, 2.9$ Hz, 1H), 6.72 (td, $J = 8.3, 2.9$ Hz, 1H), 6.60 (dd, $J = 8.6, 5.1$ Hz, 1H), 3.49 (bs, 2H), 2.88 (hept, $J = 6.8$ Hz, 1H), 1.24 (d, $J = 6.8$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 156.92 (d, $J_{\text{CF}} = 235.0$ Hz), 139.17 (d, $J_{\text{CF}} = 2.1$ Hz), 134.61 (d, $J_{\text{CF}} = 6.2$ Hz), 116.55 (d, $J_{\text{CF}} = 7.5$ Hz), 112.69 (d, $J_{\text{CF}} = 22.5$ Hz), 112.17 (d, $J_{\text{CF}} = 22.4$ Hz), 27.90, 22.11
I-47	M	228 ([M+H] ⁺)	163-17	(CDCl_3) δ 8.88 (bs, 1H), 7.42 (bs, 1H), 7.03 (dd, $J = 10.0, 2.9$ Hz, 1H), 6.93 (ddd, $J = 8.7, 7.7, 3.0$ Hz, 1H), 4.03 (bs, 2H), 3.14 – 3.00 (m, 1H), 1.23 (d, $J = 6.9$ Hz, 6H)
I-48	C	544 ([M+H] ⁺)	219-221	(300 MHz, CDCl_3) δ 9.55 (s, 1H), 8.90 (s, 1H), 8.59 (s, 1H), 8.30 – 8.21 (m, 2H), 7.92 (s, 1H), 7.85 – 7.74 (m, 4H), 7.54 (dd, $J = 8.8, 5.5$ Hz, 1H), 7.40 (d, $J = 8.6$ Hz, 2H), 7.07 (dd, $J = 10.0, 2.9$ Hz, 1H), 6.97 (td, $J = 8.2, 2.9$ Hz, 1H), 3.24 – 3.08 (m, 1H), 1.29 (d, $J = 6.9$ Hz, 6H)
I-49	M	--	--	(CDCl_3) δ 7.64 (dt, $J = 8.1, 1.2$ Hz, 1H), 7.39 (td, $J = 8.2, 5.4$ Hz, 1H), 7.31 (td, $J = 8.5, 1.2$ Hz, 1H), 5.28 (p, $J = 1.5$ Hz, 1H), 4.91 (p, $J = 1.0$ Hz, 1H), 2.16 (t, $J = 1.3$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 159.59 (d, $J = 249.3$ Hz), 149.81, 136.14, 128.57 (d, $J = 9.0$ Hz), 127.02 (d, $J = 22.0$ Hz), 119.84 (d, $J = 23.4$ Hz), 119.41 (d, $J = 3.6$ Hz), 117.25, 23.10 (d, $J = 1.9$ Hz)

ID	Synthesis Method	MS	mp (°C)	¹ H, ¹³ C, or ¹⁹ F NMR (δ) ¹
I-50	M	--	--	CDCl₃) δ 6.92 (td, <i>J</i> = 8.1, 6.1 Hz, 1H), 6.44 (ddd, <i>J</i> = 10.4, 8.1, 1.1 Hz, 2H), 3.72 (bs, 2H), 3.06 (heptd, <i>J</i> = 7.1, 1.3 Hz, 1H), 1.35 (dd, <i>J</i> = 7.1, 1.5 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 162.83 (d, <i>J</i> = 243.4 Hz), 145.29 (d, <i>J</i> = 8.8 Hz), 127.08 (d, <i>J</i> = 11.2 Hz), 119.64 (d, <i>J</i> = 16.1 Hz), 111.77 (d, <i>J</i> = 2.3 Hz), 106.47 (d, <i>J</i> = 24.2 Hz), 25.65, 20.97 (d, <i>J</i> = 3.8 Hz)
I-51	M	228 ([M+H] ⁺)	158-160	(CDCl ₃) δ 8.91 (bs, 1H), 7.42 (bs, 1H), 7.25 – 7.08 (m, 2H), 7.02 (d, <i>J</i> = 10.0 Hz, 1H), 4.04 (bs, 2H), 3.18 (hept, <i>J</i> = 7.0 Hz, 1H), 1.44 – 1.24 (m, 6H)
I-52	C	544 ([M+H] ⁺)	220-223	(CDCl ₃) δ 10.05 (s, 1H), 8.95 (s, 1H), 8.60 (s, 1H), 8.30 – 8.21 (m, 2H), 7.99 (s, 1H), 7.85 – 7.73 (m, 4H), 7.44 – 7.37 (m, 2H), 7.34 (d, <i>J</i> = 7.9 Hz, 1H), 7.24 (td, <i>J</i> = 8.1, 5.8 Hz, 1H), 7.05 (ddd, <i>J</i> = 11.1, 8.2, 1.3 Hz, 1H), 3.37 – 3.21 (m, 1H), 1.41 (dd, <i>J</i> = 7.1, 1.2 Hz, 6H)
I-53	C	527 ([M+H] ⁺)	--	(DMSO-<i>d</i>₆) δ 11.98 (s, 1H), 10.11 (s, 1H), 9.57 (s, 1H), 8.24 – 8.19 (m, 3H), 8.19 – 8.14 (m, 2H), 8.09 – 8.03 (m, 2H), 8.03 – 7.96 (m, 2H), 7.39 (dd, <i>J</i> = 8.7, 6.4 Hz, 1H), 7.22 – 7.08 (m, 2H), 3.12 (hept, <i>J</i> = 7.1 Hz, 1H), 1.19 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹F NMR (376 MHz, DMSO-<i>d</i>₆) δ -60.81, -117.72

ID	Synthesis Method	MS	mp (°C)	^1H , ^{13}C , or ^{19}F NMR (δ) ¹
I-54	C	593 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 12.07 – 11.88 (m, 1H), 10.11 (s, 1H), 9.45 (s, 1H), 8.21 (s, 1H), 8.18 – 8.13 (m, 2H), 8.13 – 8.08 (m, 2H), 8.08 – 8.03 (m, 2H), 7.67 – 7.59 (m, 2H), 7.39 (dd, <i>J</i> = 8.7, 6.5 Hz, 1H), 7.22 – 7.08 (m, 2H), 3.12 (hept, <i>J</i> = 7.0 Hz, 1H), 1.19 (d, <i>J</i> = 6.8 Hz, 6H); ^{19}F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -85.19, -86.92, -117.73
I-55	P*	402 [M-H] ⁻)	--	(CDCl ₃) δ 8.64 (d, <i>J</i> = 1.1 Hz, 1H), 8.09 (m, 3H), 7.93 (m, 3H), 7.78 (d, <i>J</i> = 8.5 Hz, 3H), 7.30 (d, <i>J</i> = 7.9 Hz, 3H), 2.42 (s, 4H); ^{19}F NMR (376 MHz, CDCl ₃) δ -75.61, -75.63, -75.63, -182.14, -182.17, -182.18
I-56	P*	418 ([M+H] ⁺)	--	(CDCl ₃) δ 10.09 (s, 1H), 8.71 (s, 1H), 8.39 (d, <i>J</i> = 8.3 Hz, 2H), 8.01 (d, <i>J</i> = 8.3 Hz, 2H), 7.95 (m, 2H), 7.82 (d, <i>J</i> = 8.6 Hz, 2H); ^{19}F NMR (376 MHz, CDCl ₃) δ -75.57, -75.59, -182.14, -182.16, -182.18
I-57	C	627 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 11.98 (s, 1H), 10.11 (s, 1H), 9.54 (s, 1H), 8.30 – 8.20 (m, 3H), 8.19 – 8.13 (m, 2H), 8.10 – 8.03 (m, 2H), 7.93 (d, <i>J</i> = 8.5 Hz, 2H), 7.39 (dd, <i>J</i> = 8.7, 6.4 Hz, 1H), 7.21 – 7.08 (m, 2H), 3.12 (hept, <i>J</i> = 6.7 Hz, 1H), 1.19 (d, <i>J</i> = 6.8 Hz, 6H); ^{19}F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -75.08 (d, <i>J</i> = 7.4 Hz), -117.73, -179.04 – -182.36 (m)

ID	Synthesis Method	MS	mp (°C)	¹ H, ¹³ C, or ¹⁹ F NMR (δ) ¹
I-58	P*	454 ([M+H] ⁺)	--	(CDCl ₃) δ 8.65 (s, 1H), 8.10 (m, 2H), 7.93 (m, 2H), 7.77 (d, <i>J</i> = 8.3 Hz, 2H), 7.30 (m, 2H), 2.42 (s, 3H); ¹⁹ F NMR (376 MHz, CDCl ₃) δ -73.89, -73.91, -73.92, -73.93, -73.94, -73.95, -73.95, -73.97, -73.97, -79.19, -79.22, -121.15, -121.18, -121.41, -121.43, -121.44, -121.46, -182.85, -182.87, -182.89, -182.90
I-59	P*	468([M+H] ⁺)	--	(CDCl ₃) δ 10.09 (s, 1H), 8.72 (s, 1H), 8.39 (m, 2H), 8.01 (m, 2H), 7.95 (m, 2H), 7.80 (d, <i>J</i> = 8.3 Hz, 2H); ¹⁹ F NMR (376 MHz, CDCl ₃) δ -73.84, -79.18, -121.08, -182.84
I-60	C	677 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 11.98 (s, 1H), 10.11 (s, 1H), 9.55 (s, 1H), 8.31 – 8.20 (m, 3H), 8.20 – 8.13 (m, 2H), 8.11 – 8.03 (m, 2H), 7.92 (d, <i>J</i> = 8.5 Hz, 2H), 7.39 (dd, <i>J</i> = 8.7, 6.5 Hz, 1H), 7.23 – 7.07 (m, 2H), 3.12 (hept, <i>J</i> = 6.7 Hz, 1H), 1.19 (d, <i>J</i> = 6.9 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -73.44 (dtd, <i>J</i> = 15.4, 8.1, 7.5, 3.0 Hz), -78.73 (d, <i>J</i> = 12.8 Hz), -117.73, -120.00 – -122.33 (m), -182.26 (tt, <i>J</i> = 12.8, 6.4 Hz)
I-61	P*	302 ([M+H] ⁺)	--	(CDCl ₃) δ 8.61 (s, 1H), 8.11 (d, <i>J</i> = 8.16 Hz, 2H), 7.84 (d, <i>J</i> = 8.68 Hz, 2H), 7.67 (d, <i>J</i> = 8.68 Hz, 2H), 7.30 (d, <i>J</i> = 7.96 Hz, 2H), 2.43 (s, 3H), 1.98 (t, <i>J</i> = 18.12 Hz, 3H)
I-62	P*	314 ([M+H] ⁺)	139-141	(CDCl ₃) δ 10.11 (s, 1H), 8.69 (s, 1H), 8.41 (d, <i>J</i> = 8.28 Hz, 2H), 8.02 (d, <i>J</i> = 8.28 Hz, 2H), 7.87 (d, <i>J</i> = 8.56 Hz, 2H), 7.71 (d, <i>J</i> = 8.56 Hz, 2H), 2.00 (t, <i>J</i> = 18.12 Hz, 3H)









ID	Synthesis Method	MS	mp (°C)	¹ H, ¹³ C, or ¹⁹ F NMR (δ) ¹
I-63	C	523 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 11.98 (s, 1H), 10.11 (s, 1H), 9.49 (s, 1H), 8.21 (d, <i>J</i> = 0.8 Hz, 1H), 8.16 (d, <i>J</i> = 8.4 Hz, 2H), 8.12 – 8.03 (m, 4H), 7.85 – 7.76 (m, 2H), 7.39 (dd, <i>J</i> = 8.7, 6.4 Hz, 1H), 7.22 – 7.08 (m, 2H), 3.12 (hept, <i>J</i> = 6.6 Hz, 1H), 2.04 (t, <i>J</i> = 18.9 Hz, 3H), 1.19 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -84.18, -117.72
I-64	C	577 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 12.04 (s, 1H), 10.17 (s, 1H), 9.62 (s, 1H), 8.30 (d, <i>J</i> = 1.6 Hz, 1H), 8.28 (d, <i>J</i> = 4.6 Hz, 2H), 8.25 – 8.19 (m, 2H), 8.17 – 8.08 (m, 2H), 8.01 (d, <i>J</i> = 8.6 Hz, 2H), 7.45 (dd, <i>J</i> = 8.7, 6.4 Hz, 1H), 7.27 – 7.12 (m, 2H), 3.17 (hept, <i>J</i> = 6.9 Hz, 1H), 1.24 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -84.03 (d, <i>J</i> = 2.6 Hz), -113.43, -117.72
I-65	C	527 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 11.92 (s, 1H), 10.05 (s, 1H), 9.57 (s, 1H), 8.29 – 7.94 (m, 9H), 7.20 (ddd, <i>J</i> = 20.5, 9.6, 4.3 Hz, 2H), 7.06 (td, <i>J</i> = 8.4, 3.0 Hz, 1H), 3.18 – 3.03 (m, 1H), 1.19 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -60.81, -114.66








NMR spectral data were acquired using a 400 MHz instrument unless otherwise noted.








P* – Prepared according to methods described in Crouse et al. PCT Int. Appl. Publ. WO2009/102736 A1 and Brown, et al, WO 2011017504 A1.

Table 3: Structures for Compounds








ID	Structure
1C	







ID	Structure
2C	
3C	
4C	
5C	
6C	
7C	
8C	
9C	








ID	Structure
10C	
11C	
12C	
13C	
14C	
15C	
16C	

ID	Structure
17C	
18C	
19C	
20C	
21C	
22C	
23C	

ID	Structure
24C	
25C	
26C	
27C	
28C	
29C	
30C	
31C	

ID	Structure
32C	
33C	
34C	
35C	
36C	
37C	
38C	







ID	Structure
39C	
40C	
41C	
42C	
43C	
44C	

ID	Structure
45C	
46C	
47C	
48C	
49C	
50C	
51C	

ID	Structure
52C	
53C	
54C	
55C	
56C	
57C	
58C	

ID	Structure
59C	
60C	
61C	
62C	
63C	
64C	











ID	Structure
65C	
66C	
67C	
68C	
69C	
70C	
71C	
72C	

ID	Structure
73C	
74C	
75C	
76C	
77C	
78C	

ID	Structure
79C	
80C	
81C	
82C	
83C	
84C	
85C	

ID	Structure
86C	
87C	
88C	
89C	
90C	
91C	
92C	
93C	

ID	Structure
94C	
95C	
96C	
97C	
98C	
99C	
100C	
101C	
102C	

ID	Structure
103C	
104C	
105C	
106C	
107C	
108C	
109C	
110C	
111C	
112C	

ID	Structure
113C	
114C	
115C	
116C	
117C	
118C	
119C	
120C	
121C	
122C	

ID	Structure
123C	
124C	
125C	
126C	
127C	
128C	
129C	
130C	
131C	
132C	

ID	Structure
133C	
134C	
135C	
136C	
137C	
138C	
139C	
140C	
141C	
142C	
143C	

ID	Structure
144C	
145C	
146C	
147C	
148C	
149C	
150C	
151C	
152C	
153C	

ID	Structure
154C	
155C	
156C	
157C	
158C	
159C	
160C	
161C	
162C	
163C	

ID	Structure
164C	
165C	
166C	
167C	
168C	
169C	
170C	
171C	
172C	
173C	

ID	Structure
174C	
175C	
176C	
177C	
178C	
179C	
180C	
181C	
182C	

ID	Structure
183C	
184C	
185C	
186C	
187C	
188C	
189C	
190C	
191C	








ID	Structure
192C	
193C	
194C	
195C	
196C	
197C	
198C	
199C	
200C	








ID	Structure
201C	
202C	
203C	
204C	
205C	
206C	
207C	
208C	
209C	







ID	Structure
210C	
211C	
212C	
213C	
214C	
215C	
216C	
217C	
218C	

ID	Structure
219C	
220C	
221C	
222C	
223C	
224C	
225C	
226C	
227C	
228C	

ID	Structure
229C	
230C	
231C	
232C	
233C	
234C	
235C	
236C	
237C	
238C	

ID	Structure
239C	
240C	
241C	
242C	
243C	
244C	
245C	

ID	Structure
246C	
247C	
248C	
249C	
250C	
251C	
252C	

ID	Structure
253C	
254C	
255C	
256C	
257C	
258C	




ID	Structure
259C	
260C	
261C	

Table 4: Analytical Data for Compounds in Table 3

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
1C	D	540 (M ⁺)	-	(DMSO- <i>d</i> ₆) 8.61 (s, 1H), 8.48 (s, 1H), 8.22 (d, <i>J</i> = 8.24 Hz, 2H), 8.17 (s, 1H), 7.89 (d, <i>J</i> = 8.24 Hz, 2H), 7.80 (d, <i>J</i> = 8.28 Hz, 2H), 7.41 (d, <i>J</i> = 8.28 Hz, 2H), 7.19 (d, <i>J</i> = 8.24 Hz, 2H), 6.71 (d, <i>J</i> = 8.24 Hz, 2H), 2.99 (s, 6H), 2.42 (s, 3H)
2C	D	580 (M ⁺)	168–171	(DMSO- <i>d</i> ₆) 9.42 (s, 1H), 8.18-8.03 (m, 5H), 7.78-7.69 (m, 2H), 7.61 (d, <i>J</i> = 8.26 Hz, 2H), 7.44 (d, <i>J</i> = 8.24 Hz, 2H), 7.18 (m, 1H), 3.09-2.99 (m, 2H), 1.39-1.32 (m, 3H)
3C	D	594	180–182	(DMSO- <i>d</i> ₆) 9.42 (s, 1H), 8.18-8.04 (m, 5H), 7.78-7.69 (m, 2H), 7.61 (d, <i>J</i> = 8.26 Hz, 2H), 7.48 (d, <i>J</i> = 8.24 Hz, 2H), 7.19 (m, 1H), 3.06-3.02 (m, 2H), 1.78-1.64 (m, 2H), 1.04-0.96 (m, 3H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
4C	D	629 (M+)		(DMSO- <i>d</i> ₆) 8.57 (s, 1H), 8.48 (d, <i>J</i> = 5.5 Hz, 1H), 8.22 (d, <i>J</i> = 8.2 Hz, 2H), 7.91-7.75 (m, 5H), 7.38 (d, <i>J</i> = 8.7 Hz, 2H), 7.22-7.07 (m, 3H), 6.50-6.19 (m, 2H), 3.85 (d, <i>J</i> = 7.2 Hz, 1H), 3.75-3.64 (m, 1H), 2.33 (s, 6H)
5C	E	636 (M+)		(300 MHz, CDCl ₃) 8.56 (s, 1H), 8.54 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.89 (d, <i>J</i> = 8.2 Hz, 3H), 7.79 (d, <i>J</i> = 9.0 Hz, 2H), 7.38 (d, <i>J</i> = 8.7 Hz, 2H), 7.23-7.00 (m, 4H), 6.88-6.74 (m, 2H), 4.44 (s, 2H), 2.33 (s, 6H)
6C	D	645 (M+H)	196–198	(methanol- <i>d</i> ₄) 9.16 (s, 1H), 8.46 (s, 1H), 8.21 (d, <i>J</i> = 8.3 Hz, 2H), 8.03 (m, 6H), 7.52 (d, <i>J</i> = 8.3 Hz, 4H), 7.28 – 6.91 (m, 3H), 4.39 (s, 2H), 2.08 (s, 6H)
7C	E	636 (M+)		(300 MHz, CDCl ₃) 8.56 (m, 2H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 (d, <i>J</i> = 8.3 Hz, 3H), 7.79 (d, <i>J</i> = 9.0 Hz, 2H), 7.55-7.42 (m, 1H), 7.37 (d, <i>J</i> = 9.0 Hz, 2H), 7.20-7.01 (m, 3H), 6.89-6.68 (m, 2H), 4.30 (s, 2H), 2.28 (s, 6H)
8C	E	684 (M+)		(CDCl ₃) 8.57 (s, 1H), 8.52 (s, 1H), 8.24 (d, <i>J</i> = 8.3 Hz, 2H), 7.91-7.84 (m, 3H), 7.80 (d, <i>J</i> = 9.1 Hz, 2H), 7.39 (d, <i>J</i> = 8.6 Hz, 4H), 7.18-7.03 (m, 5H), 4.32 (s, 2H), 2.29 (s, 6H)
9C	E	620 (M+)		(CDCl ₃) 8.57 (s, 1H), 8.47 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 (d, <i>J</i> = 8.3 Hz, 2H), 7.80 (m, 3H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.21-7.10 (m, 3H), 3.93 (s, 2H), 2.35 (s, 6H), 0.13 (s, 9H)
10C	D	600 (M+)		(DMSO- <i>d</i> ₆) 8.57 (s, 1H), 8.54 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.89 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 (s, 1H), 7.80 (d, <i>J</i> = 9.0 Hz, 2H), 7.44-7.32 (m, 4H), 7.31-7.19 (m, 3H), 7.19-7.00 (m, 3H), 4.34 (s, 2H), 2.31 (s, 6H)
11C	D	618 (M+)		(DMSO- <i>d</i> ₆) 8.57 (s, 1H), 8.55 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.89 (d, <i>J</i> = 8.3 Hz, 2H), 7.86 (s, 1H), 7.83-7.73 (m, 2H), 7.48 (td, <i>J</i> = 7.6, 1.7 Hz, 1H), 7.38 (d, <i>J</i> = 8.5 Hz, 2H), 7.23-6.91 (m, 6H), 4.39 (s, 2H), 2.30 (s, 6H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
12C	D	658 (M+)		(DMSO- <i>d</i> ₆) 8.57 (s, 1H), 8.51 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.94 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 (d, <i>J</i> = 8.2 Hz, 2H), 7.86 (s, 1H), 7.79 (d, <i>J</i> = 9.0 Hz, 2H), 7.44 (d, <i>J</i> = 8.3 Hz, 2H), 7.38 (d, <i>J</i> = 8.6 Hz, 2H), 7.20-7.05 (m, 3H), 4.35 (s, 2H), 3.88 (s, 3H), 2.28 (s, 6H)
13C	E	679 (M+)		(DMSO- <i>d</i> ₆) 8.59 (s, 1H), 8.51 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.93-7.76 (m, 7H), 7.53 (d, <i>J</i> = 8.2 Hz, 2H), 7.39 (d, <i>J</i> = 8.7 Hz, 2H), 7.20-7.06 (m, 3H), 4.88 (s, 2H), 4.36 (s, 2H), 2.28 (s, 6H)
14C	E	658 (M+)		(CDCl ₃) 8.57 (s, 1H), 8.52 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.91-7.85 (m, 4H), 7.80 (d, <i>J</i> = 9.1 Hz, 2H), 7.73 (d, <i>J</i> = 6.8 Hz, 1H), 7.52 (dd, <i>J</i> = 8.8, 6.9 Hz, 1H), 7.39 (d, <i>J</i> = 9.0 Hz, 2H), 7.13-7.01 (m, 3H), 4.88 (s, 2H), 2.27 (s, 6H)
15C	E	667 (M+)		(CDCl ₃) 8.57 (s, 1H), 8.25-8.14 (m, 3H), 7.94-7.66 (m, 7H), 7.52-7.35 (m, 6H), 7.16-7.03 (m, 3H), 4.54 (s, 2H), 2.32 (s, 6H)
16C	E	658 (M+)		(CDCl ₃) 8.57 (s, 1H), 8.49 (s, 1H), 8.24 (d, <i>J</i> = 8.4 Hz, 2H), 7.88 (d, <i>J</i> = 8.3 Hz, 2H), 7.83-7.77 (m, 3H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.19-7.07 (m, 3H), 6.69-6.65 (m, 1H), 6.39-6.35 (m, 1H), 4.36 (s, 2H), 2.29 (s, 6H)
17C	E	678 (M+)		(CDCl ₃) 8.58 (s, 1H), 8.50 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.94-7.74 (m, 7H), 7.59 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 7.20-7.04 (m, 3H), 4.37 (s, 2H), 3.01 (s, 3H), 2.29 (s, 6H)
18C	E	773 (M+)		(CDCl ₃) 8.59 (s, 1H), 8.46 (s, 1H), 8.22 (d, <i>J</i> = 8.4 Hz, 2H), 7.86 (d, <i>J</i> = 8.4 Hz, 2H), 7.83-7.75 (m, 3H), 7.63 (d, <i>J</i> = 8.4 Hz, 2H), 7.44 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 7.17-7.05 (m, 3H), 7.03-6.98 (m, 3H), 6.89 (t, <i>J</i> = 8.6 Hz, 2H), 4.30 (s, 2H), 2.24 (s, 6H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
19C	E	728 (M+)		(CDCl ₃) 8.59 (s, 2H), 8.26 (d, <i>J</i> = 8.3 Hz, 2H), 7.93 (d, <i>J</i> = 8.3 Hz, 2H), 7.89 (s, 1H), 7.82 (d, <i>J</i> = 9.1 Hz, 2H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.20-7.05 (m, 3H), 6.86 (s, 1H), 4.49 (s, 2H), 3.98 (s, 3H), 2.31 (s, 6H)
20C	E	681 (M+)		(CDCl ₃) 8.58 (s, 1H), 8.38 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.86 (d, <i>J</i> = 8.3 Hz, 3H), 7.81 (d, <i>J</i> = 9.1 Hz, 2H), 7.67-7.63 (m, 2H), 7.46-7.36 (m, 5H), 7.18-7.05 (m, 3H), 4.24 (s, 2H), 2.47 (s, 3H), 2.29 (s, 6H)
21C	E	596 (M+)		(DMSO- <i>d</i> ₆) 8.58 (s, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 2H), 7.80 (d, <i>J</i> = 9.0 Hz, 2H), 7.47-7.35 (m, 4H), 7.21-6.93 (m, 5H), 3.68 (t, <i>J</i> = 5.4 Hz, 2H), 3.35 (s, 3H), 2.65 (t, <i>J</i> = 6.2 Hz, 2H), 2.29 (s, 6H)
22C	E	626 (M+)		(DMSO- <i>d</i> ₆) 8.59 (s, 1H), 8.52 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.95-7.75 (m, 5H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.21-7.06 (m, 3H), 5.80 (s, 2H), 4.12 (s, 2H), 3.69-3.50 (m, 2H), 2.31 (s, 6H), 1.35-1.11 (m, 3H)
23C	E	731 (M+)		(DMSO- <i>d</i> ₆) 8.58 (s, 1H), 8.50 (s, 1H), 8.22 (d, <i>J</i> = 8.2 Hz, 2H), 7.93-7.70 (m, 5H), 7.45-7.28 (m, 8H), 7.23-7.03 (m, 3H), 5.79 (s, 2H), 5.38-5.27 (m, 1H), 5.11 (s, 2H), 4.07-3.98 (m, 2H), 2.30 (s, 6H)
24C	E	626 (M+)		(DMSO- <i>d</i> ₆) 8.58 (s, 1H), 8.51 (s, 1H), 8.22 (d, <i>J</i> = 8.3 Hz, 2H), 7.93-7.73 (m, 5H), 7.39 (d, <i>J</i> = 8.9 Hz, 2H), 7.21-7.07 (m, 3H), 5.76 (s, 2H), 5.05-4.70 (m, 1H), 2.32 (s, 6H), 1.38-1.17 (m, 6H)
25C	E	610 (M+)		(DMSO- <i>d</i> ₆) 8.59 (s, 1H), 8.52 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.91-7.79 (m, 5H), 7.40 (d, <i>J</i> = 8.5 Hz, 2H), 7.18-7.06 (m, 3H), 5.73 (s, 2H), 2.70-2.45 (m, 1H), 2.32 (s, 6H), 1.15 (s, 6H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
26C	E	654 (M+)		(DMSO- <i>d</i> ₆) 8.58 (s, 1H), 8.21 (d, <i>J</i> = 8.4 Hz, 2H), 7.98 (d, <i>J</i> = 8.4 Hz, 2H), 7.81 (d, <i>J</i> = 6.9 Hz, 2H), 7.69 (s, 1H), 7.40 (d, <i>J</i> = 8.8 Hz, 2H), 6.63 (s, 2H), 5.73 (s, 2H), 3.80 (s, 3H), 2.64-2.53 (m, 1H), 2.58 (s, 3H), 2.28 (s, 6H), 1.17 (d, <i>J</i> = 7.0 Hz, 6H)
27C	E	640 (M+)		(DMSO- <i>d</i> ₆) 8.58 (s, 1H), 8.50 (s, 1H), 8.23 (d, <i>J</i> = 8.2 Hz, 2H), 7.88 (d, <i>J</i> = 8.3 Hz, 2H), 7.81 (d, <i>J</i> = 9.0 Hz, 2H), 7.74 (s, 1H), 7.39 (d, <i>J</i> = 8.6 Hz, 2H), 6.63 (s, 2H), 5.71 (s, 2H), 3.79 (s, 3H), 2.74-2.43 (m, 1H), 2.27 (s, 6H), 1.16 (d, <i>J</i> = 7.0 Hz, 6H)
28C	E	761 (M+)		(300 MHz, CDCl ₃) 8.58 (s, 1H), 8.48 (s, 1H), 8.22 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 (d, <i>J</i> = 8.4 Hz, 2H), 7.80 (d, <i>J</i> = 9.0 Hz, 2H), 7.74 (s, 1H), 7.45-7.28 (m, 7H), 6.63 (s, 2H), 5.78 (s, 2H), 5.29 (m, 1H), 5.12 (s, 2H), 4.03 (d, <i>J</i> = 5.6 Hz, 2H), 3.79 (s, 3H), 2.27 (s, 6H)
29C	E	656 (M+)		(300 MHz, CDCl ₃) 8.58 (s, 1H), 8.49 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 (d, <i>J</i> = 8.4 Hz, 2H), 7.81 (d, <i>J</i> = 9.0 Hz, 2H), 7.72 (s, 1H), 7.40 (d, <i>J</i> = 8.7 Hz, 2H), 6.63 (s, 2H), 5.78 (s, 2H), 4.11 (s, 2H), 3.80 (s, 3H), 3.59 (q, <i>J</i> = 7.0 Hz, 2H), 2.27 (s, 6H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H)
30C	E	697 (M+)		(300 MHz, CDCl ₃) 8.60 (s, 1H), 8.50 (s, 1H), 8.22 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 (d, <i>J</i> = 8.2 Hz, 2H), 7.82 (s, 1H), 7.80 (d, <i>J</i> = 9.0 Hz, 2H), 7.38 (d, <i>J</i> = 8.8 Hz, 3H), 7.23-7.02 (m, 3H), 5.78 (s, 2H), 3.96 (s, 2H), 2.31 (s, 6H), 1.44 (s, 9H)
31C	E	582 (M+)		(300 MHz, CDCl ₃) 8.58 (s, 1H), 8.52 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 (m, 3H), 7.80 (d, <i>J</i> = 9.0 Hz, 2H), 7.38 (d, <i>J</i> = 8.6 Hz, 2H), 7.14 (m, 3H), 5.72 (s, 2H), 2.32 (s, 6H), 2.09 (s, 3H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
32C	E	697 (M+)		(CDCl ₃) (Mixture of atropisomers) [8.61 (s), 8.58 (s), 8.56 (s), 8.51 (s), 8.37 (d, <i>J</i> = 8.3 Hz), 8.23 (d, <i>J</i> = 8.4 Hz), 8.21-8.14 (m), 8.00 (d, <i>J</i> = 8.4 Hz), 7.89 (d, <i>J</i> = 8.2 Hz), 7.84-7.77 (m), 7.45-7.35 (m); 11H], 6.94 (s, 2H), [5.87 (s), 5.80 (s); 2H], [4.12 (s), 4.11 (s); 2H], 3.83 (s, 3H), 3.69-3.44 (m, 2H), 1.38-1.10 (m, 3H)
33C	E	697 (M+)		(CDCl ₃) 8.57 (s, 1H), 8.51 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 (d, <i>J</i> = 8.4 Hz, 2H), 7.83-7.77 (m, 3H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 6.94 (s, 2H), 5.76 (s, 2H), 4.96-4.77 (m, 1H), 3.82 (s, 3H), 1.30 (d, <i>J</i> = 6.3 Hz, 6H)
34C	E	681 (M+)		(CDCl ₃) 8.57 (s, 1H), 8.51 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.92-7.76 (m, 5H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 6.93 (s, 2H), 5.73 (s, 2H), 3.82 (s, 3H), 2.59 (m, 1H), 1.17 (d, <i>J</i> = 7.0 Hz, 6H)
35C	E	636 (M+)		(CDCl ₃) 8.57 (s, 1H), 8.50 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.92-7.73 (m, 5H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.20-6.92 (m, 3H), 5.72 (s, 2H), 2.94-2.63 (m, 1H), 2.31 (s, 6H), 2.02-1.38 (m, 8H)
36C	E	624 (M+)		(CDCl ₃) 8.56 (s, 1H), 8.49 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 (d, <i>J</i> = 8.3 Hz, 2H), 7.84 (s, 1H), 7.79 (d, <i>J</i> = 9.0 Hz, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 7.19-7.05 (m, 3H), 5.71 (s, 2H), 2.31 (s, 6H), 1.20 (s, 9H)
37C	E	691 (M+H)		(CDCl ₃) 8.59 (s, 1H), 8.50 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.93-7.77 (m, 4H), 7.72 (s, 1H), 7.40 (d, <i>J</i> = 9.0 Hz, 2H), 6.63 (s, 2H), 5.71 (s, 2H), 3.80 (s, 3H), 2.68-2.48 (m, 1H), 2.28 (s, 6H), 1.16 (d, <i>J</i> = 7.0 Hz, 6H)
38C	E	724 (M+)		(CDCl ₃) 8.58 (s, 1H), 8.47 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 (d, <i>J</i> = 8.3 Hz, 2H), 7.81 (d, <i>J</i> = 9.1 Hz, 2H), 7.71 (s, 1H), 7.39 (d, <i>J</i> = 9.0 Hz, 2H), 6.64 (s, 2H), 5.76 (dd, <i>J</i> = 37.3, 11.0 Hz, 2H), 4.19 (q, <i>J</i> = 6.9 Hz, 1H), 4.14-3.97 (m, 1H), 3.80 (s, 3H), 3.79-3.68 (m, 1H), 2.27 (s, 6H), 1.47 (d, <i>J</i> = 6.9 Hz, 3H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
39C	E	694 (M+)		(CDCl ₃) 8.58 (s, 1H), 8.48 (s, 1H), 8.24 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 (d, <i>J</i> = 8.3 Hz, 2H), 7.83 (s, 1H), 7.81 (d, <i>J</i> = 9.1 Hz, 2H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.23-6.99 (m, 3H), 5.77 (dd, <i>J</i> = 36.4, 11.0 Hz, 2H), 4.19 (q, <i>J</i> = 6.9 Hz, 1H), 4.14-3.97 (m, 1H), 3.84-3.65 (m, 1H), 2.31 (s, 6H), 1.47 (d, <i>J</i> = 6.9 Hz, 3H)
40C	E	654 (M+)		(CDCl ₃) 8.57 (s, 1H), 8.48 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 (d, <i>J</i> = 8.3 Hz, 2H), 7.80 (d, <i>J</i> = 9.0 Hz, 2H), 7.72 (s, 1H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 6.62 (s, 2H), 5.70 (s, 2H), 3.79 (s, 3H), 2.27 (s, 6H), 1.20 (s, 9H)
41C	E	670 (M+)		(CDCl ₃) 8.58 (s, 1H), 8.49 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 (d, <i>J</i> = 8.3 Hz, 2H), 7.84 (s, 1H), 7.80 (d, <i>J</i> = 9.0 Hz, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 7.23-6.96 (m, 3H), 5.77 (dd, <i>J</i> = 27.4, 10.9 Hz, 2H), 4.07 (q, <i>J</i> = 6.9 Hz, 1H), 3.78-3.70 (m, 1H), 3.66-3.39 (m, 3H), 3.35 (s, 3H), 2.31 (s, 6H), 1.42 (d, <i>J</i> = 6.9 Hz, 3H)
42C	E	700 (M+)		(CDCl ₃) 8.58 (s, 1H), 8.48 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.87 (d, <i>J</i> = 8.3 Hz, 2H), 7.80 (d, <i>J</i> = 9.1 Hz, 2H), 7.71 (s, 1H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 6.63 (s, 2H), 5.76 (dd, <i>J</i> = 27.8, 10.9 Hz, 2H), 4.07 (q, <i>J</i> = 6.9 Hz, 1H), 3.79 (s, 3H), 3.79-3.70 (m, 1H), 3.63-3.45 (m, 3H), 3.35 (s, 3H), 2.27 (s, 6H), 1.42 (d, <i>J</i> = 6.9 Hz, 3H)
43C	E	666 (M+)		(CDCl ₃) 8.57 (s, 1H), 8.49 (s, 1H), 8.22 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 (d, <i>J</i> = 8.3 Hz, 2H), 7.79 (d, <i>J</i> = 9.1 Hz, 2H), 7.74 (s, 1H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 6.62 (s, 2H), 5.71 (s, 2H), 3.79 (s, 3H), 2.85-2.65 (m, 1H), 2.27 (s, 6H), 1.98-1.51 (m, 8H)
44C	E	668 (M+)		(CDCl ₃) 8.59 (s, 1H), 8.55 (s, 1H), 8.22 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 (d, <i>J</i> = 8.3 Hz, 2H), 7.84-7.74 (m, 3H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 6.63 (s, 2H), 5.85-5.73 (m, 2H), 4.54-4.47 (m, 1H), 4.03 (dd, <i>J</i> = 14.7, 6.9 Hz, 1H), 3.91 (dd, <i>J</i> = 13.8, 7.4 Hz, 1H), 3.79 (s, 3H), 2.27 (s, 6H), 2.09-1.83 (m, 4H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
45C	E	746 (M+H)	132–137	(CDCl ₃) 8.68 (s, 1H), 8.49 (s, 1H), 8.24 (d, <i>J</i> = 8.3 Hz, 2H), 7.93 (d, <i>J</i> = 8.4 Hz, 2H), 7.88 (d, <i>J</i> = 8.3 Hz, 2H), 7.81 (d, <i>J</i> = 8.5 Hz, 2H), 7.73 (s, 1H), 7.35 (s, 5H), 6.64 (s, 2H), 5.78 (s, 2H), 5.24 (s, 1H), 5.12 (s, 2H), 4.04 (d, <i>J</i> = 5.5 Hz, 2H), 3.80 (s, 3H), 2.28 (s, 6H)
46C	E	624	108–113	(CDCl ₃) 8.68 (s, 1H), 8.50 (s, 1H), 8.24 (d, <i>J</i> = 8.3 Hz, 2H), 7.98–7.69 (m, 7H), 6.63 (s, 2H), 5.71 (s, 2H), 3.80 (s, 3H), 2.59 (heptet, <i>J</i> = 7.0 Hz, 1H), 2.29 (d, <i>J</i> = 6.9 Hz, 6H), 1.16 (d, <i>J</i> = 7.0 Hz, 6H)
47C	E		149–151	(acetone- <i>d</i> ₆) 9.20 (s, 1H), 8.52 (s, 1H), 8.40 – 8.21 (m, 2H), 8.21 – 8.01 (m, 4H), 7.61 (d, <i>J</i> = 8.3 Hz, 2H), 7.32 – 6.94 (m, 3H), 3.83 (s, 2H), 2.34 (s, 6H)
48C	E	599 (M+H)	128–137	(acetone- <i>d</i> ₆) 9.18 (s, 1H), 8.83 (s, 1H), 8.67 – 7.82 (m, 8H), 7.60 (d, <i>J</i> = 8.4 Hz, 2H), 6.78 (s, 2H), 3.99 – 3.72 (m, 3H), 2.41 – 2.20 (m, 6H)
49C	E	619 (M+H)	177–185	(methanol- <i>d</i> ₄) 9.23 (s, 1H), 8.62 (s, 1H), 8.29 (m, 2H), 8.17 – 7.98 (m, 4H), 7.60 – 7.45 (m, 2H), 7.41 – 7.19 (m, 3H), 4.22 (s, 2H), 2.34 (s, 6H)
50C	E	635 (M+H)	193–196	(methanol- <i>d</i> ₄) 9.23 (s, 1H), 8.57 (s, 1H), 8.28 (m, 3H), 8.09 – 7.98 (m, 4H), 7.50 (m, 4H), 4.19 – 4.11 (m, 2H), 3.85 (s, 3H), 2.36 (s, 3H)
51C	E	649 (M+H)	176–179	(methanol- <i>d</i> ₄) 9.23 (s, 1H), 8.60 (s, 1H), 8.30 (m, 2H), 8.14 – 8.00 (m, 4H), 7.52 (m, 2H), 6.81 (s, 2H), 4.22 (s, 2H), 3.84 – 3.81 (m, 3H), 2.33 (s, 6H)
52C	E	599 (M+H)	168–178	(methanol- <i>d</i> ₄) 9.21 (s, 1H), 8.44 (s, 1H), 8.27 (d, <i>J</i> = 8.1 Hz, 2H), 8.09 – 7.98 (m, 4H), 7.52 (d, <i>J</i> = 8.3 Hz, 2H), 7.40 (d, <i>J</i> = 8.7 Hz, 2H), 6.97 (d, <i>J</i> = 8.8 Hz, 2H), 5.40 (s, 1H), 4.37 – 4.13 (m, 2H), 3.79 (s, 3H), 1.79 (m, 3H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
53C	E	617 (M+H)	168–170	(methanol- <i>d</i> ₄) 9.21 (s, 1H), 8.44 (m, 1H), 8.28 (d, <i>J</i> = 8.2 Hz, 2H), 8.11 – 7.99 (m, 4H), 7.52 (d, <i>J</i> = 8.4 Hz, 2H), 7.25 (m, 2H), 7.14 (t, <i>J</i> = 8.5 Hz, 1H), 5.42 (m, 1H), 4.25 (m, 2H), 3.88 (s, 3H), 1.75 (m, 3H)
54C	E	569 (M+H)	167–170	(methanol- <i>d</i> ₄) 9.23 (s, 1H), 8.46 (s, 1H), 8.27 (m, 2H), 8.05 (m, 4H), 7.57 – 7.39 (m, 7H), 5.41 (m, 1H), 4.24 (m, 2H), 1.79 (m, 3H)
55C	E	624 (M+H)	90–97	(methanol- <i>d</i> ₄) 9.12 (s, 1H), 8.46 (s, 1H), 8.14 (m, 2H), 7.99 (m, 3H), 7.78 (s, 1H), 7.49 (d, <i>J</i> = 8.5 Hz, 2H), 7.12 (m, 3H), 3.69 (s, 2H), 3.22 – 2.80 (m, 2H), 2.25 (s, 6H), 2.03 (s, 2H), 1.93 – 1.66 (m, 1H), 0.92 (m, <i>J</i> = 9.7 Hz, 6H)
56C	E	765 (M+H)	148–151	(methanol- <i>d</i> ₄) 9.18 (s, 1H), 8.59 (s, 1H), 8.30 (d, <i>J</i> = 8.1 Hz, 2H), 8.12 (m, 2H), 8.07 – 8.00 (m, 2H), 7.58 – 7.43 (m, 2H), 7.33 (dd, <i>J</i> = 8.6, 6.5 Hz, 1H), 7.25 (d, <i>J</i> = 7.6 Hz, 2H), 4.02 (m, 2H), 3.97 – 3.75 (m, 2H), 3.21 (d, <i>J</i> = 6.9 Hz, 2H), 2.90 (m, 1H), 2.59 (m, 1H), 2.35 (s, 6H), 1.84 (m, 2H), 1.78 – 1.63 (m, 2H), 1.44 (s, 9H), 1.29 (m, 3H)
57C	E	737 (M+H)	151–153	(methanol- <i>d</i> ₄) 9.20 (s, 1H), 8.65 (s, 1H), 8.30 (m, 2H), 8.21 – 7.96 (m, 4H), 7.53 (d, <i>J</i> = 8.4 Hz, 2H), 7.35 (dd, <i>J</i> = 8.5, 6.5 Hz, 1H), 7.28 (d, <i>J</i> = 7.5 Hz, 2H), 4.44 (s, 2H), 3.91 – 3.40 (m, 9H), 2.38 (s, 6H), 1.50 (s, 9H)
58C	E	725 (M+H)	125–127	(methanol- <i>d</i> ₄) 9.18 (s, 1H), 8.61 (s, 1H), 8.31 (m, 2H), 8.14 (m, 2H), 8.06 (d, <i>J</i> = 9.0 Hz, 2H), 7.53 (d, <i>J</i> = 8.5 Hz, 2H), 7.32 (dt, <i>J</i> = 26.0, 7.0 Hz, 3H), 4.02 (s, 2H), 3.38 – 3.34 (m, 2H), 3.22 – 3.03 (m, 2H), 2.37 (s, 6H), 1.74 (m, 2H), 1.45 (s, 9H)
59C	E	755 (M+H)	147–149	(methanol- <i>d</i> ₄) 9.18 (s, 1H), 8.62 (s, 1H), 8.38 – 7.97 (m, 6H), 7.51 (d, <i>J</i> = 8.4 Hz, 2H), 7.32 (dd, <i>J</i> = 8.5, 6.6 Hz, 1H), 7.25 (d, <i>J</i> = 7.6 Hz, 2H), 4.40 (s, 1H), 4.06 (m, 2H), 3.91 – 3.74 (m, 2H), 3.56 – 3.41 (m, 1H), 2.36 (s, 6H), 1.44 (s, 9H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
60C	E	755 (M+H)	136–139	(methanol- <i>d</i> ₄) 9.16 (s, 1H), 8.58 (s, 1H), 8.28 (d, <i>J</i> = 7.4 Hz, 2H), 8.16–7.76 (m, 4H), 7.52 (p, <i>J</i> = 8.8 Hz, 2H), 6.83 (m, 2H), 4.04 (d, <i>J</i> = 8.5 Hz, 2H), 3.90–3.73 (m, 3H), 3.55–3.37 (m, 2H), 3.14–2.75 (m, 3H), 2.30 (s, 6H), 1.99–1.80 (m, 2H), 1.43–1.31 (m, 2H)
61C	E	738 (M+H)	70–79 dec	(methanol- <i>d</i> ₄) 9.12 (s, 1H), 8.12 – 8.07 (m, 2H), 8.02 – 7.96 (m, 2H), 7.55 – 7.50 (m, 2H), 7.50 – 7.45 (m, 2H), 7.43 (d, <i>J</i> = 7.7 Hz, 1H), 7.31 (d, <i>J</i> = 7.6 Hz, 2H), 4.03 (s, 2H), 3.25 (dt, <i>J</i> = 15.5, 7.0 Hz, 4H), 2.84 (s, 3H), 2.04 (s, 6H), 1.81 – 1.66 (m, 2H), 1.44 (s, 9H)
62C	K	665 (M+H)	110–120	(methanol- <i>d</i> ₄) δ 9.18 (s, 1H), 8.56 (m, 1H), 8.26 (m, 2H), 8.16 – 7.84 (m, 4H), 7.52 (m, 2H), 7.27 (m, 1H), 7.22 (m, 2H), 4.00 (s, 2H), 3.28 (m, 3H), 3.06 – 2.83 (m, 1H), 2.75 (t, <i>J</i> = 12.2 Hz, 1H), 2.34 (s, 6H), 2.21 – 1.83 (m, 4H), 1.72 (m, 1H), 1.47 – 1.19 (m, 2H)
63C	K	655 (M+H)	98–110	(methanol- <i>d</i> ₄) 9.18 (s, 1H), 8.63 (s, 1H), 8.28 (m, 2H), 8.13 – 7.97 (m, 4H), 7.51 (d, <i>J</i> = 8.3 Hz, 2H), 7.31 (dd, <i>J</i> = 8.5, 6.5 Hz, 1H), 7.24 (d, <i>J</i> = 7.6 Hz, 2H), 4.32 – 4.07 (m, 3H), 3.98 – 3.81 (m, 1H), 3.72 (s, 1H), 2.35 (s, 6H)
64C	K	655 (M+H)	83–112	(methanol- <i>d</i> ₄) 9.19 (s, 1H), 8.58 (s, 1H), 8.28 (m, 2H), 8.14 – 7.97 (m, 4H), 7.51 (m, 2H), 6.78 (s, 2H), 4.00 (m, 2H), 3.81 (s, 3H), 3.10 – 2.93 (m, 4H), 2.30 (s, 6H), 1.91 (m, 2H)
65C	K	667 (M+H)	128 dec	(methanol- <i>d</i> ₄) 9.20 (s, 1H), 8.65 (s, 1H), 8.27 (m 2H), 8.11 – 7.99 (m, 4H), 7.52 (d, <i>J</i> = 8.3 Hz, 2H), 6.78 (s, 2H), 4.40 (s, 2H), 3.87 (m, 4H), 3.53 (s, 3H), 2.32 (s, 6H), 1.33 (m, 4H)
66C	K	625 (M+H)	100–105	(methanol- <i>d</i> ₄) 9.20 (s, 1H), 8.56 (s, 1H), 8.27 (m, 2H), 8.12 – 7.99 (m, 3H), 7.53 (d, <i>J</i> = 8.4 Hz, 2H), 7.24 (m, 4H), 3.99 (s, 2H), 3.42 (m, 2H), 3.05 (m, 2H), 2.36 (s, 6H), 1.99 – 1.88 (m, 2H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
67C	K	636 (M+H)	237–240 dec	(methanol- <i>d</i> ₄) 9.20 (s, 1H), 8.74 (s, 1H), 8.33 – 8.25 (m, 2H), 8.12 – 7.98 (m, 4H), 7.53 (d, <i>J</i> = 8.3 Hz, 2H), 7.33 (dd, <i>J</i> = 8.5, 6.4 Hz, 1H), 7.26 (d, <i>J</i> = 7.5 Hz, 2H), 4.55 (s, 2H), 3.92 (m, 4H), 3.37 (m, 2H), 3.31 (m, 2H), 2.38 (s, 6H)
69C	F	581 (M+H)	188–190	(CDCl ₃) 8.56 (s, 1H), 8.33 (s, 1H), 8.22 (d, <i>J</i> = 8.1 Hz, 2H), 7.90 – 7.70 (m, 4H), 7.39 (d, <i>J</i> = 8.7 Hz, 2H), 6.72 (s, 2H), 4.01 (s, 2H), 3.87 – 3.73 (s, 3H), 2.18 (s, 6H)
70C	F	592 (M+)	134–138	(CDCl ₃) 8.65 (s, 1H), 8.31 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.83 (m, 4H), 7.50 (d, <i>J</i> = 8.1 Hz, 2H), 7.45 – 7.38 (m, 3H), 4.05 (s, 2H)
71C	F	551 (M+H)	104–111	(CDCl ₃) 8.62 (s, 1H), 8.32 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 – 7.74 (m, 4H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.34 – 7.26 (m, 1H), 7.20 (d, <i>J</i> = 7.5 Hz, 2H), 4.02 (s, 2H), 2.22 (s, 6H)
72C	F	565 (M+H)	118–121	(CDCl ₃) 8.58 (s, 1H), 8.33 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.81 (m, 4H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.01 (d, <i>J</i> = 0.4 Hz, 2H), 4.01 (s, 2H), 2.34 (s, 3H), 2.17 (s, 6H)
73C	F	565 (M+H)	145–150	(CDCl ₃) 8.58 (s, 1H), 8.30 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 1H), 7.81 (m, 2H), 7.49 (d, <i>J</i> = 4.0 Hz, 1H), 7.40 (d, <i>J</i> = 8.4 Hz, 1H), 7.34 (s, 1H), 7.18 (d, <i>J</i> = 7.8 Hz, 1H), 4.01 (d, <i>J</i> = 1.4 Hz, 1H), 2.83 (heptet, <i>J</i> = 6.8 Hz, 1H), 1.23 (t, <i>J</i> = 6.6 Hz, 3H).
74C	G	682 (M+H)	190–193	(methanol- <i>d</i> ₄) 9.20 (s, 1H), 8.38 (s, 1H), 8.31 – 8.24 (m, 2H), 8.08 – 8.00 (m, 2H), 7.95 – 7.88 (m, 2H), 7.55 – 7.48 (m, 3H), 7.48 – 7.36 (m, 5H), 7.31 (d, <i>J</i> = 7.7 Hz, 2H), 3.60 (q, <i>J</i> = 7.2 Hz, 4H), 2.20 (s, 6H), 1.07 (t, <i>J</i> = 7.2 Hz, 6H);
75C	G	617 (M+)		(CDCl ₃) 8.56 (s, 1H), 8.23 (s, 1H), 8.19 (d, <i>J</i> = 8.4 Hz, 2H), 7.84–7.73 (m, 5H), 7.41–7.33 (m, 3H), 7.21 (d, <i>J</i> = 7.2 Hz, 2H), 7.16 (s, 1H), 7.12 (d, <i>J</i> = 3.2 Hz, 1H), 2.20 (s, 6H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
76C	G	711 (M+)		(CDCl ₃) 8.56 (s, 1H), 8.25 (s, 1H), 8.20 (d, <i>J</i> = 8.4 Hz, 2H), 7.80 (dd, <i>J</i> = 8.7, 5.6 Hz, 4H), 7.48-7.34 (m, 8H), 7.26 (d, <i>J</i> = 7.7 Hz, 2H), 7.08 (s, 1H), 2.20 (s, 6H)
77C	G	655 (M+H)	261–263	(methanol- <i>d</i> ₄) 9.14 (s, 1H), 8.21 – 8.13 (m, 3H), 8.06 – 7.99 (m, 2H), 7.86 – 7.75 (m, 4H), 7.50 (d, <i>J</i> = 8.3 Hz, 2H), 7.28 – 7.18 (m, 3H), 7.14 (d, <i>J</i> = 7.9 Hz, 2H), 6.72 (s, 1H), 0.09 – -0.09 (m, 6H)
78C	G	694 (M+H)		(CDCl ₃) 8.55 (s, 1H), 8.22 (s, 1H), 8.18 (d, <i>J</i> = 8.3 Hz, 2H), 7.79 (dd, <i>J</i> = 8.7, 5.1 Hz, 4H), 7.37 (d, <i>J</i> = 9.0 Hz, 2H), 7.23-6.94 (m, 7H), 6.26 (s, 1H), 2.17 (s, 6H)
79C	G	678 (M+H)		(CDCl ₃) 8.55 (s, 1H), 8.23 (s, 1H), 8.19 (d, <i>J</i> = 8.3 Hz, 2H), 7.79 (d, <i>J</i> = 8.7 Hz, 4H), 7.43 (d, <i>J</i> = 8.3 Hz, 2H), 7.37 (d, <i>J</i> = 8.9 Hz, 2H), 7.23-7.16 (m, 3H), 7.08 (d, <i>J</i> = 7.4 Hz, 2H), 6.35 (s, 1H), 2.18 (s, 6H)
80C	G	609 (M+H)	215–219	(methanol- <i>d</i> ₄) 9.23 (s, 1H), 8.40 (s, 1H), 8.26 (m, 2H), 8.22 (s, 1H), 8.07 – 8.00 (m, 3H), 7.91 (d, <i>J</i> = 8.4 Hz, 2H), 7.51 (d, <i>J</i> = 8.3 Hz, 2H), 6.90 (s, 1H), 3.88 (s, 3H), 2.13 (s, 6H)
81C	I	551 (M+H)	209-213	(CDCl ₃) 9.42 (s, 1H), 8.59 (s, 1H), 8.28 (d, <i>J</i> = 8.4 Hz, 2H), 8.01 (d, <i>J</i> = 8.3 Hz, 2H), 7.80 – 7.77 (m, 2H), 7.43 – 7.34 (m, 2H), 7.07 (d, <i>J</i> = 7.5 Hz, 2H), 6.98 (dd, <i>J</i> = 8.2, 6.7 Hz, 1H), 3.90 (s, 2H), 2.17 (s, 6H)
82C	I	565 (M+H)	225-232	(CDCl ₃) 9.46 (s, 1H), 8.60 (s, 1H), 8.29 (d, <i>J</i> = 8.4 Hz, 2H), 8.02 (d, <i>J</i> = 8.4 Hz, 2H), 7.89 – 7.76 (m, 2H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 6.88 (s, 2H), 3.90 (s, 2H), 2.28 (s, 3H), 2.13 (s, 6H).
83C	I	581 (M+H)	211-215	(CDCl ₃) 9.44 (s, 1H), 8.60 (s, 1H), 8.30 (d, <i>J</i> = 8.4 Hz, 2H), 8.02 (d, <i>J</i> = 8.4 Hz, 2H), 7.82 (d, <i>J</i> = 9.1 Hz, 2H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 6.63 (s, 2H), 3.90 (s, 2H), 3.78 (s, 3H), 2.15 (s, 6H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
84C	I	591	250 dec	(CDCl ₃) 9.42 (s, 1H), 8.40 (s, 1H), 8.18 (d, <i>J</i> = 8.24 Hz, 2H), 8.07 (d, <i>J</i> = 8.28 Hz, 2H), 7.89 (d, <i>J</i> = 8.24 Hz, 2H), 7.76 (d, <i>J</i> = 8.28 Hz, 2H), 7.64-7.58 (m, 3H), 4.42 (s, 2H)
85C	I	551 (M+H)	146-149	(CDCl ₃) δ 9.36 (s, 1H), 8.60 (s, 1H), 8.30 (d, <i>J</i> = 8.4 Hz, 2H), 8.01 (d, <i>J</i> = 8.4 Hz, 2H), 7.86 – 7.77 (m, 2H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.32 (dd, <i>J</i> = 6.9, 2.3 Hz, 1H), 7.24 – 7.12 (m, 2H), 6.91 (dd, <i>J</i> = 7.1, 2.0 Hz, 1H), 3.93 (s, 2H), 3.15 – 2.97 (m, 1H), 1.21 (d, <i>J</i> = 6.9 Hz, 6H)
86C	J	566 (M+H)	163-169	(CDCl ₃) δ 8.81 (bs, 1H), 8.57 (s, 1H), 8.20 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 – 7.75 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.32 – 7.25 (m, 1H), 7.10 (2dt, <i>J</i> = 7.4, 1.5 Hz, 2H), 6.83 (d, <i>J</i> = 6.5 Hz, 1H), 3.96 (t, <i>J</i> = 6.1 Hz, 2H), 3.13 (heptet, <i>J</i> = 6.9 Hz, 1H), 2.99 – 2.88 (m, 2H), 2.49 – 2.36 (m, 2H), 1.29 – 1.21 (m, 6H).
87C	J	550 (M+H)	187-189	(CDCl ₃) δ 8.81 (s, 1H), 8.66 (s, 1H), 8.21 (d, <i>J</i> = 8.3 Hz, 2H), 7.92 (d, <i>J</i> = 8.4 Hz, 2H), 7.81 (t, <i>J</i> = 10.2 Hz, 4H), 7.30 – 7.26 (m, 2H), 7.17 – 7.04 (m, 1H), 6.83 (d, <i>J</i> = 6.4 Hz, 1H), 3.96 (t, <i>J</i> = 6.1 Hz, 2H), 3.13 (heptet, <i>J</i> = 6.9 Hz, 1H), 2.97 – 2.90 (m, 2H), 2.47 – 2.38 (m, 2H), 1.25 (d, <i>J</i> = 7.5 Hz, 6H).
88C	F	579.2 (M+H)	178-182	(CDCl ₃) δ 8.58 (s, 1H), 8.30 (s, 1H), 8.22 (d, <i>J</i> = 8.3 Hz, 2H), 7.82 (dd, <i>J</i> = 8.7, 7.2 Hz, 4H), 7.48 (dd, <i>J</i> = 4.1, 1.3 Hz, 2H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.37 – 7.30 (m, 1H), 7.17 (m, 1H), 4.23 (dq, <i>J</i> = 14.5, 7.2 Hz, 1H), 2.83 (dd, <i>J</i> = 14.6, 6.9 Hz, 1H), 1.79 (d, <i>J</i> = 7.2 Hz, 3H), 1.22 (ddd, <i>J</i> = 12.1, 6.9, 1.9 Hz, 6H).
89C	F	559 (M+H)	205-206	(CDCl ₃) δ 8.58 (s, 1H), 8.32 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.90 – 7.75 (m, 4H), 7.52 – 7.44 (m, 1H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.10 (dd, <i>J</i> = 8.6, 7.4 Hz, 2H), 4.04 (s, 2H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
90C	F	566 (M+H)	148-151	(CDCl ₃) δ 8.58 (s, 1H), 8.31 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.82 (t, <i>J</i> = 8.5 Hz, 4H), 7.46 – 7.31 (m, 3H), 7.25 – 7.18 (m, 2H), 4.02 (s, 2H), 2.53 (q, <i>J</i> = 7.6 Hz, 2H), 2.21 (s, 3H), 1.26 – 1.16 (m, 3H).
91C	F	554 (M+H)	227-235	(CDCl ₃) δ 8.58 (s, 1H), 8.36 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 – 7.76 (m, 4H), 7.49 – 7.35 (m, 3H), 7.01 (dd, <i>J</i> = 8.5, 2.5 Hz, 1H), 6.96 (dd, <i>J</i> = 7.8, 1.0 Hz, 1H), 6.91 (t, <i>J</i> = 2.2 Hz, 1H), 3.98 (s, 2H), 3.85 (s, 3H).
92C	F	554 (M+H)	104-108	(CDCl ₃) δ 8.58 (s, 1H), 8.32 (s, 1H), 8.22 (d, <i>J</i> = 8.4 Hz, 2H), 7.86 – 7.77 (m, 4H), 7.50 – 7.43 (m, 1H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.32 – 7.27 (m, 1H), 7.14 – 7.04 (m, 2H), 4.01 (d, <i>J</i> = 17.2 Hz, 1H), 3.94 (d, <i>J</i> = 17.3 Hz, 1H), 3.84 (s, 3H).
93C	F	572 (M+H)	183-186	(CDCl ₃) δ 8.58 (s, 1H), 8.31 (s, 1H), 8.27 – 8.18 (m, 2H), 7.88 – 7.77 (m, 4H), 7.43 – 7.37 (m, 3H), 7.34 (t, <i>J</i> = 7.8 Hz, 1H), 7.30 – 7.26 (m, 1H), 4.07 (d, <i>J</i> = 17.4 Hz, 1H), 4.00 (d, <i>J</i> = 17.4 Hz, 1H), 2.29 (s, 3H).
94C	F	552 (M+H)	134-136	(CDCl ₃) δ 8.58 (s, 1H), 8.31 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.86 – 7.78 (m, 4H), 7.49 – 7.32 (m, 5H), 7.24 – 7.18 (m, 1H), 4.06 – 3.94 (m, 2H), 2.56 (q, <i>J</i> = 7.6 Hz, 2H), 1.26 – 1.18 (m, 3H).
95C	F	576.1 (M+H)	195-201	(CDCl ₃) δ 8.59 (d, <i>J</i> = 4.8 Hz, 1H), 8.26 (m, 3H), 7.89 – 7.74 (m, 4H), 7.52 – 7.31 (m, 4H), 7.24 – 7.13 (m, 1H), 4.05 (d, <i>J</i> = 0.9 Hz, 2H).
96C	F	600 (M+H)	182-185	(300 MHz, CDCl ₃) δ 8.58 (s, 1H), 8.33 (d, <i>J</i> = 7.9 Hz, 1H), 8.24 (s, 1H), 8.21 (s, 1H), 7.86 – 7.76 (m, 4H), 7.53 (t, <i>J</i> = 5.9 Hz, 3H), 7.44 – 7.29 (m, 8H), 3.80 – 3.73 (m, 1H), 3.59 – 3.51 (m, 1H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
97C	F	567 (M+H)	234-236	(CDCl ₃) δ 8.57 (s, 1H), 8.37 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.89 – 7.73 (m, 4H), 7.45 – 7.29 (m, 3H), 6.79 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 6.70 (d, 1H), 6.57 (s, 1H), 3.96 (s, 2H), 2.98 (s, 6H)
98C	F	612 (M+H)	225-226	(CDCl ₃) δ 8.55 (s, 1H), 8.29 (s, 1H), 8.21 (d, <i>J</i> = 8.4 Hz, 2H), 7.86 – 7.71 (m, 4H), 7.42 – 7.23 (m, 3H), 6.63 (d, <i>J</i> = 8.5 Hz, 2H), 4.07 (q, <i>J</i> = 7.0 Hz, 4H), 3.94 (s, 2H), 1.31 (t, <i>J</i> = 7.0 Hz, 6H)
99C	F	679 (M-H)	230-231	(CDCl ₃) δ 8.58 (s, 1H), 8.32 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.89 – 7.77 (m, 4H), 7.70 (d, <i>J</i> = 8.1 Hz, 2H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.29 – 7.20 (m, 1H), 4.04 (s, 2H)
100C	F	602 (M+H)	118-120	(CDCl ₃) δ 8.58 (s, 1H), 8.30 (s, 1H), 8.22 (d, <i>J</i> = 8.4 Hz, 2H), 7.93 – 7.70 (m, 4H), 7.39 (d, <i>J</i> = 9.0 Hz, 2H), 7.28 (t, 1H), 7.19 (d, <i>J</i> = 7.7 Hz, 2H), 4.01 (s, 2H), 2.21 (s, 6H).
101C	F	583 (M+H)	106-107	(CDCl ₃) δ 8.60 (s, 1H), 8.32 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.89 – 7.74 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 6.56 (s, 1H), 4.01 (s, 2H), 3.94 (s, 3H), 2.32 (s, 3H), 2.16 (s, 3H)
102C	F	589 (M-H)	123-126	(CDCl ₃) δ 8.27 (s, 1H), 7.95 – 7.71 (m, 5H), 7.60 (d, <i>J</i> = 1.3 Hz, 1H), 7.53 – 7.43 (m, 4H), 7.45 – 7.32 (m, 3H), 4.04 (s, 2H)
103C	F	551 (M+H)	194-196	(CDCl ₃) δ 8.28 (s, 1H), 7.93 (dd, <i>J</i> = 5.4, 4.1 Hz, 3H), 7.78 (m, 4H), 7.36 – 7.23 (m, 3H), 7.19 (d, <i>J</i> = 7.6 Hz, 2H), 6.81 (d, <i>J</i> = 2.5 Hz, 1H), 4.00 (s, 2H), 2.21 (s, 6H)
104C	F	551 (M+H)	100-102	(CDCl ₃) δ 8.27 (s, 1H), 8.16 (s, 1H), 8.03 (s, 1H), 7.80 – 7.71 (m, 4H), 7.57 (d, <i>J</i> = 8.3 Hz, 2H), 7.30 (dd, <i>J</i> = 28.7, 5.8 Hz, 3H), 7.19 (d, <i>J</i> = 7.6 Hz, 2H), 4.01 (s, 2H), 2.21 (s, 6H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
105C	F	586 (M+H)	209-211	(CDCl ₃) δ 8.58 (s, 1H), 8.31 (s, 1H), 8.23 (d, <i>J</i> = 7.8 Hz, 2H), 7.82 (m, 4H), 7.39 (d, <i>J</i> = 8.0 Hz, 2H), 7.19 (s, 2H), 4.01 (s, 2H), 2.19 (s, 6H)
106C	F	558 (M+H)	180-182	(CDCl ₃) δ 8.58 (s, 1H), 8.30 (s, 1H), 8.22 (d, <i>J</i> = 8.2 Hz, 2H), 7.81 (m, 4H), 7.58 (dd, <i>J</i> = 6.0, 3.3 Hz, 1H), 7.43 (ddd, <i>J</i> = 23.4, 11.3, 5.5 Hz, 5H), 4.02 (dd, <i>J</i> = 29.9, 17.4 Hz, 2H)
107C	F	596 (M+H)	227-232	(CDCl ₃) δ 8.58 (s, 1H), 8.32 (s, 1H), 8.22 (dd, <i>J</i> = 10.0, 8.6 Hz, 4H), 7.82 (m, 4H), 7.49 (d, <i>J</i> = 8.5 Hz, 2H), 7.40 (d, <i>J</i> = 8.6 Hz, 2H), 4.42 (q, <i>J</i> = 7.1 Hz, 2H), 4.00 (s, 2H), 1.41 (t, <i>J</i> = 7.1 Hz, 3H)
108C	F	580 (M+H)	167-171	(CDCl ₃) δ 8.58 (s, 1H), 8.28 (d, <i>J</i> = 15.0 Hz, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 – 7.76 (m, 4H), 7.53 – 7.30 (m, 5H), 7.18 (ddd, <i>J</i> = 7.8, 4.2, 1.2 Hz, 1H), 4.03 – 3.98 (m, 2H), 2.53 (dd, <i>J</i> = 14.1, 7.0 Hz, 1H), 1.77 – 1.56 (m, 2H), 1.26 – 1.16 (m, 3H), 0.78 (td, <i>J</i> = 7.4, 2.3 Hz, 3H).
109C	F	652 (M+H)	105-111	(CDCl ₃) δ 8.25 (s, 1H), 7.73 (d, <i>J</i> = 7.4 Hz, 4H), 7.55 – 7.43 (m, 2H), 7.43 – 7.36 (m, 1H), 7.10 (t, <i>J</i> = 11.6 Hz, 4H), 4.90 – 4.79 (m, 1H), 4.04 (s, 2H), 3.76 (s, 3H), 3.73 – 3.62 (m, 1H), 3.52 – 3.35 (m, 1H)
110C	F	611 (M+H)	Oil	(CDCl ₃) δ 8.25 (s, 1H), 7.82 – 7.64 (m, 4H), 7.30 (t, 1H), 7.22 – 6.99 (m, 6H), 4.83 (dd, <i>J</i> = 12.8, 6.5 Hz, 1H), 4.00 (s, 2H), 3.89 – 3.59 (m, 4H), 3.44 (dd, <i>J</i> = 17.2, 6.5 Hz, 1H), 2.20 (s, 6H).
111C	F	580 (M+H)	209-210	(CDCl ₃) δ 8.58 (s, 1H), 8.30 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.86 – 7.77 (m, 4H), 7.39 (t, <i>J</i> = 7.8 Hz, 3H), 7.34 – 7.27 (m, 1H), 7.20 (d, <i>J</i> = 7.4 Hz, 1H), 4.03 (s, 2H), 2.86 – 2.71 (m, 1H), 2.21 (s, 3H), 1.21 (2d, <i>J</i> = 6.7 Hz, 6H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
112C	F	564 (M+H)	154-158	(CDCl ₃) δ 8.58 (s, 1H), 8.32 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.87 – 7.75 (m, 4H), 7.43 – 7.33 (m, 4H), 7.26 – 7.19 (m, 2H), 4.02 (s, 2H), 1.86 – 1.77 (m, 1H), 0.90 – 0.83 (m, 2H), 0.77 – 0.68 (m, 1H), 0.67 – 0.59 (m, 1H).
113C	F	538 (M+H)	111-116; 210-212	(Acetone-D ₆) δ 9.20 (s, 1H), 8.28 (d, <i>J</i> = 8.2 Hz, 3H), 8.13 (d, <i>J</i> = 9.0 Hz, 2H), 7.94 (d, <i>J</i> = 8.2 Hz, 2H), 7.60 (d, <i>J</i> = 8.8 Hz, 2H), 7.39 (t, <i>J</i> = 17.1 Hz, 4H), 4.15 (q, <i>J</i> = 17.3 Hz, 2H), 2.23 (s, 3H)
114C	F	568 (M+H)	203-205	(CDCl ₃) δ 8.58 (s, 1H), 8.33 (s, 1H), 8.22 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 – 7.67 (m, 4H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 7.14 (d, <i>J</i> = 8.3 Hz, 1H), 6.87 (d, <i>J</i> = 8.9 Hz, 2H), 3.98 (s, 2H), 3.83 (s, 3H), 2.20 (s, 3H)
115C	F	554 (M+H)	261-264	(CDCl ₃) δ 8.58 (s, 1H), 8.35 (s, 1H), 8.23 (d, <i>J</i> = 8.2 Hz, 2H), 7.82 (m, 4H), 7.40 (d, <i>J</i> = 8.6 Hz, 2H), 7.30 (d, 2H), 7.03 (d, <i>J</i> = 8.8 Hz, 2H), 3.97 (s, 2H), 3.86 (s, 3H)
116C	F	568 (M+H)	92-97	(CDCl ₃) δ 8.58 (s, 1H), 8.31 (s, 1H), 8.22 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 – 7.72 (m, 4H), 7.48 – 7.32 (m, 3H), 7.31 – 7.20 (m, 1H), 7.13 – 6.97 (m, 2H), 4.09 (q, <i>J</i> = 7.0 Hz, 2H), 3.95 (t, <i>J</i> = 11.7 Hz, 2H), 1.33 (t, <i>J</i> = 7.0 Hz, 3H).
117C	F	539 (M+H)	127-132	(CDCl ₃) δ 8.59 (s, 1H), 8.54 (dd, <i>J</i> = 4.8, 1.3 Hz, 1H), 8.28 (s, 1H), 8.22 (d, <i>J</i> = 8.4 Hz, 2H), 7.84 – 7.77 (m, 4H), 7.77 – 7.72 (m, 1H), 7.38 (dd, <i>J</i> = 7.7, 5.0 Hz, 3H), 4.02 (d, <i>J</i> = 1.2 Hz, 2H), 2.30 (s, 3H)
118C	F	539 (M+H)	215 (dec)	(CDCl ₃) δ 8.67 (s, 1H), 8.59 (s, 1H), 8.24 (d, <i>J</i> = 8.4 Hz, 2H), 7.99 (d, <i>J</i> = 8.4 Hz, 1H), 7.84 (dd, <i>J</i> = 8.3, 3.8 Hz, 4H), 7.80 (s, 1H), 7.42 – 7.39 (m, 3H), 4.03 (d, <i>J</i> = 1.3 Hz, 2H), 2.26 (s, 3H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
119C	F	580 (M+H)	124-138	(CDCl ₃) δ 8.58 (s, 1H), 8.29 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.88 – 7.77 (m, 4H), 7.48 – 7.34 (m, 5H), 7.23 – 7.18 (m, 1H), 4.06 – 3.93 (m, 2H), 2.40 (qd, <i>J</i> = 14.2, 7.3 Hz, 2H), 1.94 – 1.81 (m, 1H), 0.89 (d, <i>J</i> = 6.6 Hz, 6H).
120C	F	549.7 (M+H)	153-159	(CDCl ₃) δ 8.67 (s, 1H), 8.30 (s, 1H), 8.24 (d, <i>J</i> = 8.3 Hz, 2H), 7.92 (d, <i>J</i> = 8.5 Hz, 2H), 7.82 (m, 3H), 4.01 (d, <i>J</i> = 1.5 Hz, 2H), 3.80 – 3.64 (m, 2H), 2.91 – 2.76 (m, 2H), 1.30 – 1.14 (m, 6H)
121C	F	578 (M+H)	143-147; 148-151	(CDCl ₃) δ 8.57 (d, <i>J</i> = 7.4 Hz, 1H), 8.30 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.87 – 7.78 (m, 4H), 7.49 – 7.33 (m, 5H), 7.29 – 7.26 (m, 1H), 6.03 (s, 1H), 3.95 (s, 2H), 1.84 (d, <i>J</i> = 1.3 Hz, 3H), 1.71 (d, <i>J</i> = 1.2 Hz, 3H).
122C	F	579.3 (M+1)	169-171	(CDCl ₃) δ 8.58 (s, 1H), 8.24 – 8.18 (m, 2H), 7.99 – 7.94 (m, 2H), 7.84 – 7.78 (m, 2H), 7.47 (dd, <i>J</i> = 5.0, 1.1 Hz, 2H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.34 (ddd, <i>J</i> = 7.9, 5.1, 3.7 Hz, 1H), 7.18 (d, <i>J</i> = 7.6 Hz, 1H), 4.00 (d, <i>J</i> = 1.5 Hz, 2H), 3.72 (dd, <i>J</i> = 7.0, 5.1 Hz, 2H), 2.94 – 2.80 (m, 1H), 2.22 (s, 3H), 1.23 (m, 9H).
123C	F	553 (M+H)	130-135	(CDCl ₃) δ 8.62 (s, 1H), 8.54 (d, <i>J</i> = 3.2 Hz, 1H), 8.28 – 8.19 (m, 3H), 7.82 (d, <i>J</i> = 8.8 Hz, 5H), 7.43 – 7.37 (m, 3H), 4.02 (s, 2H), 2.63 (d, <i>J</i> = 7.6 Hz, 2H), 1.22 (s, 3H)
124C	F	608 (M+H)	140-145	(CDCl ₃) δ 8.58 (s, 1H), 8.29 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.89 – 7.75 (m, 4H), 7.58 – 7.51 (m, 1H), 7.49 – 7.36 (m, 5H), 4.04 (d, <i>J</i> = 17.4 Hz, 1H), 3.97 (d, <i>J</i> = 17.4 Hz, 1H).
125C	F	580 (M+H)	130-140	(CDCl ₃) δ 8.58 (s, 1H), 8.31 (s, 1H), 8.22 (d, <i>J</i> = 8.4 Hz, 2H), 7.86 – 7.78 (m, 4H), 7.65 (dd, <i>J</i> = 8.1, 1.4 Hz, 1H), 7.49 – 7.42 (m, 1H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.35 (dt, <i>J</i> = 7.6, 1.5 Hz, 1H), 7.05 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 3.95 (s, 2H), 1.38 (s, 9H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
126C	F	590 (M+H)	175-177	(CDCl ₃) δ 8.58 (s, 1H), 8.29 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.87 – 7.77 (m, 4H), 7.52 (ddd, <i>J</i> = 8.1, 6.0, 3.4 Hz, 1H), 7.44 – 7.34 (m, 5H), 6.46 (t, <i>J</i> _{HF} = 73.5 Hz, 1H), 4.05 – 3.95 (m, 2H).
127C	F	578 (M+H)	112-115	(CDCl ₃) δ 8.58 (s, 1H), 8.32 (s, 1H), 8.22 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 – 7.75 (m, 4H), 7.43 – 7.32 (m, 4H), 7.26 – 7.24 (m, 2H), 4.23 (q, <i>J</i> = 7.3 Hz, 1H), 1.85 – 1.78 (m, 4H), 0.90 – 0.78 (m, 2H), 0.78 – 0.69 (m, 1H), 0.65 – 0.55 (m, 1H).
128C	F	580 (M+H)	164-171	(CDCl ₃) δ 8.58 (s, 1H), 8.29 (d, <i>J</i> = 7.8 Hz, 1H), 8.22 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 – 7.74 (m, 4H), 7.48 – 7.30 (m, 5H), 7.20 (t, <i>J</i> = 11.1 Hz, 1H), 4.26 – 4.14 (m, 1H), 2.50 – 2.46 (m, 2H), 1.79 (d, <i>J</i> = 7.3 Hz, 3H), 1.69 – 1.56 (m, 2H), 0.93 (t, <i>J</i> = 7.3 Hz, 3H).
129C	F	606 (M+H)	140-142	(CDCl ₃) δ 8.58 (s, 1H), 8.30 (s, 1H), 8.22 (d, <i>J</i> = 8.4 Hz, 2H), 7.87 – 7.76 (m, 4H), 7.53 – 7.47 (m, 2H), 7.44 – 7.35 (m, 3H), 4.27 (q, <i>J</i> = 7.3 Hz, 1H), 1.82 (d, <i>J</i> = 7.3 Hz, 3H).
130C	F	590 (M+H)	93-97; 191-194	(CDCl ₃) δ 8.58 (s, 1H), 8.31 (s, 1H), 8.22 (d, <i>J</i> = 8.4 Hz, 2H), 7.88 – 7.76 (m, 4H), 7.48 – 7.34 (m, 4H), 7.20 (tt, <i>J</i> = 12.4, 6.1 Hz, 1H), 4.35 – 4.18 (m, 1H), 1.81 (2d, <i>J</i> = 7.3 Hz, 3H).
131C	F	572 (M-H)	93-98; 185-186	(CDCl ₃) δ 8.58 (s, 1H), 8.32 (s, 1H), 8.26 – 8.20 (m, 2H), 7.86 – 7.78 (m, 4H), 7.53 – 7.42 (m, 1H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.09 (t, <i>J</i> = 8.1 Hz, 2H), 4.26 (q, <i>J</i> = 7.3 Hz, 1H), 1.80 (d, <i>J</i> = 7.3 Hz, 3H).
132C	J	552 (M+H)	193-196	(CDCl ₃) δ 8.56 (s, 1H), 8.22 (s, 1H), 8.17 (d, <i>J</i> = 8.4 Hz, 2H), 7.80 (ddd, <i>J</i> = 9.5, 6.9, 4.9 Hz, 4H), 7.43 – 7.33 (m, 4H), 7.31 – 7.21 (m, 2H), 4.05 (td, <i>J</i> = 9.4, 7.1 Hz, 1H), 3.97 – 3.87 (m, 1H), 3.42 – 3.33 (m, 1H), 3.33 – 3.24 (m, 1H), 3.12 (heptet, <i>J</i> = 6.8 Hz, 1H), 1.27 (d, <i>J</i> = 6.8 Hz, 3H), 1.22 (d, <i>J</i> = 6.9 Hz, 3H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
133C	J	538 (M+H)	167-169	(CDCl ₃) δ 8.55 (d, <i>J</i> = 7.1 Hz, 1H), 8.23 (s, 1H), 8.17 (d, <i>J</i> = 8.4 Hz, 2H), 7.80 (dt, <i>J</i> = 11.4, 6.2 Hz, 4H), 7.43 – 7.23 (m, 6H), 4.00 (s, 2H), 3.32 (s, 2H), 2.67 (q, <i>J</i> = 7.6 Hz, 2H), 1.25 (dd, <i>J</i> = 9.6, 5.5 Hz, 3H).
134C	J	536 (M+H)	217-220; 230-232	(CDCl ₃) δ 8.65 (s, 1H), 8.22 (s, 1H), 8.18 (d, <i>J</i> = 8.4 Hz, 2H), 7.94 – 7.88 (m, 2H), 7.81- 7.78 (m, 4H), 7.41 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.39 – 7.33 (m, 1H), 7.30 – 7.24 (m, 1H), 7.23 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 4.09 – 4.02 (m, 1H), 3.98 – 3.88 (m, 1H), 3.43 – 3.24 (m, 2H), 3.12 (heptet, <i>J</i> = 6.9 Hz, 1H), 1.27 (d, <i>J</i> = 6.8 Hz, 3H), 1.22 (d, <i>J</i> = 6.9 Hz, 3H).
135C	J	566 (M+H)	167-169	(CDCl ₃) δ 8.56 (s, 1H), 8.19 (dd, <i>J</i> = 12.7, 9.0 Hz, 3H), 7.84 – 7.74 (m, 4H), 7.37 (dd, <i>J</i> = 14.9, 6.1 Hz, 4H), 7.26 (s, 1H), 7.21 (d, <i>J</i> = 7.6 Hz, 1H), 4.17 – 3.85 (m, 2H), 3.42 – 3.22 (m, 2H), 2.82 (d, <i>J</i> = 23.6 Hz, 1H), 1.80 – 1.55 (m, 2H), 1.23 (2d, <i>J</i> = 6.9 Hz, 3H), 0.82 (2t, <i>J</i> = 7.4 Hz, 3H).
136C	J	552 (M+H)	143-147	(CDCl ₃) δ 8.56 (s, 1H), 8.22 (s, 1H), 8.17 (d, <i>J</i> = 8.4 Hz, 2H), 7.84 – 7.74 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.24 (d, <i>J</i> = 7.5 Hz, 1H), 7.19 (d, <i>J</i> = 6.4 Hz, 1H), 7.15 (d, <i>J</i> = 7.3 Hz, 1H), 3.92 (qt, <i>J</i> = 10.1, 7.3 Hz, 2H), 3.43 – 3.28 (m, 2H), 2.72 – 2.51 (m, 2H), 2.27 (s, 3H), 1.25 (t, <i>J</i> = 7.6 Hz, 3H).
137C	J	554 (M+H)	183-186	(CDCl ₃) δ 8.56 (d, <i>J</i> = 5.3 Hz, 1H), 8.26 (s, 1H), 8.17 (d, <i>J</i> = 8.4 Hz, 2H), 7.84 – 7.74 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.18 (d, <i>J</i> = 8.5 Hz, 1H), 6.81 (dt, <i>J</i> = 8.4, 2.9 Hz, 2H), 3.96 (t, <i>J</i> = 6.6 Hz, 2H), 3.81 (s, 3H), 3.30 (t, <i>J</i> = 6.9 Hz, 2H), 2.28 (s, 3H).
138C	J	568 (M+H)	231-233	(CDCl ₃) δ 8.56 (d, <i>J</i> = 5.4 Hz, 1H), 8.25 (s, 1H), 8.17 (d, <i>J</i> = 8.4 Hz, 2H), 7.84 – 7.72 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 6.67 (s, 2H), 3.92 – 3.85 (m, 2H), 3.79 (s, 3H), 3.34 (t, <i>J</i> = 7.1 Hz, 2H), 2.25 (s, 6H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
139C	J	552 (M+H)	195-197	(CDCl ₃) δ 8.56 (s, 1H), 8.24 (s, 1H), 8.17 (d, <i>J</i> = 8.3 Hz, 2H), 7.83 – 7.73 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 6.95 (s, 2H), 3.90 (t, <i>J</i> = 7.1 Hz, 2H), 3.35 (t, <i>J</i> = 7.1 Hz, 2H), 2.30 (s, 3H), 2.23 (s, 6H).
140C	J	540 (M+H)	181-184	(CDCl ₃) δ 8.56 (s, 1H), 8.24 (s, 1H), 8.17 (d, <i>J</i> = 8.3 Hz, 2H), 7.84 – 7.75 (m, 4H), 7.43 – 7.36 (m, 3H), 7.30 (ddd, <i>J</i> = 12.6, 6.9, 3.1 Hz, 1H), 7.06 – 6.97 (m, 2H), 4.04 (t, <i>J</i> = 7.0 Hz, 2H), 3.86 (s, 3H), 3.29 (t, <i>J</i> = 7.0 Hz, 2H).
141C	J	524 (M+H)	173-176	(CDCl ₃) δ 8.56 (s, 1H), 8.25 (s, 1H), 8.18 (d, <i>J</i> = 8.4 Hz, 2H), 7.83 – 7.75 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.34 – 7.23 (m, 4H), 4.01 (t, <i>J</i> = 6.9 Hz, 2H), 3.32 (t, <i>J</i> = 6.9 Hz, 2H), 2.31 (s, 3H).
142C	J	538 (M+H)	210-213	(CDCl ₃) δ 8.56 (s, 1H), 8.23 (s, 1H), 8.17 (d, <i>J</i> = 8.4 Hz, 2H), 7.84 – 7.74 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.22 – 7.10 (m, 3H), 3.92 (t, <i>J</i> = 7.1 Hz, 2H), 3.36 (t, <i>J</i> = 7.1 Hz, 2H), 2.28 (s, 6H).
143C	J	562 (M+H)	221-224	(CDCl ₃) δ 8.56 (s, 1H), 8.23 (s, 1H), 8.18 (d, <i>J</i> = 8.4 Hz, 2H), 7.83 – 7.74 (m, 4H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.30 (dt, <i>J</i> = 7.4, 4.8 Hz, 2H), 7.15 – 7.09 (m, 1H), 4.05 (ddd, <i>J</i> = 9.4, 7.3, 5.2 Hz, 1H), 4.00 – 3.89 (m, 1H), 3.46 – 3.30 (m, 2H).
144C	J	586 (M+H)	117-123; 134-138	(300 MHz, CDCl ₃) δ 8.56 (d, <i>J</i> = 4.3 Hz, 1H), 8.34 (s, 1H), 8.21 (s, 1H), 8.18 (s, 1H), 7.81 (dd, <i>J</i> = 8.9, 2.3 Hz, 4H), 7.52 (d, <i>J</i> = 6.7 Hz, 1H), 7.50 – 7.31 (m, 10H), 3.53 – 3.49 (m, 2H), 2.95 – 2.90 (d, <i>J</i> = 6.8 Hz, 2H).
145C	J	550 (M+H)	207-209	(CDCl ₃) δ 8.56 (s, 1H), 8.26 (s, 1H), 8.18 (d, <i>J</i> = 8.3 Hz, 2H), 7.84 – 7.74 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.32 – 7.21 (m, 3H), 7.01 (dd, <i>J</i> = 8.9, 2.5 Hz, 1H), 4.12 – 4.04 (s, 2H), 3.34 (t, <i>J</i> = 6.9 Hz, 2H), 2.09 – 1.98 (m, 1H), 0.95 (dd, <i>J</i> = 8.5, 1.7 Hz, 2H), 0.72 (bs, 2H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
146C	J	554 (M+H)	141-144	(CDCl ₃) δ 8.56 (d, <i>J</i> = 5.2 Hz, 1H), 8.24 (s, 1H), 8.17 (d, <i>J</i> = 8.3 Hz, 2H), 7.80 (dt, <i>J</i> = 8.2, 4.6 Hz, 4H), 7.45 – 7.36 (m, 3H), 7.30 – 7.24 (m, 1H), 7.05 – 6.95 (m, 2H), 4.13 – 4.02 (m, 4H), 3.28 (t, <i>J</i> = 7.0 Hz, 2H), 1.44 – 1.35 (m, 3H).
147C	J	540 (M+H)	168-170	(CDCl ₃) δ 8.57 (s, 1H), 8.37 (s, 1H), 8.21 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 – 7.76 (m, 4H), 7.40 (d, <i>J</i> = 8.4 Hz, 2H), 7.29 (dd, <i>J</i> = 14.2, 6.0 Hz, 1H), 7.24 (d, <i>J</i> = 2.3 Hz, 1H), 7.09 – 7.02 (m, 1H), 6.72 (dd, <i>J</i> = 8.0, 2.1 Hz, 1H), 4.20 (t, <i>J</i> = 6.9 Hz, 2H), 3.83 (d, <i>J</i> = 8.7 Hz, 3H), 3.24 (t, <i>J</i> = 6.9 Hz, 2H).
148C	J	546 (M+H)	213-216	(CDCl ₃) δ 8.56 (s, 1H), 8.24 (s, 1H), 8.18 (d, <i>J</i> = 8.3 Hz, 2H), 7.80 (dt, <i>J</i> = 4.0, 2.5 Hz, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.30 (ddd, <i>J</i> = 8.5, 7.4, 4.2 Hz, 1H), 7.05 – 6.97 (m, 2H), 4.02 (t, <i>J</i> = 6.9 Hz, 2H), 3.36 (t, <i>J</i> = 6.9 Hz, 2H).
149C	J	612 (M+H)	200-203	(CDCl ₃) δ 8.56 (s, 1H), 8.18 (d, <i>J</i> = 2.6 Hz, 2H), 8.16 (s, 1H), 7.80 (dt, <i>J</i> = 8.3, 4.7 Hz, 4H), 7.71 (t, <i>J</i> = 8.6 Hz, 2H), 7.47 (t, <i>J</i> = 7.7 Hz, 1H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 4.18 – 4.07 (m, 1H), 3.93 – 3.84 (m, 1H), 3.46 (td, <i>J</i> = 10.7, 7.3 Hz, 1H), 3.35 – 3.25 (m, 1H).
150C	J	566 (M+H)	169-172	(CDCl ₃) δ 8.56 (s, 1H), 8.22 (s, 1H), 8.17 (d, <i>J</i> = 8.4 Hz, 2H), 7.80 (dt, <i>J</i> = 11.5, 6.2 Hz, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.31 – 7.27 (m, 3H), 7.26 – 7.24 (m, 1H), 4.10 – 3.89 (m, 2H), 3.38 – 3.32 (m, 2H), 2.48 (s, 2H), 2.01 – 1.84 (m, 1H), 0.91 (d, <i>J</i> = 6.2 Hz, 6H).
151C	J	564 (M+H)	149-153	(CDCl ₃) δ 8.57 (s, 1H), 8.25 (s, 1H), 8.18 (d, <i>J</i> = 8.3 Hz, 2H), 7.99 (s, 1H), 7.81 (dt, <i>J</i> = 8.3, 4.5 Hz, 4H), 7.39 (dd, <i>J</i> = 6.1, 3.5 Hz, 3H), 7.33 – 7.27 (m, 2H), 6.21 (s, 1H), 3.92 (t, <i>J</i> = 6.9 Hz, 2H), 3.26 (t, <i>J</i> = 6.8 Hz, 2H), 1.89 (d, <i>J</i> = 1.1 Hz, 3H), 1.79 (d, <i>J</i> = 1.1 Hz, 3H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
152C	J	576 (M+H)	161-163	(CDCl ₃) δ 8.57 (s, 1H), 8.23 – 8.16 (m, 3H), 7.83 – 7.77 (m, 4H), 7.48 (dd, <i>J</i> = 7.5, 2.0 Hz, 1H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.33 (dt, <i>J</i> = 7.2, 2.1 Hz, 2H), 7.28 (dd, <i>J</i> = 9.8, 1.9 Hz, 1H), 6.52 (t, <i>J</i> _{HF} = 74.1 Hz, 1H), 4.06 (t, <i>J</i> = 6.9 Hz, 2H), 3.33 (t, <i>J</i> = 6.9 Hz, 2H).
153C	J	594 (M+H)	195-197	(CDCl ₃) δ 8.57 (s, 1H), 8.25 (s, 1H), 8.19 (d, <i>J</i> = 8.4 Hz, 2H), 7.81 (dt, <i>J</i> = 4.1, 2.6 Hz, 4H), 7.58 – 7.52 (m, 1H), 7.42 – 7.33 (m, 5H), 4.05 (t, <i>J</i> = 6.9 Hz, 2H), 3.31 (t, <i>J</i> = 6.9 Hz, 2H).
154C	J	538 (M+H)	164-167	CDCl ₃) δ 8.56 (s, 1H), 8.23 (d, <i>J</i> = 9.8 Hz, 1H), 8.17 (d, <i>J</i> = 8.3 Hz, 2H), 7.84 – 7.74 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.35 – 7.27 (m, 3H), 7.19 (s, 1H), 3.54 – 3.31 (m, 1H), 3.07 – 2.93 (m, 1H), 2.31 (d, <i>J</i> = 9.0 Hz, 3H), 1.62 – 1.56 (m, 1H), 1.31 – 1.19 (m, 3H).
155C	J	566 (M+H)	201-204	Two Isomers (CDCl ₃) δ 8.56 (s, 2H), 8.18 (dd, <i>J</i> = 10.8, 7.4 Hz, 6H), 7.84 – 7.73 (m, 8H), 7.45 – 7.30 (m, 8H), 7.30 – 7.23 (m, 2H), 7.20 (d, <i>J</i> = 6.7 Hz, 1H), 7.12 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 4.43 – 4.33 (m, 1H), 4.16 (dd, <i>J</i> = 12.6, 6.3 Hz, 1H), 3.48 (dt, <i>J</i> = 13.3, 6.7 Hz, 1H), 3.37 (dd, <i>J</i> = 10.8, 6.2 Hz, 1H), 3.24 (dt, <i>J</i> = 13.7, 6.9 Hz, 1H), 3.08 – 2.92 (m, 3H), 1.33 – 1.16 (m, 18H).
156C	J	566 (M+H)	105-110	(CDCl ₃) δ 8.56 (s, 1H), 8.20 (d, <i>J</i> = 3.4 Hz, 1H), 8.16 (d, <i>J</i> = 8.4 Hz, 2H), 7.84 – 7.73 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.25 – 7.09 (m, 3H), 4.39 – 4.23 (m, 1H), 3.53 – 3.35 (m, 1H), 3.04 – 3.00 (m, 1H), 2.78 – 2.49 (m, 2H), 2.28 (2s, 3H), 1.34 – 1.08 (m, 6H).
157C	J	592 (M+H)	175-176	(CDCl ₃) δ 8.56 (d, <i>J</i> = 0.6 Hz, 1H), 8.21 (s, 1H), 8.17 (d, <i>J</i> = 8.2 Hz, 2H), 7.82 – 7.77 (m, 4H), 7.49 – 7.35 (m, 4H), 7.30 – 7.28 (m, 1H), 4.64 – 4.57 (m, 1H), 3.44 (dd, <i>J</i> = 10.2, 6.3 Hz, 1H), 3.16 – 3.01 (m, 1H), 1.27 (d, <i>J</i> = 6.3 Hz, 3H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
158C	J	572 (M+H)	99-102	Two Isomers (CDCl ₃) δ 8.56 (s, 2H), 8.20 (s, 2H), 8.19 – 8.12 (m, 4H), 7.84 – 7.73 (m, 8H), 7.39 (d, <i>J</i> = 8.3 Hz, 4H), 7.36 – 7.29 (m, 2H), 7.25 – 7.17 (m, 4H), 4.78 – 4.55 (m, 1H), 4.35 (dt, <i>J</i> = 9.4, 6.3 Hz, 1H), 3.48 (dd, <i>J</i> = 10.7, 6.5 Hz, 1H), 3.38 (dd, <i>J</i> = 10.7, 6.2 Hz, 1H), 3.11 (dd, <i>J</i> = 10.7, 9.4 Hz, 1H), 3.01 (dd, <i>J</i> = 10.7, 8.3 Hz, 1H), 2.35 (s, 3H), 2.30 (s, 3H), 1.26 (d, <i>J</i> = 6.3 Hz, 3H), 1.21 (d, <i>J</i> = 6.4 Hz, 3H)
159C	J	607 (M+H)	85 (dec)	(CDCl ₃) δ 8.56 (s, 1H), 8.18 (dd, <i>J</i> = 11.9, 5.3 Hz, 3H), 7.79 (dd, <i>J</i> = 8.7, 6.5 Hz, 4H), 7.47 (dd, <i>J</i> = 7.8, 2.3 Hz, 1H), 7.42 – 7.32 (m, 5H), 4.48 – 4.29 (m, 1H), 3.45 (dd, <i>J</i> = 10.7, 6.4 Hz, 1H), 2.98 (dd, <i>J</i> = 10.7, 7.1 Hz, 1H), 1.26 (d, <i>J</i> = 6.3 Hz, 3H)
160C	J	626 (M+H)	93 (dec)	Two Isomers (CDCl ₃) δ 8.56 (s, 2H), 8.19 – 8.12 (m, 6H), 7.84 – 7.73 (m, 10H), 7.71 (d, <i>J</i> = 8.2 Hz, 2H), 7.47 (t, <i>J</i> = 8.0 Hz, 2H), 7.39 (d, <i>J</i> = 8.3 Hz, 4H), 4.76 – 4.64 (m, 1H), 4.48 (dd, <i>J</i> = 14.6, 6.3 Hz, 1H), 3.43 (dd, <i>J</i> = 10.6, 6.2 Hz, 1H), 3.29 (dd, <i>J</i> = 10.5, 5.5 Hz, 1H), 3.16 – 3.00 (m, 2H), 1.27 (d, <i>J</i> = 6.4 Hz, 3H), 1.17 (d, <i>J</i> = 6.4 Hz, 3H)
161C	J	566 (M+H)	105 (dec)	(CDCl ₃) δ 8.56 (s, 1H), 8.22 (s, 1H), 8.16 (d, <i>J</i> = 8.4 Hz, 2H), 7.83 – 7.70 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 6.94 (d, <i>J</i> = 9.3 Hz, 2H), 4.43 – 4.22 (m, 1H), 3.42 (dd, <i>J</i> = 10.8, 6.5 Hz, 1H), 3.00 (dd, <i>J</i> = 10.8, 8.5 Hz, 1H), 2.30 (s, 3H), 2.25 (s, 3H), 2.21 (s, 3H), 1.20 (d, <i>J</i> = 6.3 Hz, 3H)
162C	J	568 (M+H)	100 (dec)	(CDCl ₃) δ 8.56 (s, 1H), 8.24 (s, 1H), 8.17 (d, <i>J</i> = 8.4 Hz, 2H), 7.83 – 7.73 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.18 – 7.09 (m, 1H), 6.86 – 6.76 (m, 2H), 4.33 – 4.19 (m, 1H), 3.82 (s, 3H), 3.47 – 3.38 (m, 1H), 3.00 – 2.99 (m, 1H), 2.29 – 2.27 (m, 3H), 1.33 – 1.15 (m, 3H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
163C	J	580 (M+H)	92-102	(CDCl ₃) δ 8.56 (s, 2H), 8.18 (dd, <i>J</i> = 10.7, 5.3 Hz, 6H), 7.84 – 7.74 (m, 8H), 7.42 – 7.30 (m, 8H), 7.23 – 7.10 (m, 2H), 4.37 (dd, <i>J</i> = 19.5, 13.6 Hz, 1H), 4.16 (dd, <i>J</i> = 13.1, 6.6 Hz, 1H), 3.56 – 3.42 (m, 1H), 3.34 (dd, <i>J</i> = 10.8, 6.0 Hz, 1H), 3.08 – 2.87 (m, 3H), 2.70 (dd, <i>J</i> = 16.0, 7.0 Hz, 1H), 1.71 – 1.56 (m, 4H), 1.34 – 1.25 (m, 6H), 1.24 – 1.14 (m, 6H), 0.93 – 0.73 (m, 6H)
164C	J	589 (M+H)	80 (dec)	(CDCl ₃) δ 8.56 (s, 1H), 8.22 – 8.14 (m, 3H), 7.84 – 7.76 (m, 4H), 7.42 – 7.27 (m, 6H), 6.51 (t, <i>J</i> _{HF} = 74.3 Hz, 1H), 4.52 – 4.31 (m, 1H), 3.44 (dd, <i>J</i> = 10.8, 6.5 Hz, 1H), 2.99 (dd, <i>J</i> = 10.8, 7.6 Hz, 1H), 1.25 (d, <i>J</i> = 6.3 Hz, 3H)
165C	J	580 (M+H)	143 (dec)	Two Isomers (CDCl ₃) δ 8.56 (s, 2H), 8.22 (s, 1H), 8.20 (s, 1H), 8.16 (d, <i>J</i> = 8.3 Hz, 4H), 7.84 – 7.74 (m, 8H), 7.58 (ddd, <i>J</i> = 9.7, 8.0, 1.7 Hz, 2H), 7.39 (d, <i>J</i> = 8.4 Hz, 4H), 7.36 – 7.27 (m, 4H), 7.15 (dd, <i>J</i> = 7.7, 1.6 Hz, 1H), 7.09 (dd, <i>J</i> = 7.6, 1.7 Hz, 1H), 4.38 – 4.22 (m, 2H), 3.61 (dd, <i>J</i> = 10.8, 7.0 Hz, 1H), 3.24 (dd, <i>J</i> = 10.7, 5.6 Hz, 1H), 3.07 – 2.94 (m, 1H), 2.91 (dd, <i>J</i> = 10.8, 1.5 Hz, 1H), 1.47 – 1.38 (m, 24H)
166C	J	552 (M+H)	93 (dec)	(CDCl ₃) δ 8.56 (s, 1H), 8.21 (s, 1H), 8.16 (d, <i>J</i> = 8.4 Hz, 2H), 7.84 – 7.73 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.32 – 7.28 (m, 3H), 7.20 (s, 1H), 4.20 – 4.06 (m, 1H), 3.41 (s, 1H), 3.05 (dd, <i>J</i> = 10.8, 8.2 Hz, 1H), 2.31 – 32.30 (m, 3H), 1.66 (s, 2H), 0.90 – 0.88 (m, 3H)
167C	J	586 (M+H)	105 (dec)	Two Isomers (CDCl ₃) δ 8.56 (s, 2H), 8.20 (s, 2H), 8.16 (d, <i>J</i> = 8.3 Hz, 4H), 7.83 – 7.74 (m, 8H), 7.43 – 7.28 (m, 6H), 7.21 (dd, <i>J</i> = 5.4, 3.3 Hz, 4H), 4.49 – 4.36 (m, 1H), 4.17 – 4.05 (m, 1H), 3.49 (dd, <i>J</i> = 10.7, 6.6 Hz, 1H), 3.40 (dd, <i>J</i> = 10.7, 6.3 Hz, 1H), 3.10 (dd, <i>J</i> = 10.7, 9.4 Hz, 1H), 3.04 (dd, <i>J</i> = 10.8, 8.2 Hz, 1H), 2.34 (s, 3H), 2.30 (s, 3H), 1.73 – 1.48 (m, 4H), 0.91 (m, 6H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
168C	J	560 (M+H)	199-200	(CDCl ₃) δ 8.56 (s, 1H), 8.18 (m, 2H), 7.79 (m, 4H), 7.47 (dd, <i>J</i> = 7.8, 2.3 Hz, 1H), 7.42 – 7.32 (m, 5H), 4.48 – 4.29 (m, 1H), 3.45 (dd, <i>J</i> = 10.7, 6.4 Hz, 1H), 2.98 (dd, <i>J</i> = 10.7, 7.1 Hz, 1H), 1.26 (d, <i>J</i> = 6.3 Hz, 3H)
169C	G	623 (M+H)	Oil	(CDCl ₃) δ 10.45 (s, 1H), 8.59 (s, 1H), 8.25 (d, <i>J</i> = 8.3 Hz, 2H), 7.88 (d, <i>J</i> = 8.3 Hz, 2H), 7.81 (d, <i>J</i> = 8.9 Hz, 2H), 7.61 (t, <i>J</i> = 7.5 Hz, 2H), 7.40 (d, <i>J</i> = 8.7 Hz, 2H), 7.11 (t, <i>J</i> = 8.0 Hz, 1H), 5.71 (d, <i>J</i> = 1.1 Hz, 1H), 2.35 (s, 3H) ¹⁹ F NMR (376 MHz, CDCl ₃) δ -58.02, -62.31
170C	G	606 (M+H)	157-159	(CDCl ₃) δ 8.56 (s, 1H), 8.19 – 8.14 (m, 3H), 7.79 (m, 4H), 7.56 – 7.46 (m, 2H), 7.46 – 7.43 (m, 2H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 5.88 (d, <i>J</i> = 1.3 Hz, 1H), 1.86 (d, <i>J</i> = 1.2 Hz, 3H)
171C	G	558 (M+H)	236-237	(CDCl ₃) δ 8.56 (s, 1H), 8.19 (d, <i>J</i> = 5.9 Hz, 2H), 8.16 (s, 1H), 7.83 – 7.76 (m, 4H), 7.45 (tt, <i>J</i> = 8.4, 6.1 Hz, 1H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.10 (dd, <i>J</i> = 8.5, 7.3 Hz, 2H), 5.90 (d, <i>J</i> = 1.3 Hz, 1H), 1.92 (s, 3H)
172C	G	580 (M+H)	103-108	(CDCl ₃) δ 8.56 (d, <i>J</i> = 3.7 Hz, 1H), 8.21 (s, 1H), 8.16 (d, <i>J</i> = 8.4 Hz, 2H), 7.84 – 7.72 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 6.72 (s, 2H), 5.89 (d, <i>J</i> = 1.3 Hz, 1H), 3.82 (s, 3H), 2.14 (s, 6H), 1.75 (d, <i>J</i> = 1.2 Hz, 3H).
173C	G	536 (M+H)	87 (dec)	(CDCl ₃) δ 8.56 (s, 1H), 8.19-8.15 (m, 3H), 7.82 – 7.75 (m, 4H), 7.43 – 7.30 (m, 5H), 7.24 (d, <i>J</i> = 7.3 Hz, 1H), 5.88 (s, 1H), 2.21 (s, 3H), 1.80 (d, <i>J</i> = 1.2 Hz, 3H)
174C	G	570 (M+H)	95 (dec)	(CDCl ₃) δ 8.56 (s, 1H), 8.20 – 8.12 (m, 3H), 7.83 – 7.74 (m, 4H), 7.43 – 7.36 (m, 3H), 7.32 (t, <i>J</i> = 7.7 Hz, 1H), 7.29-7.27 (m, 1H), 5.92 (d, <i>J</i> = 1.3 Hz, 1H), 2.26 (s, 3H), 1.81 (d, <i>J</i> = 1.2 Hz, 3H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
175C	G	550 (M+H)	132-136	(CDCl ₃) δ 8.56 (d, <i>J</i> = 5.0 Hz, 1H), 8.21 – 8.13 (m, 3H), 7.83 – 7.74 (m, 4H), 7.39 (d, <i>J</i> = 8.2 Hz, 2H), 7.29 – 7.23 (m, 1H), 7.19 (d, <i>J</i> = 7.7 Hz, 2H), 5.92 (d, <i>J</i> = 1.3 Hz, 1H), 2.18 (s, 6H), 1.75 (d, <i>J</i> = 1.2 Hz, 3H).
176C	G	564 (M+H)	123-138	(CDCl ₃) δ 8.56 (s, 1H), 8.19 – 8.14 (m, 3H), 7.83 – 7.75 (m, 4H), 7.49 – 7.43 (m, 2H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.33 (ddd, <i>J</i> = 7.8, 5.9, 3.0 Hz, 1H), 7.19 – 7.17 (m, 1H), 5.88 (d, <i>J</i> = 1.3 Hz, 1H), 2.96 – 2.76 (m, 1H), 1.81 (d, <i>J</i> = 1.2 Hz, 3H), 1.24 (t, <i>J</i> = 6.4 Hz, 3H), 1.22 – 1.16 (m, 3H).
177C	J	566 (M+H)	185-187	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 2H), 8.05 (s, 1H), 7.84 – 7.77 (m, 2H), 7.74 (d, <i>J</i> = 8.3 Hz, 2H), 7.42 – 7.35 (m, 3H), 7.32 (dd, <i>J</i> = 10.6, 4.3 Hz, 1H), 7.28 – 7.24 (m, 1H), 7.18 (dd, <i>J</i> = 7.8, 1.4 Hz, 1H), 3.80 – 3.69 (m, 1H), 3.59 – 3.48 (m, 1H), 3.11 (dd, <i>J</i> = 13.2, 6.8 Hz, 3H), 2.41 – 2.27 (m, 2H), 1.22 (t, <i>J</i> = 5.6 Hz, 6H).
178C	J	580 (M+H)	186-190	(CDCl ₃) δ 8.55 (d, <i>J</i> = 3.6 Hz, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 2H), 8.06 (s, 1H), 7.84 – 7.77 (m, 2H), 7.74 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 (d, <i>J</i> = 9.0 Hz, 3H), 7.32 (td, <i>J</i> = 7.5, 1.4 Hz, 1H), 7.26 (s, 1H), 7.17 (t, <i>J</i> = 7.1 Hz, 1H), 3.69 – 3.26 (m, 1H), 3.55 – 3.37 (m, 1H), 3.18 – 2.98 (m, 2H), 2.93 – 2.80 (m, 1H), 2.47 (d, <i>J</i> = 35.9 Hz, 1H), 1.31 – 1.12 (m, 9H).
179C	J	550 (M+H)	212-213	(CDCl ₃) δ 8.64 (s, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 2H), 8.06 (s, 1H), 7.91 (d, <i>J</i> = 8.5 Hz, 2H), 7.79 (d, <i>J</i> = 8.6 Hz, 2H), 7.75 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 7.33 (td, <i>J</i> = 7.5, 1.4 Hz, 1H), 7.29 – 7.23 (m, 1H), 7.18 (dd, <i>J</i> = 7.8, 1.4 Hz, 1H), 3.78 – 3.72 (m, 1H), 3.59 – 3.48 (m, 1H), 3.18 – 3.04 (m, 3H), 2.40 – 2.30 (m, 2H), 1.26 – 1.20 (m, 6H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
180C	J	566 (M+H)	127-133	(300 MHz, CDCl ₃) δ 8.55 (s, 1H), 8.13 (d, <i>J</i> = 8.3 Hz, 2H), 8.05 (s, 1H), 7.76 (dd, <i>J</i> = 17.0, 8.7 Hz, 4H), 7.37 (t, <i>J</i> = 8.4 Hz, 2H), 7.18 (dd, <i>J</i> = 12.7, 9.6 Hz, 3H), 3.54 – 3.49 (m, 2H), 3.12 – 3.08 (m, 2H), 2.70 – 2.55 (m, 2H), 2.39 – 2.31 (m, 2H), 2.28 (s, 3H), 1.25 (t, <i>J</i> = 7.6 Hz, 3H).
181C	J	582 (M+H)	170-174	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.3 Hz, 2H), 8.08 (s, 1H), 7.84 – 7.76 (m, 2H), 7.74 (d, <i>J</i> = 8.3 Hz, 2H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 6.65 (s, 2H), 3.79 (s, 3H), 3.52 – 3.45 (m, 2H), 3.10 – 3.07 (m, 2H), 2.38 – 2.31 (d, <i>J</i> = 5.7 Hz, 2H), 2.25 (s, 6H).
182C	J	552 (M+H)	148-155; 166-168	(300 MHz, CDCl ₃) δ 8.55 (d, <i>J</i> = 1.0 Hz, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 2H), 8.05 (s, 1H), 7.83 – 7.76 (m, 2H), 7.74 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 (d, <i>J</i> = 9.0 Hz, 2H), 7.14 – 7.09 (m, 3H), 3.51 (dd, <i>J</i> = 9.1, 3.5 Hz, 2H), 3.15 – 3.03 (m, 2H), 2.36 (s, 2H), 2.28 (s, 6H).
183C	J	580 (M+H)	159-162	(CDCl ₃) δ 8.55 (d, <i>J</i> = 3.7 Hz, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 2H), 8.03 (d, <i>J</i> = 19.3 Hz, 1H), 7.84 – 7.77 (m, 2H), 7.74 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.32 (d, <i>J</i> = 3.8 Hz, 2H), 7.25 (d, <i>J</i> = 6.6 Hz, 1H), 7.19 (t, <i>J</i> = 8.0 Hz, 1H), 3.76 (ddd, <i>J</i> = 24.2, 12.0, 5.9 Hz, 1H), 3.58 – 3.46 (m, 1H), 3.11 (dd, <i>J</i> = 15.3, 6.1 Hz, 2H), 2.82 (dd, <i>J</i> = 14.6, 7.2 Hz, 1H), 2.41 – 2.29 (m, 2H), 1.71-1.55 (m, 2H), 1.20 (d, <i>J</i> = 6.8 Hz, 3H), 0.87 – 0.76 (m, 3H).
184C	J	566 (M+H)	194-198	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 2H), 8.07 (s, 1H), 7.83 – 7.76 (m, 2H), 7.74 (d, <i>J</i> = 8.4 Hz, 2H), 7.40 (t, <i>J</i> = 10.1 Hz, 2H), 6.93 (s, 2H), 3.53 – 3.47 (m, 2H), 3.12 – 3.05 (m, 2H), 2.34 (dt, <i>J</i> = 11.7, 5.8 Hz, 2H), 2.30 (s, 3H), 2.23 (s, 6H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
185C	J	552 (M+H)	157-160	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 2H), 8.06 (s, 1H), 7.83 – 7.77 (m, 2H), 7.74 (d, <i>J</i> = 8.3 Hz, 2H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.36 – 7.27 (m, 3H), 7.23 – 7.19 (m, 1H), 3.74 (m, 1H), 3.50 (m, 1H), 3.10 (d, <i>J</i> = 5.9 Hz, 2H), 2.64 (q, <i>J</i> = 7.6 Hz, 2H), 2.40 – 2.29 (m, 2H), 1.28 – 1.21 (m, 3H).
186C	J	564 (M+H)	173-177	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 2H), 8.09 (s, 1H), 7.83 – 7.77 (m, 2H), 7.81 – 7.77 (m, 2H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.24 – 7.22 (m, 3H), 7.05 – 6.95 (m, 1H), 3.77 – 3.63 (m, 2H), 3.14 – 3.07 (m, 2H), 2.45 – 2.29 (m, 2H), 2.09 – 1.92 (m, 1H), 0.97 – 0.82 (m, 3H), 0.53 (bs, 1H).
187C	J	593 (M+H)	180-182	(300 MHz, CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 2H), 8.05 (d, <i>J</i> = 4.9 Hz, 1H), 7.77 (dd, <i>J</i> = 11.4, 8.6 Hz, 4H), 7.39 (t, <i>J</i> = 8.1 Hz, 4H), 7.21 (dd, <i>J</i> = 13.2, 5.6 Hz, 1H), 3.65 – 3.58 (m, 2H), 3.09 (t, <i>J</i> = 5.5 Hz, 2H), 2.45 – 2.35 (m, 2H).
188C	J	576 (M+H)	209-212	(CDCl ₃) δ 8.56 (s, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 2H), 8.07 (s, 1H), 7.79 (ddd, <i>J</i> = 15.8, 7.8, 5.8 Hz, 4H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.31 – 7.21 (m, 2H), 7.10 (ddd, <i>J</i> = 9.7, 7.8, 2.0 Hz, 1H), 3.64 (t, <i>J</i> = 5.4 Hz, 2H), 3.11 (t, <i>J</i> = 6.0 Hz, 2H), 2.46 – 2.33 (m, 2H).
189C	J	560 (M+H)	217-219	(CDCl ₃) δ 8.56 (s, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 2H), 8.08 (s, 1H), 7.83 – 7.74 (m, 4H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.31 – 7.21 (m, 1H), 7.03 – 6.94 (m, 2H), 3.72 – 3.62 (m, 2H), 3.15 – 3.07 (m, 2H), 2.40 – 2.34 (m, 2H).
190C	J	626 (M+H)	190-193	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.3 Hz, 2H), 8.00 (s, 1H), 7.83 – 7.73 (m, 4H), 7.71 (d, <i>J</i> = 8.1 Hz, 1H), 7.67 (d, <i>J</i> = 7.7 Hz, 1H), 7.40 (dd, <i>J</i> = 15.8, 8.2 Hz, 3H), 3.79 – 3.69 (m, 1H), 3.55 – 3.49 (m, 1H), 3.16 – 3.04 (m, 2H), 2.47 – 2.31 (m, 2H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
191C	J	554 (M+H)	150-155	(CDCl ₃) δ 8.54 (d, <i>J</i> = 4.3 Hz, 1H), 8.13 (d, <i>J</i> = 8.3 Hz, 2H), 8.05 (d, <i>J</i> = 6.3 Hz, 1H), 7.77 (dd, <i>J</i> = 15.4, 8.7 Hz, 4H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.29 (dd, <i>J</i> = 8.0, 4.8 Hz, 2H), 7.04 – 6.93 (m, 2H), 3.85 (s, 3H), 3.65 – 3.61 (m, 2H), 3.10 – 3.06 (m, 2H), 2.36 – 2.28 (s, 2H).
192C	J	568 (M+H)	164-167; 168-173	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 2H), 8.09 (s, 1H), 7.82 – 7.77 (m, 2H), 7.74 (d, <i>J</i> = 6.7 Hz, 2H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.13 (d, <i>J</i> = 8.3 Hz, 1H), 6.79 (dd, <i>J</i> = 11.9, 3.3 Hz, 2H), 3.81 (s, 3H), 3.74 – 3.66 (m, 1H), 3.57 – 3.48 (m, 1H), 3.12 – 3.04 (m, 2H), 2.36 – 2.30 (m, 2H), 2.25 (s, 3H).
193C	J	580 (M+H)	155-158	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 2H), 8.04 (s, 1H), 7.83 – 7.77 (m, 2H), 7.74 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.31 – 7.24 (m, 3H), 7.23 – 7.20 (m, 1H), 3.82 – 3.71 (m, 1H), 3.56 – 3.47 (m, 1H), 3.17 – 3.02 (m, 2H), 2.46 (t, <i>J</i> = 6.7 Hz, 2H), 2.39 – 2.27 (m, 2H), 1.99 (heptet, <i>J</i> = 6.8 Hz, 1H), 0.95 – 0.92 (m, 6H).
194C	J	600 (M+H)	102-108	(CDCl ₃) δ 8.56 (s, 1H), 8.17 (m, 3H), 7.80 (m, 4H), 7.52 – 7.47 (m, 2H), 7.47 – 7.31 (m, 9H), 3.42 – 3.05 (m, 2H), 2.86 (bs, 2H), 2.04 – 1.71 (m, 2H).
195C	J	538 (M+H)	159-162	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.3 Hz, 2H), 8.08 (s, 1H), 7.84 – 7.77 (m, 2H), 7.75 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 (d, <i>J</i> = 8.5 Hz, 2H), 7.31 – 7.19 (m, 4H), 3.81 – 3.47 (m, 2H), 3.20 – 3.00 (m, 2H), 2.35 (dt, <i>J</i> = 11.7, 5.8 Hz, 2H), 2.28 (s, 3H).
196C	J	572 (M+H)	140-143	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.1 Hz, 2H), 8.05 (s, 1H), 7.80 (d, <i>J</i> = 8.9 Hz, 2H), 7.75 (d, <i>J</i> = 8.2 Hz, 2H), 7.38 (d, <i>J</i> = 8.8 Hz, 2H), 7.33 (dd, <i>J</i> = 6.1, 3.4 Hz, 1H), 7.21 – 7.15 (m, 2H), 3.72 – 3.66 (m, 1H), 3.55 – 3.41 (m, 1H), 3.16 – 3.05 (m, 2H), 2.48 – 2.34 (m, 2H), 2.32 (s, 3H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
197C	J	578 (M+H)	151-155	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.2 Hz, 2H), 8.06 (s, 1H), 7.80 (d, <i>J</i> = 8.9 Hz, 2H), 7.75 (d, <i>J</i> = 8.2 Hz, 2H), 7.38 (d, <i>J</i> = 8.8 Hz, 2H), 7.29 (dd, <i>J</i> = 10.7, 4.6 Hz, 4H), 6.20 (s, 1H), 3.59 – 3.48 (m, 2H), 3.10 – 3.01 (m, 2H), 2.34 – 2.20 (m, 2H), 1.90 (s, 3H), 1.78 (s, 3H).
198C	J	539 (M+H)	186-189	(CDCl ₃) δ 8.56 (s, 1H), 8.36 (dd, <i>J</i> = 4.8, 1.3 Hz, 1H), 8.15 (d, <i>J</i> = 8.3 Hz, 2H), 8.09 (s, 1H), 7.78 (m, 4H), 7.54 (dd, <i>J</i> = 7.5, 0.9 Hz, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 2H), 7.13 (dd, <i>J</i> = 7.4, 4.8 Hz, 1H), 3.87 (t, <i>J</i> = 5.7 Hz, 2H), 3.12 – 3.03 (m, 2H), 2.40 – 2.32 (m, 2H), 2.24 (s, 3H).
199C	J	608 (M+H)	207-208	(CDCl ₃) δ 8.55 (s, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 2H), 8.05 (s, 1H), 7.83 – 7.78 (m, 2H), 7.76 (d, <i>J</i> = 8.4 Hz, 2H), 7.43 – 7.36 (m, 3H), 7.34 (t, <i>J</i> = 4.7 Hz, 3H), 3.71 – 3.64 (m, 2H), 3.12 – 3.06 (m, 2H), 2.39 – 2.30 (m, 2H).
200C	J	590 (M+H)	170-172	(CDCl ₃) δ 8.56 (s, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 2H), 8.03 (s, 1H), 7.83 – 7.77 (m, 2H), 7.76 (d, <i>J</i> = 8.3 Hz, 2H), 7.42 – 7.27 (m, 6H), 6.74 – 6.29 (m, 1H), 3.70 – 3.64 (m, 2H), 3.13 – 3.06 (m, 2H), 2.40 – 2.31 (m, 2H).
201C	J	626 (M+H)	190-193	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.3 Hz, 2H), 8.00 (s, 1H), 7.83 – 7.73 (m, 4H), 7.71 (d, <i>J</i> = 8.1 Hz, 1H), 7.67 (d, <i>J</i> = 7.7 Hz, 1H), 7.40 (dd, <i>J</i> = 15.8, 8.2 Hz, 3H), 3.79 – 3.69 (m, 1H), 3.55 – 3.49 (m, 1H), 3.16 – 3.04 (m, 2H), 2.47 – 2.31 (m, 2H).
202C	J	554 (M+H)	231-234	(CDCl ₃) δ 8.56 (s, 1H), 8.19 – 8.08 (m, 3H), 7.84 – 7.72 (m, 4H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.25 – 7.20 (m, 2H), 6.96 – 6.88 (m, 2H), 3.83 (s, 3H), 3.76 – 3.68 (m, 2H), 3.13 – 3.03 (m, 2H), 2.39 – 2.27 (m, 2H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
203C	J	631 (M+H)	200-201	(CDCl ₃) δ 8.56 (s, 1H), 8.15 (d, <i>J</i> = 8.2 Hz, 2H), 8.06 (s, 1H), 7.83 – 7.77 (m, 2H), 7.75 (d, <i>J</i> = 8.2 Hz, 2H), 7.39 (d, <i>J</i> = 8.5 Hz, 2H), 7.28 – 7.25 (m, 2H), 3.51 – 3.42 (m, 2H), 3.14 – 3.05 (m, 2H), 2.35 (s, 2H), 2.25 (s, 6H).
204C	J	568 (M+H)	193-196	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 2H), 8.09 (s, 1H), 7.84 – 7.77 (m, 2H), 7.75 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.08 (t, <i>J</i> = 4.0 Hz, 2H), 6.88 (d, <i>J</i> = 8.6 Hz, 1H), 3.82 (s, 3H), 3.66 – 3.58 (m, 2H), 3.11 – 3.03 (m, 2H), 2.36 – 2.27 (m, 5H).
205C	J	539 (M+H)	Oil	(CDCl ₃) δ 8.55 (s, 1H), 8.45 (dd, <i>J</i> = 4.8, 1.6 Hz, 1H), 8.18 – 8.12 (m, 2H), 8.06 (s, 1H), 7.82 – 7.72 (m, 4H), 7.53 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.40 – 7.33 (m, 2H), 7.24 – 7.18 (m, 1H), 3.63 (br s, 2H), 3.18 – 3.03 (m, 2H), 2.51 (s 3H), 2.35 (dt, <i>J</i> = 11.7, 5.7 Hz, 2H)
206C	J	554 (M+H)	177-178	(CDCl ₃) δ 8.56 (s, 1H), 8.16 (d, <i>J</i> = 8.9 Hz, 3H), 7.84 – 7.73 (m, 4H), 7.39 (d, <i>J</i> = 8.8 Hz, 2H), 7.30 (t, <i>J</i> = 8.1 Hz, 1H), 6.95 – 6.85 (m, 2H), 6.78 (dt, <i>J</i> = 11.1, 5.5 Hz, 1H), 3.81 (s, 3H), 3.79 – 3.73 (m, 2H), 3.12 – 3.04 (m, 2H), 2.38 – 2.28 (m, 2H).
207C	J	596 (M+H)	171-173	(CDCl ₃) δ 8.57 (s, 1H), 8.23 – 8.13 (m, 3H), 8.06 (d, <i>J</i> = 8.5 Hz, 2H), 7.80 (dd, <i>J</i> = 8.5, 4.5 Hz, 4H), 7.39 (d, <i>J</i> = 8.5 Hz, 4H), 4.38 (q, <i>J</i> = 7.2 Hz, 2H), 3.82 (t, <i>J</i> = 6.0 Hz, 2H), 3.14 – 3.03 (m, 2H), 2.37 (s, 2H), 1.40 (t, <i>J</i> = 7.1 Hz, 3H).
208C	J	568 (M+H)	171-173	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.3 Hz, 2H), 8.07 (s, 1H), 7.84 – 7.77 (m, 2H), 7.75 (d, <i>J</i> = 8.3 Hz, 2H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.32 – 7.23 (m, 2H), 6.99 (ddd, <i>J</i> = 8.3, 5.5, 1.4 Hz, 2H), 4.08 (q, <i>J</i> = 7.0 Hz, 2H), 3.69 – 3.57 (m, 2H), 3.16 – 3.02 (m, 2H), 2.32 (dt, <i>J</i> = 11.7, 5.9 Hz, 2H), 1.39 (t, <i>J</i> = 7.0 Hz, 3H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
209C	J	550 (M+H)	212-213	(CDCl ₃) δ 8.64 (s, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 2H), 8.06 (s, 1H), 7.91 (d, <i>J</i> = 8.5 Hz, 2H), 7.79 (d, <i>J</i> = 8.6 Hz, 2H), 7.75 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 7.33 (td, <i>J</i> = 7.5, 1.4 Hz, 1H), 7.29 – 7.23 (m, 1H), 7.18 (dd, <i>J</i> = 7.8, 1.4 Hz, 1H), 3.78 – 3.72 (m, 1H), 3.59 – 3.48 (m, 1H), 3.18 – 3.04 (m, 3H), 2.40 – 2.30 (m, 2H), 1.26 – 1.20 (m, 6H).
210C	J	580 (M+H)	136-139	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 2H), 8.07 (s, 1H), 7.83 – 7.77 (m, 2H), 7.75 (d, <i>J</i> = 8.4 Hz, 2H), 7.55 – 7.49 (m, 1H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.32 – 7.26 (m, 2H), 7.19 – 7.13 (m, 1H), 3.72 (ddd, <i>J</i> = 12.9, 9.3, 3.8 Hz, 1H), 3.60 – 3.51 (m, 1H), 3.15 (ddd, <i>J</i> = 13.3, 9.4, 4.0 Hz, 1H), 3.10 – 3.01 (m, 1H), 2.51 – 2.36 (m, 1H), 2.36 – 2.22 (m, 1H), 1.43 (s, 9H).
211C	J	566 (M+H)	100-106	(CDCl ₃) δ 8.55 (s, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 2H), 8.10 (s, 1H), 7.79 (dt, <i>J</i> = 10.4, 5.8 Hz, 4H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.11 (s, 3H), 3.85 – 3.78 (m, 2H), 3.20 – 3.12 (m, 2H), 2.30 (s, 6H), 2.13 – 2.07 (m, 2H), 1.87 – 1.82 (m, 2H).
212C	J	580 (M+H)	186-188	(CDCl ₃) δ 8.55 (s, 1H), 8.19 – 8.10 (m, 3H), 7.79 (dt, <i>J</i> = 10.7, 5.9 Hz, 4H), 7.38 (dd, <i>J</i> = 8.5, 2.6 Hz, 3H), 7.30 (td, <i>J</i> = 7.5, 1.4 Hz, 1H), 7.23 (td, <i>J</i> = 7.5, 1.7 Hz, 1H), 7.13 (dd, <i>J</i> = 7.8, 1.4 Hz, 1H), 3.94 (bs, 2H), 3.24 – 3.02 (m, 3H), 2.13 – 2.05 (m, 2H), 1.84 – 1.73 (m, 2H), 1.24 (t, <i>J</i> = 10.5 Hz, 6H).
213C	J	580 (M+H)	123-127	(CDCl ₃) δ 8.55 (s, 1H), 8.13 (d, <i>J</i> = 8.4 Hz, 2H), 8.03 (d, <i>J</i> = 4.4 Hz, 1H), 7.83 – 7.76 (m, 2H), 7.74 (d, <i>J</i> = 8.0 Hz, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 7.24 – 7.15 (m, 2H), 7.12 (dd, <i>J</i> = 11.9, 4.6 Hz, 1H), 3.82 – 3.71 (m, 1H), 3.30 – 3.18 (m, 1H), 3.07 – 2.94 (m, 1H), 2.72 – 2.40 (m, 3H), 2.30 – 2.16 (m, 4H), 1.30 – 1.12 (m, 6H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
214C	J	622 (M+H)	160-162	(CDCl ₃) δ 8.55 (s, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 2H), 8.06 (s, 1H), 7.83 – 7.72 (m, 4H), 7.38 (m, 3H), 7.34 (dd, <i>J</i> = 2.9, 1.5 Hz, 3H), 3.58 (ddd, <i>J</i> = 12.3, 3.9, 1.4 Hz, 1H), 3.39 (dd, <i>J</i> = 12.2, 9.2 Hz, 1H), 3.04 (ddd, <i>J</i> = 12.2, 3.9, 1.4 Hz, 1H), 2.84 (dd, <i>J</i> = 12.2, 9.5 Hz, 1H), 2.61 – 2.42 (m, 1H), 1.18 (d, <i>J</i> = 6.7 Hz, 3H)
215C	J	640 (M+H)	116 (dec)	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (dd, <i>J</i> = 8.3, 1.5 Hz, 2H), 8.00 (d, <i>J</i> = 4.0 Hz, 1H), 7.84 – 7.72 (m, 4H), 7.72 – 7.63 (m, 2H), 7.45 – 7.32 (m, 3H), 3.60 – 3.44 (m, 1H), 3.37 – 3.27 (m, 1H), 3.03 – 2.92 (m, 1H), 2.92 – 2.82 (m, 1H), 2.69 – 2.54 (m, 1H), 1.19 – 1.12 (m, 3H)
216C	J	622 (M+H)	132-135	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 2H), 8.02 (s, 1H), 7.82 – 7.71 (m, 4H), 7.44 – 7.30 (m, 6H), 3.87 (d, <i>J</i> = 6.3 Hz, 1H), 3.23 (td, <i>J</i> = 11.9, 3.8 Hz, 1H), 3.07 – 2.94 (m, 1H), 2.54 – 2.43 (m, 1H), 2.19 (ddd, <i>J</i> = 13.9, 9.0, 5.0 Hz, 1H), 1.31 (d, <i>J</i> = 6.6 Hz, 3H)
217C	J	640 (M+H)	93 (dec)	Two isomers (CDCl ₃) δ 8.55 (s, 2H), 8.14 (dd, <i>J</i> = 8.4, 2.7 Hz, 4H), 7.98 (d, <i>J</i> = 4.2 Hz, 2H), 7.83 – 7.72 (m, 8H), 7.67 (dt, <i>J</i> = 12.9, 7.4 Hz, 4H), 7.40 (dd, <i>J</i> = 15.3, 8.1 Hz, 6H), 4.17 (s, 1H), 3.96 (td, <i>J</i> = 6.6, 3.1 Hz, 1H), 3.24 – 3.12 (m, 2H), 3.12 – 3.01 (m, 2H), 2.41 (dddd, <i>J</i> = 10.8, 10.0, 8.9, 4.2 Hz, 2H), 2.30 – 2.15 (m, 2H), 1.24 (d, <i>J</i> = 6.7 Hz, 3H), 1.04 (d, <i>J</i> = 6.7 Hz, 3H)
218C	J	580 (M+H)	95 (dec)	(CDCl ₃) δ 8.55 (s, 1H), 8.18 – 8.10 (m, 2H), 8.05 (s, 1H), 7.83 – 7.76 (m, 2H), 7.73 (d, <i>J</i> = 8.4 Hz, 2H), 7.41 – 7.37 (m, 2H), 6.93 (d, <i>J</i> = 9.4 Hz, 2H), 3.76 (dd, <i>J</i> = 10.8, 4.6 Hz, 1H), 3.29 – 3.16 (m, 1H), 2.99 (ddd, <i>J</i> = 12.2, 5.9, 3.9 Hz, 1H), 2.54 – 2.37 (m, 1H), 2.31 (s, 3H), 2.22 (d, <i>J</i> = 6.4 Hz, 7H), 1.19 (d, <i>J</i> = 6.7 Hz, 3H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
219C	J	592 (M+H)	100 (dec)	(CDCl ₃) δ 8.55 (s, 1H), 8.14 – 8.06 (m, 3H), 7.91 – 7.65 (m, 4H), 7.44 – 7.37 (m, 2H), 7.16 – 7.09 (m, 1H), 6.93 – 6.77 (m, 2H), 4.06 – 3.64 (m, 4H), 3.31 – 3.16 (m, 1H), 3.02 – 2.92 (m, 1H), 2.51 – 2.40 (m, 1H), 2.25 – 2.17 (m, 4H), 1.41 – 1.14 (m, 3H)
220C	J	593 (M+H)	95 (dec)	Two isomers: (CDCl ₃) δ 8.55 (s, 1H), 8.16 – 8.09 (m, 2H), 8.01 (m, 1H), 7.86 – 7.76 (m, 2H), 7.76 – 7.70 (m, 2H), 7.64 – 7.28 (m, 4H), 7.24 – 7.14 (m, 2H), 4.08 – 3.65 (m, 1H), 3.37 – 3.15 (m, 1H), 3.09 – 2.92 (m, 1H), 2.80 (td, <i>J</i> = 14.2, 6.8 Hz, 1H), 2.45 m, 1H), 2.35 – 2.09 (m, 1H), 1.76 – 1.58 (m, 1H), 1.48 – 1.35 (m, 2H), 1.27 – 1.19 (m, 2H), 1.19 – 1.13 (m, 2H), 1.06 – 0.92 (m, 1H), 0.92 – 0.72 (m, 3H)
221C	J	603 (M+H)	113 (dec)	(400 MHz, CDCl ₃) δ 8.56 (s, 1H), 8.20 – 8.10 (m, 2H), 8.00 (s, 1H), 7.83 – 7.77 (m, 2H), 7.75 (d, <i>J</i> = 8.4 Hz, 2H), 7.42 – 7.28 (m, 6H), 6.72 – 6.25 (m, 1H), 3.90 (d, <i>J</i> = 6.4 Hz, 1H), 3.24 (td, <i>J</i> = 12.0, 3.6 Hz, 1H), 3.05 – 2.93 (m, 1H), 2.49 (tt, <i>J</i> = 11.7, 4.0 Hz, 1H), 2.21 (td, <i>J</i> = 8.7, 4.4 Hz, 1H), 1.29 (d, <i>J</i> = 6.6 Hz, 3H)
222C	J	594 (M+H)	124 (dec)	(CDCl ₃) δ 8.55 (s, 1H), 8.14 (dd, <i>J</i> = 8.4, 2.1 Hz, 2H), 8.05 (d, <i>J</i> = 2.8 Hz, 1H), 7.87 – 7.72 (m, 4H), 7.61 – 7.49 (m, 1H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.33 – 7.21 (m, 2H), 7.15 – 7.05 (m, 1H), 3.79 – 3.68 (m, 1H), 3.51 – 3.29 (m, 1H), 3.12 – 2.93 (m, 1H), 2.66 – 2.52 (m, 1H), 2.18 – 2.12 (m, 1H), 1.43 (m, 12H)
223C	L	566 (M+H)	75-87	(CDCl ₃) δ 8.58 (s, 1H), 8.21 (d, <i>J</i> = 8.4 Hz, 2H), 8.16 (s, 1H), 7.85 – 7.77 (m, 4H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.23 (dd, <i>J</i> = 8.4, 6.6 Hz, 1H), 7.15 (d, <i>J</i> = 7.5 Hz, 2H), 3.24 – 3.14 (m, 4H), 2.18 (s, 6H).

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
224C	L	580 (M+H)	118 (dec)	(CDCl ₃) δ 8.57 (s, 1H), 8.21 (d, <i>J</i> = 8.4 Hz, 2H), 8.16 (s, 1H), 7.85 – 7.75 (m, 4H), 7.46 – 7.36 (m, 4H), 7.33 – 7.26 (m, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 1H), 3.26 – 3.14 (m, 4H), 2.81 (sept, <i>J</i> = 6.9 Hz, 1H), 1.21 (t, <i>J</i> = 7.2 Hz, 6H).
225C	L	580 (M+H)	111 (dec)	(CDCl ₃) δ 8.57 (s, 1H), 8.21 (d, <i>J</i> = 8.4 Hz, 2H), 8.15 (s, 1H), 7.86 – 7.76 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.29 (t, <i>J</i> = 7.6 Hz, 1H), 7.21 – 7.15 (m, 2H), 3.27 – 3.10 (m, 4H), 2.50 (q, <i>J</i> = 7.5 Hz, 2H), 2.18 (s, 3H), 1.20 (t, <i>J</i> = 7.6 Hz, 3H).
226C	L	573 (M+H)	196-200	(CDCl ₃) δ 8.57 (s, 1H), 8.24 – 8.16 (m, 3H), 7.85 – 7.76 (m, 4H), 7.43 – 7.34 (m, 3H), 7.03 (dd, <i>J</i> = 8.5, 7.4 Hz, 2H), 3.21 (s, 4H)
227C	L	586 (M+H)	Oil	(CDCl ₃) δ 8.57 (s, 1H), 8.21 (d, <i>J</i> = 8.3 Hz, 2H), 8.15 (s, 1H), 7.81 (t, <i>J</i> = 9.1 Hz, 4H), 7.43 – 7.31 (m, 3H), 7.28 – 7.21 (m, 2H), 3.36 – 3.07 (m, 4H), 2.24 (s, 3H); ¹⁹ F NMR (376 MHz, CDCl ₃) δ -58.02
228C	L	640 (M+H)	99 (dec)	(CDCl ₃) δ 8.57 (s, 1H), 8.21 (d, <i>J</i> = 8.3 Hz, 2H), 8.11 (s, 1H), 7.81 (dd, <i>J</i> = 11.5, 4.7 Hz, 4H), 7.72 (dd, <i>J</i> = 17.3, 8.0 Hz, 2H), 7.51 (dd, <i>J</i> = 10.0, 5.4 Hz, 1H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 3.36 – 3.03 (m, 4H)
229C	L	622 (M+H)	95 (dec)	(CDCl ₃) δ 8.57 (s, 1H), 8.21 (d, <i>J</i> = 8.4 Hz, 2H), 8.13 (s, 1H), 7.80 (dt, <i>J</i> = 5.5, 4.9 Hz, 4H), 7.44 – 7.34 (m, 6H), 3.29 – 3.10 (m, 4H)
230C	L	594 (M+H)	94 (dec)	(CDCl ₃) δ 8.57 (s, 1H), 8.21 (d, <i>J</i> = 8.3 Hz, 2H), 8.14 (d, <i>J</i> = 15.4 Hz, 1H), 7.83 – 7.76 (m, 4H), 7.43 – 7.37 (m, 4H), 7.32 – 7.26 (m, 1H), 7.16 – 7.09 (m, 1H), 3.24 – 3.12 (m, 4H), 2.61 – 2.44 (m, 1H), 1.75 – 1.50 (m, 2H), 1.17 (dd, <i>J</i> = 6.9, 3.3 Hz, 3H), 0.87 – 0.73 (m, 3H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
231C	L	582 (M+H)	105 (dec)	(CDCl ₃) δ 8.58 (s, 1H), 8.22 (s, 1H), 8.19 (d, <i>J</i> = 5.0 Hz, 2H), 7.81 (dd, <i>J</i> = 8.7, 5.5 Hz, 4H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.05 (d, <i>J</i> = 8.3 Hz, 1H), 6.90 – 6.76 (m, 2H), 3.83 (s, 3H), 3.22 – 3.11 (m, 4H), 2.16 (s, 3H)
232C	L	593 (M+H)	120 (dec)	(CDCl ₃) δ 8.57 (s, 1H), 8.21 (d, <i>J</i> = 8.4 Hz, 2H), 8.16 (s, 1H), 7.81 (dd, <i>J</i> = 8.7, 5.3 Hz, 4H), 7.58 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.38 (dd, <i>J</i> = 13.2, 5.1 Hz, 3H), 7.33 – 7.27 (m, 1H), 7.02 – 6.96 (m, 1H), 3.37 – 3.01 (m, 4H), 1.36 (s, 9H)
233C	L	604 (M+H)	92 (dec)	(CDCl ₃) δ 8.58 (s, 1H), 8.21 (d, <i>J</i> = 8.4 Hz, 2H), 8.14 (s, 1H), 7.86 – 7.72 (m, 4H), 7.48 – 7.28 (m, 6H), 6.40 (t, <i>J</i> _{HF} = 74.3 Hz, 1H), 3.25 – 3.11 (m, 4H)
240C	J	538 (M+H)	113-116	(300 MHz, CDCl ₃) δ 8.57 (s, 1H), 8.31 (s, 1H), 8.21 (s, 1H), 8.18 (s, 1H), 7.86 – 7.76 (m, 4H), 7.48 – 7.31 (m, 4H), 7.31 – 7.20 (m, 2H), 4.92 (s, 2H), 3.42 – 3.27 (m, 1H), 1.31 (s, 3H), 1.28 (s, 3H)
241C	J	524 (M+H)	Oil	(CDCl ₃) δ 8.56 (s, 1H), 8.29 (s, 1H), 8.19 (d, <i>J</i> = 8.4 Hz, 2H), 7.83 – 7.76 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.18 (dd, <i>J</i> = 8.4, 6.6 Hz, 1H), 7.09 (d, <i>J</i> = 7.7 Hz, 2H), 4.87 (s, 2H), 2.40 (s, 6H); ¹⁹ F NMR (376 MHz, CDCl ₃) δ -58.04
242C	J	554 (M+H)	147-159	(CDCl ₃) δ 8.57 (s, 1H), 8.30 (s, 1H), 8.19 (d, <i>J</i> = 8.3 Hz, 2H), 7.84 – 7.76 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 6.62 (s, 2H), 4.84 (s, 2H), 3.78 (s, 3H), 2.37 (s, 6H)
243C	J	538 (M+H)	131-135	(CDCl ₃) δ 8.57 (s, 1H), 8.29 (s, 1H), 8.19 (d, <i>J</i> = 8.4 Hz, 2H), 7.85 – 7.76 (m, 4H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.23 (d, <i>J</i> = 7.6 Hz, 1H), 7.17 – 7.08 (m, 2H), 4.88 (q, <i>J</i> = 4.1 Hz, 2H), 2.87 – 2.65 (m, 2H), 2.40 (s, 3H), 1.28 (t, <i>J</i> = 7.5 Hz, 3H)
244C	J	564 (M+H)	145-146	(CDCl ₃) δ 8.57 (s, 1H), 8.31 (s, 1H), 8.19 (d, <i>J</i> = 8.3 Hz, 2H), 7.83 – 7.79 (m, 4H), 7.42 – 7.38 (m, 4H), 7.31 – 7.27 (m, 1H), 5.02 (s, 2H)

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
245C	J	532 (M+H)	144-146	(CDCl ₃) δ 8.58 (s, 1H), 8.34 (s, 1H), 8.20 (d, <i>J</i> = 8.3 Hz, 2H), 7.81 (d, <i>J</i> = 8.8 Hz, 4H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.31 – 7.23 (m, 1H), 7.03 – 6.97 (m, 2H), 5.05 (s, 2H)
246C	J	544 (M+H)	157-160	(CDCl ₃) δ 8.57 (s, 1H), 8.30 (s, 1H), 8.19 (d, <i>J</i> = 8.3 Hz, 2H), 7.84 – 7.77 (m, 4H), 7.39 (d, <i>J</i> = 8.2 Hz, 2H), 7.34 – 7.28 (m, 1H), 7.25 – 7.15 (m, 2H), 5.19 (s, 1H), 4.81 (s, 1H), 2.46 (s, 3H)
247C	J	587 ([M+H] ⁺)	79-85	(CDCl ₃) δ 8.58 (s, 1H), 8.31 (s, 1H), 8.20 (d, <i>J</i> = 8.4 Hz, 2H), 7.86 – 7.78 (m, 4H), 7.49 – 7.28 (m, 5H), 7.26 – 7.21 (m, 1H), 4.93 (s, 2H), 3.35 (dt, <i>J</i> = 13.7, 6.9 Hz, 1H), 1.30 (d, <i>J</i> = 6.9 Hz, 6H); ¹⁹ F NMR (376 MHz, CDCl ₃) δ -85.90, -87.84
248C	J	551 ([M+H] ⁺)	--	(CDCl ₃) δ 8.60 – 8.58 (m, 1H), 8.28 – 8.14 (m, 2H), 8.00 – 7.91 (m, 2H), 7.82 (tdd, <i>J</i> = 5.5, 3.5, 1.7 Hz, 2H), 7.53 – 7.25 (m, 4H), 7.11 – 6.91 (m, 2H), 4.94 (s, 2H), 3.26 (dt, <i>J</i> = 13.8, 6.9 Hz, 1H), 2.60 – 2.37 (m, 3H), 1.31 – 1.17 (m, 6H); ¹⁹ F NMR (376 MHz, CDCl ₃) δ -58.02
249C	J	533 ([M+H] ⁺)	73-90	(CDCl ₃) δ 8.53 (s, 1H), 8.31 (s, 1H), 8.18 (d, <i>J</i> = 8.3 Hz, 2H), 7.80 (d, <i>J</i> = 8.3 Hz, 2H), 7.57 (d, <i>J</i> = 2.1 Hz, 1H), 7.50 – 7.43 (m, 3H), 7.33 (dtd, <i>J</i> = 9.1, 7.8, 1.5 Hz, 2H), 7.21 (ddd, <i>J</i> = 13.8, 7.9, 3.5 Hz, 2H), 4.93 (s, 2H), 3.41 – 3.27 (m, 1H), 1.30 (d, <i>J</i> = 6.9 Hz, 6H); ¹⁹ F NMR (376 MHz, CDCl ₃) δ -49.65
250C	J	555 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 9.44 (s, 1H), 8.27 (s, 1H), 8.21 – 8.12 (m, 2H), 8.13 – 8.06 (m, 2H), 7.85 – 7.75 (m, 2H), 7.67 – 7.60 (m, 2H), 7.46 (td, <i>J</i> = 8.1, 5.8 Hz, 1H), 7.18 – 7.31 (m, 2H), 5.05 (s, 2H), 3.22 – 3.32 (m, 1H), 1.25 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -56.95, -120.51

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
251C	J	555 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 9.44 (s, 1H), 8.32 (s, 1H), 8.21 – 8.13 (m, 2H), 8.13 – 8.05 (m, 2H), 7.89 – 7.79 (m, 2H), 7.70 – 7.59 (m, 2H), 7.54 – 7.40 (m, 2H), 7.19 (td, <i>J</i> = 8.5, 2.8 Hz, 1H), 5.16 (s, 2H), 3.29 (hept, <i>J</i> = 6.9 Hz, 1H), 1.23 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -56.97, -115.87
252C	J	555 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 9.44 (s, 1H), 8.28 (s, 1H), 8.21 – 8.13 (m, 2H), 8.13 – 8.05 (m, 2H), 7.85 – 7.78 (m, 2H), 7.67 – 7.61 (m, 2H), 7.58 (dd, <i>J</i> = 8.8, 5.6 Hz, 1H), 7.26 (dd, <i>J</i> = 10.4, 3.0 Hz, 1H), 7.12 (ddd, <i>J</i> = 8.8, 8.0, 3.0 Hz, 1H), 5.10 (s, 2H), 3.32 – 3.21 (m, 1H), 1.24 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -56.96, -112.55
253C	J	555 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 9.43 (s, 1H), 8.30 (s, 1H), 8.18 – 8.12 (m, 2H), 8.12 – 8.05 (m, 2H), 7.85 – 7.77 (m, 2H), 7.68 – 7.58 (m, 2H), 7.40 (dd, <i>J</i> = 8.0, 1.3 Hz, 1H), 7.32 (td, <i>J</i> = 8.1, 5.9 Hz, 1H), 7.17 (ddd, <i>J</i> = 11.7, 8.2, 1.3 Hz, 1H), 5.13 (s, 2H), 3.32 – 3.23 (m, 1H), 1.35 (dd, <i>J</i> = 7.0, 1.3 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -56.96, -112.92
254C	J	523 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 9.46 (s, 1H), 8.34 (s, 1H), 8.22 – 8.15 (m, 2H), 8.15 – 8.06 (m, 2H), 7.90 – 7.80 (m, 2H), 7.70 – 7.62 (m, 2H), 7.63 – 7.55 (m, 1H), 7.42 – 7.24 (m, 3H), 5.16 (s, 2H), 2.79 (q, <i>J</i> = 7.5 Hz, 2H), 1.24 (t, <i>J</i> = 7.5 Hz, 3H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -56.95
255C	J	539 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 9.57 (s, 1H), 8.33 (s, 1H), 8.26 – 8.12 (m, 4H), 8.05 – 7.95 (m, 2H), 7.89 – 7.79 (m, 2H), 7.55 – 7.39 (m, 2H), 7.19 (td, <i>J</i> = 8.5, 2.8 Hz, 1H), 5.16 (s, 2H), 3.23 – 3.32 (m, 1H), 1.23 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -60.81, -115.86

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
256C	J	605 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 9.45 (s, 1H), 8.32 (s, 1H), 8.20 – 8.14 (m, 2H), 8.14 – 8.07 (m, 2H), 7.91 – 7.78 (m, 2H), 7.68 – 7.59 (m, 2H), 7.47 (ddd, <i>J</i> = 15.2, 9.4, 4.6 Hz, 2H), 7.19 (td, <i>J</i> = 8.5, 2.8 Hz, 1H), 5.16 (s, 2H), 3.32 – 3.24 (m, 1H), 1.23 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -85.18, -86.91, -115.87
257C	J	639 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 9.54 (s, 1H), 8.33 (s, 1H), 8.29 – 8.21 (m, 2H), 8.21 – 8.15 (m, 2H), 7.93 (d, <i>J</i> = 8.5 Hz, 2H), 7.89 – 7.79 (m, 2H), 7.47 (ddd, <i>J</i> = 15.1, 9.4, 4.6 Hz, 2H), 7.19 (td, <i>J</i> = 8.5, 2.8 Hz, 1H), 5.16 (s, 2H), 3.32 – 3.23 (m, 1H), 1.23 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -75.06 (d, <i>J</i> = 7.5 Hz), -115.87, -181.30 (p, <i>J</i> = 7.8 Hz)
258C	J	689 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 9.55 (s, 1H), 8.33 (s, 1H), 8.28 – 8.20 (m, 2H), 8.21 – 8.15 (m, 2H), 7.98 – 7.89 (m, 2H), 7.88 – 7.80 (m, 2H), 7.47 (ddd, <i>J</i> = 15.2, 9.4, 4.6 Hz, 2H), 7.19 (td, <i>J</i> = 8.5, 2.8 Hz, 1H), 5.16 (s, 2H), 3.31 – 3.25 (m, 1H), 1.23 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -72.98 – -73.71 (m), -78.73 (d, <i>J</i> = 12.8 Hz), -115.87, -120.53 – -121.42 (m), -182.23 (dt, <i>J</i> = 25.7, 15.5 Hz)
259C	J	535 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 9.49 (s, 1H), 8.32 (s, 1H), 8.24 – 8.13 (m, 2H), 8.12 – 8.03 (m, 2H), 7.91–7.75 (m, 4H), 7.47 (ddd, <i>J</i> = 15.2, 9.4, 4.6 Hz, 2H), 7.19 (td, <i>J</i> = 8.5, 2.8 Hz, 1H), 5.16 (s, 2H), 3.31 – 3.23 (m, 1H), 2.04 (t, <i>J</i> = 18.9 Hz, 3H), 1.23 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -84.17, -115.86

ID	Synthesis Method	MS	mp (°C)	¹ H NMR (δ) ¹
260C	J	589 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 9.57 (s, 1H), 8.33 (s, 1H), 8.24 (d, <i>J</i> = 8.5 Hz, 2H), 8.20 – 8.15 (m, 2H), 7.96 (d, <i>J</i> = 8.6 Hz, 2H), 7.90 – 7.78 (m, 2H), 7.54 – 7.39 (m, 2H), 7.19 (td, <i>J</i> = 8.5, 2.8 Hz, 1H), 5.16 (s, 2H), 3.32 – 3.23 (m, 1H), 1.24 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -84.02 (t, <i>J</i> = 2.3 Hz), -113.41, -115.87
261C	J	539 ([M+H] ⁺)	--	(DMSO- <i>d</i> ₆) δ 9.57 (s, 1H), 8.28 (s, 1H), 8.23 – 8.15 (m, 4H), 8.01 – 7.98 (m, 2H), 7.86 – 7.78 (m, 2H), 7.58 (dd, <i>J</i> = 8.8, 5.6 Hz, 1H), 7.26 (dd, <i>J</i> = 10.4, 3.0 Hz, 1H), 7.13 (ddd, <i>J</i> = 8.7, 8.0, 3.0 Hz, 1H), 5.10 (s, 2H), 3.28 (td, <i>J</i> = 6.8, 1.8 Hz, 1H), 1.24 (d, <i>J</i> = 6.8 Hz, 6H); ¹⁹ F NMR (376 MHz, DMSO- <i>d</i> ₆) δ -60.81, -112.54

NMR spectral data were acquired using a 400 MHz instrument unless otherwise noted.

Table 4A: Analytical Data for Optically Active Compounds in Table 3

ID	Separation Method	MS	Chiral Purity (%)	¹ H NMR (δ) ¹
234C	A	571 (M+H)	98.73	(CDCl ₃) δ 8.58 (s, 1H), 8.31 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.87 – 7.78 (m, 4H), 7.41 (t, <i>J</i> = 6.3 Hz, 3H), 7.37 – 7.31 (m, 1H), 7.28 (d, <i>J</i> = 7.0 Hz, 1H), 4.09 – 3.98 (m, 2H), 2.29 (s, 3H)
235C	A	571 (M+H)	95.75	(CDCl ₃) δ 8.58 (s, 1H), 8.31 (s, 1H), 8.23 (d, <i>J</i> = 8.3 Hz, 2H), 7.87 – 7.78 (m, 4H), 7.41 (dd, <i>J</i> = 7.0, 5.6 Hz, 3H), 7.34 (t, <i>J</i> = 7.8 Hz, 1H), 7.28 (d, <i>J</i> = 6.0 Hz, 1H), 4.09 – 3.98 (m, 2H), 2.29 (s, 3H)

ID	Separation Method	MS	Chiral Purity (%)	¹ H NMR (δ) ¹
236C	A	565 (M+H)	96.32	(CDCl ₃) δ 8.58 (s, 1H), 8.31 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.81 (dd, <i>J</i> = 11.7, 5.1 Hz, 4H), 7.40 (d, <i>J</i> = 8.4 Hz, 2H), 7.35 (t, <i>J</i> = 7.7 Hz, 1H), 7.24 – 7.18 (m, 2H), 4.02 (s, 2H), 2.53 (q, <i>J</i> = 7.5 Hz, 2H), 2.21 (s, 3H), 1.21 (t, <i>J</i> = 7.6 Hz, 3H)
237C	A	565 (M+H)	92.33	(CDCl ₃) δ 8.58 (s, 1H), 8.31 (s, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.81 (dd, <i>J</i> = 11.7, 5.1 Hz, 4H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.35 (dd, <i>J</i> = 10.4, 4.9 Hz, 1H), 7.24 – 7.20 (m, 2H), 4.02 (s, 2H), 2.59 – 2.45 (m, 2H), 2.21 (s, 3H), 1.21 (t, <i>J</i> = 7.6 Hz, 3H)
238C	B	579 (M+H)	95.41	(CDCl ₃) δ 8.58 (s, 1H), 8.29 (d, <i>J</i> = 3.9 Hz, 1H), 8.23 (d, <i>J</i> = 8.4 Hz, 2H), 7.82 (t, <i>J</i> = 8.8 Hz, 4H), 7.40 (d, <i>J</i> = 8.3 Hz, 3H), 7.31 (d, <i>J</i> = 6.9 Hz, 1H), 7.19 (dd, <i>J</i> = 7.6, 5.2 Hz, 1H), 4.03 (s, 2H), 2.83 – 2.73 (m, 1H), 2.21 (s, 3H), 1.25 – 1.18 (m, 6H)
239C	B	579 (M+H)	92.68	(CDCl ₃) δ 8.58 (s, 1H), 8.30 (s, 1H), 8.22 (t, <i>J</i> = 8.7 Hz, 2H), 7.82 (t, <i>J</i> = 8.7 Hz, 4H), 7.40 (d, <i>J</i> = 8.2 Hz, 3H), 7.31 (d, <i>J</i> = 8.0 Hz, 1H), 7.20 (d, <i>J</i> = 7.3 Hz, 1H), 4.03 (s, 2H), 2.83 – 2.73 (m, 1H), 2.21 (s, 3H), 1.25 – 1.18 (m, 6H)

NMR spectral data were acquired using a 400 MHz instrument unless otherwise noted.

Table 5: Biological Results

Compound Number	% Mortality CEW 50 µg/cm ²	% Mortality BAW 50 µg/cm ²	% Mortality GPA 200 ppm
1C	A	A	D
2C	A	A	D
3C	A	A	D
4C	A	A	B

Compound Number	% Mortality CEW 50 $\mu\text{g}/\text{cm}^2$	% Mortality BAW 50 $\mu\text{g}/\text{cm}^2$	% Mortality GPA 200 ppm
5C	A	A	B
6C	A	A	D
7C	A	D	D
8C	A	A	B
9C	A	A	D
10C	A	A	D
11C	A	A	D
12C	A	A	B
13C	A	A	B
14C	A	A	B
15C	A	A	A
16C	A	A	D
17C	A	A	B
18C	A	A	B
19C	A	A	B
20C	A	A	D
21C	C	C	D
22C	A	A	B
23C	A	A	D
24C	A	A	B
25C	A	A	D
26C	C	C	D
27C	A	A	B

Compound Number	% Mortality CEW 50 $\mu\text{g}/\text{cm}^2$	% Mortality BAW 50 $\mu\text{g}/\text{cm}^2$	% Mortality GPA 200 ppm
28C	A	A	B
29C	A	A	B
30C	A	A	B
31C	A	A	B
32C	C	C	B
33C	A	A	B
34C	C	C	B
35C	A	A	B
36C	A	A	D
37C	A	A	D
38C	A	A	D
39C	C	C	D
40C	A	A	B
41C	A	A	D
42C	A	A	D
43C	A	A	B
44C	A	A	D
45C	A	A	C
46C	A	A	D
47C	A	A	B
48C	A	A	C
49C	A	A	B
50C	A	A	C

Compound Number	% Mortality CEW 50 $\mu\text{g}/\text{cm}^2$	% Mortality BAW 50 $\mu\text{g}/\text{cm}^2$	% Mortality GPA 200 ppm
51C	A	A	D
52C	D	B	B
53C	D	B	B
54C	A	A	D
55C	A	A	D
56C	A	A	C
57C	A	A	B
58C	A	A	B
59C	A	A	B
60C	A	A	D
61C	A	A	C
62C	A	A	B
63C	A	A	D
64C	A	A	D
65C	A	A	B
66C	A	A	B
67C	A	A	D
68C	A	A	B
69C	A	A	C
70C	A	A	D
71C	A	A	D
72C	A	A	B
73C	A	A	B

Compound Number	% Mortality CEW 50 $\mu\text{g}/\text{cm}^2$	% Mortality BAW 50 $\mu\text{g}/\text{cm}^2$	% Mortality GPA 200 ppm
74C	A	A	D
75C	A	A	B
76C	A	A	B
77C	A	A	B
78C	A	A	B
79C	A	A	B
80C	A	A	D
81C	A	A	D
82C	A	A	C
83C	A	A	C
84C	A	A	D
85C	A	A	B
86C	A	A	D
87C	C	C	B
88C	A	A	B
89C	A	A	D
90C	A	A	B
91C	D	D	C
92C	A	A	B
93C	A	A	D
94C	A	A	D
95C	A	A	B
96C	A	A	B

Compound Number	% Mortality CEW 50 $\mu\text{g}/\text{cm}^2$	% Mortality BAW 50 $\mu\text{g}/\text{cm}^2$	% Mortality GPA 200 ppm
97C	A	A	C
98C	C	A	C
99C	A	A	C
100C	A	A	C
101C	A	A	C
102C	A	A	C
103C	A	A	C
104C	A	A	C
105C	A	A	C
106C	A	A	C
107C	D	D	C
108C	A	A	D
109C	A	A	C
110C	A	A	C
111C	A	A	B
112C	A	A	B
113C	A	A	C
114C	A	A	C
115C	D	B	C
116C	A	A	C
117C	A	A	D
118C	A	A	D
119C	A	A	D

Compound Number	% Mortality CEW 50 µg/cm²	% Mortality BAW 50 µg/cm²	% Mortality GPA 200 ppm
120C	A	A	C
121C	A	A	B
122C	A	A	C
123C	A	A	C
124C	A	A	C
125C	A	A	C
126C	A	A	C
127C	A	A	C
128C	A	A	C
129C	A	A	C
130C	A	A	C
131C	A	A	D
132C	A	A	B
133C	A	A	B
134C	A	A	C
135C	A	A	D
136C	A	A	D
137C	A	A	D
138C	A	A	B
139C	A	A	B
140C	A	A	B
141C	A	A	D
142C	A	A	D

Compound Number	% Mortality CEW 50 µg/cm²	% Mortality BAW 50 µg/cm²	% Mortality GPA 200 ppm
143C	A	A	C
144C	A	A	C
145C	A	A	B
146C	A	A	B
147C	A	A	B
148C	A	A	C
149C	A	A	D
150C	A	A	D
151C	A	A	B
152C	A	A	C
153C	A	D	C
154C	A	A	B
155C	A	A	D
156C	A	A	B
157C	A	A	B
158C	A	A	B
159C	A	A	C
160C	A	A	C
161C	A	A	C
162C	A	A	C
163C	A	A	C
164C	A	A	C
165C	A	A	C

Compound Number	% Mortality CEW 50 $\mu\text{g}/\text{cm}^2$	% Mortality BAW 50 $\mu\text{g}/\text{cm}^2$	% Mortality GPA 200 ppm
166C	A	A	C
167C	A	A	C
168C	A	A	D
169C	A	A	C
170C	A	A	C
171C	A	A	C
172C	A	A	D
173C	A	A	D
174C	A	A	B
175C	A	A	D
176C	A	A	C
177C	A	A	D
178C	A	A	D
179C	A	A	D
180C	A	A	B
181C	A	A	B
182C	A	A	B
183C	A	A	D
184C	A	A	D
185C	A	A	D
186C	A	A	B
187C	A	A	D
188C	A	A	B

Compound Number	% Mortality CEW 50 $\mu\text{g}/\text{cm}^2$	% Mortality BAW 50 $\mu\text{g}/\text{cm}^2$	% Mortality GPA 200 ppm
189C	A	A	B
190C	A	A	B
191C	A	A	D
192C	A	A	B
193C	A	A	B
194C	A	A	B
195C	A	A	B
196C	A	A	D
197C	A	A	D
198C	A	A	D
199C	A	A	C
200C	A	A	C
201C	A	A	B
202C	A	A	B
203C	A	A	B
204C	A	A	B
205C	A	A	B
206C	A	A	D
207C	d	D	C
208C	A	A	D
209C	A	A	D
210C	A	A	C
211C	A	A	D


Compound Number	% Mortality CEW 50 $\mu\text{g}/\text{cm}^2$	% Mortality BAW 50 $\mu\text{g}/\text{cm}^2$	% Mortality GPA 200 ppm
212C	A	A	D
213C	A	A	B
214C	A	A	C
215C	A	A	C
216C	A	A	C
217C	A	A	C
218C	A	A	C
219C	A	A	C
220C	A	A	C
221C	A	A	C
222C	A	A	C
223C	A	A	C
224C	A	A	B
225C	A	A	C
226C	A	A	C
227C	A	A	C
228C	A	A	C
229C	A	A	C
230C	A	A	C
231C	A	A	C
232C	A	A	C
233C	A	A	C
234C	A	A	C

Compound Number	% Mortality CEW 50 $\mu\text{g}/\text{cm}^2$	% Mortality BAW 50 $\mu\text{g}/\text{cm}^2$	% Mortality GPA 200 ppm
235C	A	A	C
236C	A	A	C
237C	A	A	C
238C	A	A	C
239C	A	A	C
240C	A	A	C
241C	A	A	C
242C	A	A	C
243C	A	A	D
244C	A	A	D
245C	A	A	D
246C	A	A	C
247C	A	A	C
248C	A	A	C
249C	A	A	C
250C	A	A	C
251C	A	A	C
252C	A	A	C
253C	A	A	C
254C	A	A	C
255C	A	A	C
256C	A	A	C
257C	A	A	C


Compound Number	% Mortality CEW 50 $\mu\text{g}/\text{cm}^2$	% Mortality BAW 50 $\mu\text{g}/\text{cm}^2$	% Mortality GPA 200 ppm
258C	A	B	C
259C	A	A	C
260C	A	A	C
261C	A	A	C

WE CLAIM

1. A composition comprising a molecule according to Formulas Two or Three



Formula 2



Formula 3

wherein:

- 5 (a) Ar₁ is

- (1) furanyl, phenyl, pyridazinyl, pyridyl, pyrimidinyl, thienyl, or
- (2) substituted furanyl, substituted phenyl, substituted pyridazinyl,

substituted pyridyl, substituted pyrimidinyl, or substituted thienyl,

wherein said substituted furanyl, substituted phenyl, substituted

- 10 pyridazinyl, substituted pyridyl, substituted pyrimidinyl, and substituted thienyl, have one or more substituents independently selected from H, F, Cl, Br, I, CN, NO₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl),
- 15 C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, phenoxy, substituted phenyl, and substituted phenoxy,

- 20 wherein such substituted phenyl and substituted phenoxy have one or more substituents independently selected from H, F, Cl, Br, I, CN, NO₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl),
- 25 C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl) phenyl, and phenoxy;

- 30 (b) Het is a 5 or 6 membered, saturated or unsaturated, heterocyclic ring,

containing one or more heteroatoms independently selected from nitrogen, sulfur, or oxygen, and where Ar₁ and Ar₂ are not ortho to each other (but may be meta or para, such as, for a five membered ring they are 1,3 and for a 6 membered ring they are either 1,3 or 1,4), and where said heterocyclic ring may also be substituted with one or more substituents

- 5 independently selected from H, F, Cl, Br, I, CN, NO₂, oxo, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, phenoxy, substituted phenyl and substituted phenoxy, wherein such substituted phenyl and substituted phenoxy have one or more substituents independently selected from H, F, Cl, Br, I, CN, NO₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, and phenoxy;

(c) Ar₂ is

- (1) furanyl, phenyl, pyridazinyl, pyridyl, pyrimidinyl, thienyl, or
 25 (2) substituted furanyl, substituted phenyl, substituted pyridazinyl, substituted pyridyl, substituted pyrimidinyl, or substituted thienyl,

wherein said substituted furanyl, substituted phenyl, substituted pyridazinyl, substituted pyridyl, substituted pyrimidinyl, and substituted thienyl, have one or more substituents independently selected from H, F, Cl, Br, I, CN, NO₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl),

C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, phenoxy, substituted phenyl and substituted phenoxy,

wherein such substituted phenyl and substituted phenoxy have one or
 5 more substituents independently selected from H, F, Cl, Br, I, CN, NO₂, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, and phenoxy;

(d) R₁ is selected from H, CN, F, Cl, Br, I, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkoxy, C₁-C₆ alkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), OSO₂(C₁-C₆ alkyl), C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, or phenoxy,

wherein each alkyl, cycloalkyl, cycloalkoxy, alkoxy, alkenyl, alkynyl, phenyl, and phenoxy, are optionally substituted with one or more substituents independently selected from F, Cl, Br, I, CN, NO₂, oxo, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, and phenoxy;

(g) R₄ is H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C(=O)H, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl),

(C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, C₁-C₆ alkylphenyl, C₁-C₆ alkyl-O-phenyl, C(=O)Het-1, Het-1, C₁-C₆ alkylHet-1, or C₁-C₆ alkyl-O-Het-1,

wherein each alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, and Het-1 are

5 optionally substituted with one or more substituents independently selected from F, Cl, Br, I, CN, NO₂, NR_xR_y, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₃-C₆ cycloalkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, phenoxy, and Het-1;

15 (h) **R5 is a 1 membered saturated hydrocarbyl linkage** where said linkage may also be substituted with F, Cl, Br, I, CN, NO₂, oxo, NR_xR_y, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₃-C₆ cycloalkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)OH, C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, phenoxy, and Het-1,

25 wherein each alkyl, cycloalkyl, cycloalkoxy, alkoxy, alkenyl, alkynyl, phenyl, phenoxy, and Het-1, are optionally substituted with one or more substituents independently selected from F, Cl, Br, I, CN, NO₂, oxo, NR_xR_y, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₃-C₆ cycloalkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)OH, C(=O)NR_xR_y, (C₁-C₆ alkyl)NR_xR_y, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, halophenyl, phenoxy,

and Het-1;

(i) $n = 0, 1, \text{ or } 2$;

5 (j) R_x and R_y are independently selected from H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl),
10 (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), and phenyl,

wherein each alkyl, cycloalkyl, cycloalkoxy, alkoxy, alkenyl, alkynyl, phenyl, phenoxy, and Het-1, are optionally substituted with one or more substituents independently selected from F, Cl, Br, I, CN, NO₂, oxo, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-
15 C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₃-C₆ cycloalkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)H, C(=O)OH, C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl),
20 C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, halophenyl, phenoxy, and Het-1,

or R_x and R_y together can optionally form a 5- to 7-membered saturated or unsaturated cyclic group which may contain one or more heteroatoms selected from nitrogen, sulfur, and oxygen, and where said cyclic group can contain $>C=O$ or $>C=S$, and where said
25 cyclic group may be substituted with F, Cl, Br, I, CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₃-C₆ halocycloalkyl, C₃-C₆ cycloalkoxy, C₃-C₆ halocycloalkoxy, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₂-C₆ alkenyl, C₃-C₆ cycloalkenyl, C₂-C₆ alkynyl, S(=O)_n(C₁-C₆ alkyl), S(=O)_n(C₁-C₆ haloalkyl), OSO₂(C₁-C₆ alkyl), OSO₂(C₁-C₆ haloalkyl), C(=O)(C₁-C₆ alkyl), C(=O)O(C₁-C₆ alkyl), C(=O)(C₁-C₆ haloalkyl), C(=O)O(C₁-C₆ haloalkyl), C(=O)(C₃-C₆ cycloalkyl), C(=O)O(C₃-C₆ cycloalkyl), C(=O)(C₂-C₆ alkenyl), C(=O)O(C₂-C₆ alkenyl), (C₁-C₆ alkyl)O(C₁-C₆ alkyl), (C₁-C₆ alkyl)S(C₁-C₆ alkyl), C(=O)(C₁-C₆ alkyl)C(=O)O(C₁-C₆ alkyl), phenyl, substituted phenyl, phenoxy, and Het-1; and

(k) Het-1 is a 5- or 6-membered, saturated or unsaturated, heterocyclic ring,


containing one or more heteroatoms independently selected from nitrogen, sulfur or oxygen.

2. A molecule according to claim 1 wherein Ar₁ is a substituted phenyl wherein said substituted phenyl has one or more substituents independently selected from C₁-C₆ haloalkyl and C₁-C₆ haloalkoxy.


3. A molecule according to claim 1 wherein Ar₁ is a substituted phenyl wherein said substituted phenyl, has one or more substituents independently selected from CF₃, OCF₃, and OCF₂CF₃.

4. A molecule according to claim 1 wherein Het is selected from triazolyl, imidazolyl, or pyrazolyl, which can be substituted or unsubstituted.


5. A molecule according to claim 1 wherein Het is a 1,2,4-triazolyl



6. A molecule according to claim 1 wherein Het is a 1,4-imidazolyl




7. A molecule according to claim 1 wherein Het is a 1,3-pyrazolyl



8. A molecule according to claim 1 wherein Het is a substituted 1,3-pyrazolyl.

9. A molecule according to claim 1 wherein Het is a 1,4-pyrazolyl




10. A molecule according to claim 1 wherein Ar₂ is a phenyl.
- 5 11. A molecule according to claim 1 wherein R₁ is H or C₁-C₆ alkyl.
12. A molecule according to claim 1 wherein R₁ is H or CH₃.
13. A molecule according to claim 1 wherein R₄ is phenyl, C₁-C₆ alkylphenyl, or C₁-C₆ alkyl-O-phenyl, wherein each alkyl and phenyl are optionally substituted with one or more substituents independently selected from F, Cl, NR_xR_y, C₁-C₆ alkyl, or C₁-C₆ alkoxy.
- 10 14. A molecule according to claim 1 wherein R₅ is unsubstituted.
- 15 15. A molecule according to claim 1 wherein R_x and R_y are independently selected from H and phenyl, wherein said phenyl, may be optionally substituted with one or more substituents independently selected from F and Cl.
16. A molecule according to claim 1 wherein Het-1 is selected from benzofuranyl, benzoisothiazolyl, benzoisoxazolyl, benzoxazolyl, benzothienyl, benzothiazolyl cinnolyl, furanyl, indazolyl, indolyl, imidazolyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, phthalazinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrazolyl, thiazolyl, thienyl, triazinyl, triazolyl, piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydro-quinolyl, 4,5-dihydro-oxazolyl, 4,5-dihydro-1H-pyrazolyl, 4,5-dihydro-isoxazolyl, and 2,3-dihydro-[1,3,4]-oxadiazolyl.
- 20 17. A molecule according to claim 1 wherein Het is selected benzofuranyl, benzoisothiazolyl, benzoisoxazolyl, benzoxazolyl, benzothienyl, benzothiazolyl cinnolyl, furanyl, indazolyl, indolyl, imidazolyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl,
- 25 30








oxadiazolyl, oxazoliny, oxazolyl, phthalazinyl, pyrazinyl, pyrazoliny, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinoliny, quinoxaliny, tetrazolyl, thiazoliny, thiazolyl, thienyl, triazinyl, triazolyl, piperazinyl, piperidiny, morpholiny, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydro-quinoliny, 4,5-dihydro-oxazolyl, 4,5-dihydro-1H-pyrazolyl, 4,5-dihydro-isoxazolyl, and 2,3-dihydro-[1,3,4]-oxadiazolyl.







18. A molecule according to claim 1 wherein Het-1 is selected from benzofuranyl, benzoisothiazolyl, benzoisoxazolyl, benzoxazolyl, benzothienyl, benzothiazolyl, benzothiadizolyl, cinnoliny, furanyl, indazolyl, indolyl, imidazolyl, isoindolyl, isoquinoliny, isothiazolyl, isoxazolyl, oxadiazolyl, oxazoliny, oxazolyl, phthalazinyl, pyrazinyl, pyrazoliny, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinoliny, quinoxaliny, tetrazolyl, thiazoliny, thiazolyl, thienyl, thienylpyrazolyl, triazinyl, triazolyl, piperazinyl, piperidiny, morpholiny, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydro-quinoliny, 4,5-dihydro-oxazolyl, 4,5-dihydro-1H-pyrazolyl, 4,5-dihydro-isoxazolyl, and 2,3-dihydro-[1,3,4]-oxadiazolyl.








19. A molecule according to claim 1 wherein Het-1 is selected from benzothiadizolyl, furanyl, oxazolyl, and thienylpyrazolyl.

20. A molecule according to claim 1 wherein said molecule is selected from



242C	
243C	
244C	
245C	
246C	
247C	
248C	







249C	
250C	
251C	
252C	
253C	
254C	


255C	
256C	
257C	
258C	
259C	
260C	
261C	

21. A process to apply a composition according to claim 1 said process comprising applying a composition according to claim 1, to an area to control a pest, in an amount sufficient to control such pest.

5

22. A process according to claim 21 wherein said molecule is selected from

240C	
241C	
242C	
243C	
244C	
245C	



and said pest is BAW, CEW, or GPA.

- 5 23. A process according to claim 21 wherein said area is an area where apples, corn, cotton, soybeans, canola, wheat, rice, sorghum, barley, oats, potatoes, oranges, alfalfa, lettuce, strawberries, tomatoes, peppers, crucifers, pears, tobacco, almonds, sugar beets, or beans, are growing, or the seeds thereof are going to be planted
- 10 24. A composition according to claim 1 comprising a pesticidally acceptable acid addition salt, a salt derivative, a solvate, or an ester derivative, of a molecule according to claim 1.
25. A composition according to claim 1 comprising a polymorph of a molecule according to claim 1.
- 15 26. A composition according to claim 1 comprising a molecule according to claim 1 wherein at least one H is ^2H or at least one C is ^{14}C .
27. A composition comprising a molecule according to claim 1 and at least one other
- 20 compound selected from the Insecticide Group, Acaricide Group, Nematicide Group, Fungicide Group, Herbicide Group, AI Group, or Synergist Group.
28. A composition comprising a composition according to claim 1 and a seed.
- 25 29. A composition according to claim 28 wherein said seed has been genetically modified to express one or more specialized traits.
- 30 30. A composition according to claim 1 and at least one compound that has a mode of action selected from acetylcholinesterase inhibitor, sodium channel modulator, chitin biosynthesis inhibitor, GABA-gated chloride channel antagonist, GABA and glutamate-gated

chloride channel agonist, acetylcholine receptor agonist, MET I inhibitor, Mg-stimulated ATPase inhibitor, nicotinic acetylcholine receptor, Midgut membrane disrupter, oxidative phosphorylation disrupter, and ryanodine receptor (RyRs).

- 5 31. A process comprising applying a composition according to claim 1 to a genetically modified plant that has been genetically modified to express one or more specialized traits.
32. A process comprising: orally administering; or topically applying; a composition according to claim 1, to a non-human animal, to control endoparasites, ectoparasites, or both.

10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 13/22659

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A01N 43/78 (2013.01)

USPC - 504/266

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): A01N 43/78 (2013.01)

USPC: 504/266

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC: 504/209, 261, 275, 280; 548/182, 190-191, 198; 424/405 (text search) Find search terms below

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PubWEST (PGPB,USPT,USOC,EPAB,JPAB), Google Scholar, SureChem, PatBase
imidazole, triazole, pyrazole, thiazetidin\$, phenylthiazetidin\$, hydraz\$, phenyl hydrazone, pesticide, insecticide, agrochemical, thiazolidin\$, phenylthiazolidin\$

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2009/0209476 A1 (CROUSE et al.) 20 August 2009 (20.08.2009) para [0002], [0016]-[0035], [0054], [0067], [0071]-[0082], [0195], [0198], [0344], [0358], [0410], [0447]-[0475], [0482], [0508]-[0509]	1-32
Y	US 2010/0010058 A1 (KORADIN et al.) 14 January 2010 (14.01.2010) para [0006]-[0007], [0012]-[0015], [0024]-[0027], [0034], [0090]-[0092]	1-32
Y	DE 42 09 561 A1 (ROSENBAUM et al.) 23 September 1993 (23.09.1993) Abstract	1-32
Y	WO 2009/007022 A2 (SCHWARZ et al.) 15 January 2009 (15.01.2009) pg 1, ln 2-4; pg 3, ln 1-4; pg 15, structures shown; pg 6, ln 7-14	26

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 March 2013 (20.03.2013)

Date of mailing of the international search report

10 APR 2013

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774